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Abstract
Oxidative phosphorylation (OXPHOS) and glycolysis are two cellular metabolic pathways that play a
crucial role in the functions of biological systems. Currently, magnetic resonance spectroscopy (MRS)
(13C, 31P, and 1H) and positron emission tomography (PET) methods are used to investigate changes in
these pathways that result from metabolic dysfunction. However, MRS methods are limited by low
resolution and long acquisition times. While 18F-fluoro-2-deoxy-D-glucose (18F-FDG) PET is a widely used
clinical modality, it requires the use of radioactive ligands. Thus, there is an unmet need for techniques to
image these metabolic processes noninvasively, and with higher resolution in vivo. In this dissertation, we
exploited the chemical exchange saturation (CEST) phenomenon to develop and optimize endogenous
CEST magnetic resonance imaging (MRI) methods to measure OXPHOS and glycolysis, and
demonstrated application of those techniques to study impaired metabolism in vivo. These CEST
methods offer several orders of magnitude higher sensitivity compared to traditional spectroscopic
techniques. Recently developed CEST imaging of free creatine (CrCEST) was targeted as a means of
measuring OXPHOS. We optimized and validated this technique in healthy human skeletal muscle,
showing that CrCEST imaging in dynamic exercise studies provides a measure of the mitochondrial rate
of OXPHOS. CrCEST imaging was then implemented in a cohort of subjects affected by genetic disorders
of the mitochondria. The results of these studies demonstrate that CrCEST has the capability to
distinguish between healthy and impaired OXPHOS in muscle. In some diseases with altered metabolism,
like cancer, aerobic glycolysis dominates, leading to increased lactate production. Existing methods for
imaging lactate in vivo involve expensive, radiolabeled tracers. In this work, we demonstrated the
feasibility of imaging lactate with CEST (“LATEST”) in phantoms with physiological concentrations. Then,
we validated the method dynamically in vivo by measuring lactate production and clearance in intensely
exercised human skeletal muscle, which utilizes anaerobic glycolysis. Finally, we infused rats bearing
lymphoma tumors with non-labeled pyruvate and demonstrated the ability of LATEST MRI to image
tumors and measure dynamic lactate changes over time. Together, these studies demonstrate that
metabolic processes can be monitored in vivo using CEST MRI, with potential for widespread clinical
applications.
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ABSTRACT
CHEMICAL EXCHANGE SATURATION TRANSFER IMAGING OF
ENDOGENOUS METABOLITES FOR MONITORING OXIDATIVE
PHOSPHORYLATION AND GLYCOLYSIS IN VIVO
Catherine DeBrosse
Ravinder Reddy
Oxidative phosphorylation (OXPHOS) and glycolysis are two cellular metabolic
pathways that play a crucial role in the functions of biological systems. Currently,
magnetic resonance spectroscopy (MRS) (13C,

31

P, and 1H) and positron emission

tomography (PET) methods are used to investigate changes in these pathways that result
from metabolic dysfunction. However, MRS methods are limited by low resolution and
long acquisition times. While

18

F-fluoro-2-deoxy-D-glucose (18F-FDG) PET is a widely

used clinical modality, it requires the use of radioactive ligands. Thus, there is an unmet
need for techniques to image these metabolic processes noninvasively, and with higher
resolution in vivo. In this dissertation, we exploited the chemical exchange saturation
(CEST) phenomenon to develop and optimize endogenous CEST magnetic resonance
imaging (MRI) methods to measure OXPHOS and glycolysis, and demonstrated
application of those techniques to study impaired metabolism in vivo. These CEST
methods offer several orders of magnitude higher sensitivity compared to traditional
spectroscopic techniques. Recently developed CEST imaging of free creatine (CrCEST)
was targeted as a means of measuring OXPHOS. We optimized and validated this
technique in healthy human skeletal muscle, showing that CrCEST imaging in dynamic
v

exercise studies provides a measure of the mitochondrial rate of OXPHOS. CrCEST
imaging was then implemented in a cohort of subjects affected by genetic disorders of the
mitochondria. The results of these studies demonstrate that CrCEST has the capability to
distinguish between healthy and impaired OXPHOS in muscle. In some diseases with
altered metabolism, like cancer, aerobic glycolysis dominates, leading to increased lactate
production. Existing methods for imaging lactate in vivo involve expensive, radiolabeled
tracers. In this work, we demonstrated the feasibility of imaging lactate with CEST
(“LATEST”) in phantoms with physiological concentrations. Then, we validated the
method dynamically in vivo by measuring lactate production and clearance in intensely
exercised human skeletal muscle, which utilizes anaerobic glycolysis. Finally, we infused
rats bearing lymphoma tumors with non-labeled pyruvate and demonstrated the ability of
LATEST MRI to image tumors and measure dynamic lactate changes over time.
Together, these studies demonstrate that metabolic processes can be monitored in vivo
using CEST MRI, with potential for widespread clinical applications.

vi

TABLE OF CONTENTS
ABSTRACT ...................................................................................................................... V
LIST OF TABLES ........................................................................................................... X
LIST OF ILLUSTRATIONS ......................................................................................... XI
CHAPTER 1 - CHEMICAL EXCHANGE SATURATION TRANSFER (CEST)
AND METABOLISM ....................................................................................................... 1
1.1 Introduction ................................................................................................................. 1
1.2 Chemical Exchange Saturation Transfer ................................................................. 6
1.2.1 CEST theory ........................................................................................................... 6
1.2.2 Calculation of the CEST effect ............................................................................ 10
1.2.3 CEST optimization ............................................................................................... 14
1.2.4 CEST of endogenous metabolites ........................................................................ 15
1.3 Metabolic Dysfunction .............................................................................................. 21
1.4 Mitochondria and Oxidative Phosphorylation....................................................... 25
1.4.1 Mitochondrial structure ........................................................................................ 26
1.4.2 Respiratory chain components ............................................................................. 27
1.4.3 Oxidative phosphorylation ................................................................................... 31
1.4.4 Respiratory states ................................................................................................. 34
1.4.5 Reactive oxygen species (ROS) and mitochondrial damage ............................... 35
1.5 Glycolysis ................................................................................................................... 39
1.6 Summary.................................................................................................................... 40
CHAPTER 2 - DEVELOPMENT OF CREATINE CHEMICAL EXCHANGE
SATURATION TRANSFER (CRCEST) ..................................................................... 42
2.1 Introduction ............................................................................................................... 42
2.1.1 Skeletal muscle metabolism ................................................................................. 43
2.1.2 The creatine-kinase reaction................................................................................. 45
2.1.3 31Phosphorus MRS ............................................................................................... 48
2.2 Development and application of CrCEST .............................................................. 51
2.2.1 CrCEST in phantoms ........................................................................................... 51
2.2.2 in vivo CrCEST: skeletal muscle exercise at ultra-high field .............................. 58
2.2.3 Implementation of in vivo CrCEST at clinical-strength field .............................. 65
vii

2.2.4 Application of CrCEST in imaging of myocardial metabolism ........................... 67
2.2.5 CrCEST application in brain imaging .................................................................. 71
2.3 Preliminary Reproducibility Study ......................................................................... 73
2.3.1 Methods ................................................................................................................ 73
2.3.2 Results .................................................................................................................. 84
2.3.3 Discussion ............................................................................................................ 86
2.4 Summary.................................................................................................................... 87
CHAPTER 3 - APPLICATION OF CRCEST FOR MEASURING IMPAIRED
MUSCLE OXIDATIVE PHOSPHORYLATION IN VIVO ....................................... 89
3.1 Introduction ............................................................................................................... 89
3.2 The mitochondrial genome and mutations that disrupt OXPHOS ...................... 89
3.2.1 Missense mutations .............................................................................................. 92
3.2.3 Insertion-deletion mutations ................................................................................. 92
3.2.4 Copy number mutations ....................................................................................... 93
3.2.5 Biogenesis mutations............................................................................................ 93
3.3 Mitochondrial involvement in other disorders....................................................... 95
3.3.1 Mitochondrial impairment in cancer .................................................................... 95
3.3.2 Mitochondrial impairment in neurodegenerative disease and aging .................... 96
3.3.3 Mitochondria in cardiovascular disease and diabetes .......................................... 96
3.4 31P MRS and mitochondrial impairment................................................................ 97
3.5 Clinical MRI Study ................................................................................................... 99
3.5.1 Motivation ............................................................................................................ 99
3.5.2 Methods .............................................................................................................. 100
3.5.3 Results ................................................................................................................ 107
3.5.4 Discussion .......................................................................................................... 127
3.6 Summary.................................................................................................................. 136
CHAPTER 4 - DEVELOPMENT OF LACTATE CEST AND ITS APPLICATIONS
FOR MONITORING GLYCOLYSIS IN VIVO ........................................................ 137
4.1 Introduction ............................................................................................................. 137
4.1.1 Lactate metabolism ............................................................................................ 137
4.1.2 Lactate in skeletal and cardiac muscle ............................................................... 138
4.1.3 Lactate in cancer................................................................................................. 139
4.1.4 in vivo measurement of lactate........................................................................... 140
viii

4.2 Methods.................................................................................................................... 141
4.2.1 Phantom studies ................................................................................................. 142
4.2.2 Animal studies .................................................................................................... 145
4.2.3 Human imaging .................................................................................................. 148
4.2.4 Post processing Methods .................................................................................... 151
4.3 Results ...................................................................................................................... 153
4.3.1 Phantom studies ................................................................................................. 153
4.3.2 Animal model studies ......................................................................................... 164
4.3.3 Human studies: LATEST imaging of healthy human calf muscle..................... 169
4.4 Discussion ................................................................................................................ 174
4.5 Summary.................................................................................................................. 178
THESIS SUMMARY AND FUTURE DIRECTIONS .............................................. 178
BIBLIOGRAPHY ......................................................................................................... 181

ix

LIST OF TABLES
Table 1-1 CEST equations ................................................................................................ 13
Table 1-2 Electron transfer in mitochondria ..................................................................... 29
Table 1-3 Properties of the components of the mitochondrial respiratory chain .............. 31
Table 1-4 Summary of respiration states .......................................................................... 34
Table 3-1 Respiratory complexes encoded for by mtDNA .............................................. 90
Table 3-2 Subject characteristics .................................................................................... 108
Table 3-3 Creatine CEST imaging results ...................................................................... 110
Table 3-4 Diagnoses in individuals with mitochondrial respiratory chain diseases ....... 111
Table 3-5 Mixed effects regression models of log-transformed post-exercise CrCEST
decline time constant (τCr, in minutes) .................................................................. 113
Table 3-6 Mixed effects regression models of log-transformed resting CrCEST (%
asymmetry) ............................................................................................................. 117
Table 3-7 Mixed effects regression models including the association of intentional
exercise with (Model 1) log-transformed post-exercise CrCEST decline time
constant (τCr, in minutes) ....................................................................................... 124

x

LIST OF ILLUSTRATIONS
Figure 1.1 CEST theory diagram. ....................................................................................... 8
Figure 1.2 The CEST effect. ............................................................................................. 11
Figure 1.3 GluCEST imaging and 1H MRS from a healthy human brain acquired at 7T. 19
Figure 1.4 4 GluCEST maps and corresponding immunohistochemistry (IHC). ............. 20
Figure 1.5 Summary of key metabolic pathways.............................................................. 22
Figure 2.1 31P MRS spectra. ............................................................................................. 49
Figure 2.2 High-resolution NMR-derived location of exchangeable protons and CEST
maps. ......................................................................................................................... 52
Figure 2.3 Schematic for the CEST pulse sequence ......................................................... 54
Figure 2.4 CEST effect from creatine. .............................................................................. 55
Figure 2.5 Sensitivity of CrCEST compared to 1H MRS. ................................................ 57
Figure 2.6 CEST asymmetry vs. SNR. ............................................................................. 59
Figure 2.7 CrCEST application in healthy skeletal muscle. ............................................. 62
Figure 2.8 CrCEST vs. 31P MRS. ..................................................................................... 64
Figure 2.9 CrCEST in skeletal muscle at 3T. ................................................................... 67
Figure 2.10 Ex vivo CrCEST of noninfarcted and infarcted myocardial tissue from swine.
................................................................................................................................... 68
Figure 2.11 In vivo CrCEST data. .................................................................................... 70
Figure 2.12 CrCEST of a rat brain tumor model. ............................................................. 72
Figure 2.13 Coil positioning around the calf muscle for CrCEST imaging. .................... 74
Figure 2.14 Anatomical, axial calf muscle image............................................................. 75
Figure 2.15 Custom-built MRI-compatible ergometer. .................................................... 76
Figure 2.16 Schematic for pneumatic air cylinder. ........................................................... 77
Figure 2.17 Air cylinder and pressure gauge. ................................................................... 78
Figure 2.18 Flowchart for the GUI processing application. ............................................. 80
xi

Figure 2.19 GUI interface for processing CrCEST exercise data. .................................... 81
Figure 2.20 GUI image output. ......................................................................................... 82
Figure 2.21 GUI ROI calculation output. ......................................................................... 83
Figure 2.22 Reproducibility of baseline CrCEST % asymmetry, an index of free creatine
concentration. ............................................................................................................ 85
Figure 2.23 Reproducibility of post-exercise CrCEST decline exponential time constant
(τCr), an index of free creatine concentration........................................................... 86
Figure 3.1 Example resting and post-exercise CrCEST recovery images and summary
curves. ..................................................................................................................... 114
Figure 3.2 Box plots for post-exercise CrCEST exponential time constant (τCr), an index
of skeletal muscle OXPHOS capacity. ................................................................... 116
Figure 3.3 τPCr/τCr correlation. ..................................................................................... 119
Figure 3.4 Example of muscle group-specific metabolic variation captured by CrCEST.
................................................................................................................................. 120
Figure 3.5 Correlogram of the association between intentional exercise) and measured
imaging parameters. ................................................................................................ 122
Figure 3.6 Resting-state CrCEST vs. age. ...................................................................... 126
Figure 3.7 The τCr values plotted vs. age of controls (0) and affected subjects (1). ...... 127
Figure 4.1 Determination of lactate –OH resonance. ..................................................... 153
Figure 4.2 Initial phantom experiments on 50mM lactate solution at 7T: titration of B1
pulse power. ............................................................................................................ 155
Figure 4.3 B1 dependence of LATEST in phantoms at 7T. ............................................ 156
Figure 4.4 Initial phantom experiments on 50mM lactate solution at 7T: titration of B1
pulse duration. ......................................................................................................... 157
Figure 4.5 Concentration dependence of LATEST at 7T. .............................................. 158
Figure 4.6 pH dependence of LATEST at 7T. ................................................................ 159
Figure 4.7 Phantom temperature dependence at 7T, acquired on a 50mM lactate phantom.
................................................................................................................................. 160
Figure 4.8 Characterization of LATEST at 9.4T. ........................................................... 162
Figure 4.9 Characterization of LATEST. ....................................................................... 163
xii

Figure 4.10 LATEST from lymphoma tumors. .............................................................. 164
Figure 4.11 Z-spectra from the tumor region in a representative animal. ...................... 165
Figure 4.12 pre- and post-infusion B0 and B1 maps for three animals with flank tumors.
................................................................................................................................. 166
Figure 4.13 LATEST from 9L glioma rat brain model. ................................................. 168
Figure 4.14 LATEST asymmetry plots from glioma model. .......................................... 169
Figure 4.15 In vivo LATEST in healthy skeletal muscle. .............................................. 170
Figure 4.16 Z-spectra for skeletal muscle. ...................................................................... 171
Figure 4.17 In vivo LATEST and SEL-MQC spectroscopy........................................... 172
Figure 4.18 B0 and B1 correction of in vivo calf muscle CEST. .................................... 173
Figure 4.19 Gastrocnemius muscle T2 measurements. ................................................... 174

xiii

Chapter 1 - Chemical Exchange Saturation Transfer (CEST) and Metabolism
1.1 Introduction
The motivation for this dissertation work was to develop chemical exchange saturation
transfer (CEST) magnetic resonance imaging (MRI) biomarkers of metabolism and
demonstrate in vivo applications. In this chapter we will review the benefits of molecular
imaging techniques for studying metabolism, describe the CEST theory and current
applications, and then discuss the motivation for using CEST for imaging metabolic
dysfunction.
Molecular imaging techniques have become vital tools for investigating biochemical
processes in vivo (James and Gambhir 2012). They are particularly useful for studying
disease mechanisms and pathology in living tissue. As we investigate the molecular basis
of disease, the capability of measuring biological functions within a living subject
becomes more and more important, particularly as the new molecular therapies are
developed. Imaging techniques can be used in combination with other modalities to aid
in diagnostics, drug development, and evaluating therapeutic efficacy.
Compared to traditional in vitro or ex vivo methods, molecular imaging has several key
advantages (Wouters, Verveer et al. 2001). First, molecular imaging methods are
relatively non-invasive. This allows us to study organisms, such as cells, living tissue, or
live subjects, without disrupting the natural environment (Massoud and Gambhir 2003).
Therefore, we can track dynamic biological processes in vivo and in real time, which
provides a more comprehensive picture of the organism. Pre-clinical animal studies are
1

greatly benefitted by molecular imaging techniques as we can perform multiple studies
per animal, ultimately using fewer research animals and gaining the ability to perform
longitudinal studies. Molecular imaging also improves the development of therapeutics
by aiding in vivo assessment of pharmaceutical metabolism and safety (Willmann, van
Bruggen et al. 2008). Finally, most molecular imaging techniques provide sufficient
temporal and spatial resolution, making them ideal for studying physiological processes
in real time.
Many molecular imaging techniques, such as positron emission tomography (PET)
(Phelps 2000, Blake, Johnson et al. 2003), computed tomography (CT) (Agatston,
Janowitz et al. 1990, Lardinois, Weder et al. 2003), ultrasound (Christiansen and Lindner
2005), optical imaging (Couillard-Despres, Finkl et al. 2008), and photoacoustic imaging
(de la Zerda, Liu et al. 2010, Wang and Hu 2012) have been developed in recent decades.
While these techniques have many advantages (Plathow and Weber 2008) particularly in
cancer imaging, they also possess some limitations, primarily use of ionizing radiation,
limited tissue-penetration depth, or inherent low-quality soft tissue contrast that requires
use of injected contrast agents (James and Gambhir 2012).
The work presented in this thesis utilized MRI, which has been used for decades to
provide high-resolution anatomical images of human tissue (Lauterbur 1973). Compared
to most other modalities MRI has excellent spatial and temporal resolution. Through the
use of specialized pulse sequences we can acquire dynamic contrast-enhanced (DCE)
images to study vasculature (Padhani and Husband 2001), diffusion-weighted (DW)
images (de Figueiredo, Borgonovi et al. 2011) for determining tissue architecture, arterial
2

spin-labeling (ASL) to image cerebral perfusion (Alsop and Detre 1998), and bloodoxygen level dependent (BOLD) (Ogawa, Lee et al. 1990) for measuring the oxygenation
status of red blood cells. Molecular imaging with MRI is often performed with the aid of
contrast agents that respond to changes in the environment by changing the measured
MRI signal. These contrast agents are used to mitigate the inherently lower sensitivity of
MRI compared to the other available techniques. Some of these commonly used MRI
contrast agents such as gadolinium (Gd) (Caravan, Ellison et al. 1999) or
superparamagnetic iron oxide (SPIO) act by shortening the T1 (longitudinal) or T2
(transverse) relaxation times of water protons. This causes a change in the signal intensity
in the MR images where the contrast agent is present. T1 or T2 contrast agents respond to
changes in the local microenvironment such as enzymatic activity or changes in
concentration of a target molecule (Moats, Fraser et al. 1997, De Leon-Rodriguez, Lubag
et al. 2009). A primary goal for these contrast agents is the ability to image change in
tissue pH or metabolite levels to observe defects in metabolism (Aime, Botta et al. 2005,
Aime, Fedeli et al. 2006). However, there are challenges to utilizing these contrast agents
in vivo due to low specificity and some concerns about use of these agents in patients
with impaired renal function – an important consideration in patient populations with
impaired metabolic function due to disease such as diabetes. Recent reports also suggest
that Gd from these agents is retained in tissues for several months, the consequences of
which are under investigation (Rogosnitzky and Branch 2016). Furthermore, the behavior
of some of these agents at the higher-strength fields (>3T), i.e., decreased relaxivity

3

effects, precludes more widespread use (Terreno, Delli Castelli et al. 2010, Viswanathan,
Kovacs et al. 2010).
In an effort to overcome some of the sensitivity limitations of the above techniques, a
hyperpolarized magnetic resonance spectroscopy (MRS) technique has been developed to
enhance the signal-to-noise (SNR) by ~10,000-fold (Albert, Cates et al. 1994, Middleton,
Black et al. 1995, Navon, Song et al. 1996, Golman, in't Zandt et al. 2006). With this
technique, the distribution of spin is artificially altered, creating a larger difference in the
spin states (anti-parallel vs. parallel). Essentially, this enhances the sensitivity by greatly
increasing the polarization of the spins compared to the thermal equilibrium state.
Typically, the

13

C labeled compound (e.g., pyruvate) is mixed with a free radical, the

mixture is frozen to liquid helium temperature, and then the electron spin states of the
free radical are saturated by microwave irradiation. The saturated magnetization is then
transferred to the

13

C pyruvate spins through dipolar relaxation (Maly, Debelouchina et

al. 2008). The magnetization of

13

C pyruvate is enhanced by two effects: (i) since the

electron spin magnetic moment is 1000 times higher than that of nuclear spin,

13

C

polarization is enhanced a thousand-fold, and (ii) the liquid helium temperature further
enhances the magnetization by a factor of 10. This technique can be used to track
molecules labeled with 13C, which is otherwise difficult to measure due to its low natural
abundance. Biochemical processes such as glycolysis can be studied in vivo with
hyperpolarization by labeling important intermediates like pyruvate.
hyperpolarized

13

To date,

C MRS has proved an extremely useful technique for studying cancer

metabolism (Golman, in't Zandt et al. 2006, Day, Kettunen et al. 2007, Kennedy,
4

Kettunen et al. 2012, Nelson, Kurhanewicz et al. 2013). Typically, the method used to
create this hyperpolarization is a process called dynamic nuclear polarization (DNP)
(Chen, Albers et al. 2007, Comment, van den Brandt et al. 2007). Since the
hyperpolarization (of

13

C-labeled pyruvate) created by this method only lasts for

approximately as long as the T1 of

13

C pyruvate (~20-30s), there is a short window of

time in which measurements can be made. Therefore, this technique can only be used to
probe fast kinetics in vivo.
This thesis will focus on chemical exchange saturation transfer (CEST) contrast agents
(Ward, Aletras et al. 2000, Sherry and Woods 2008, van Zijl and Yadav 2011),
specifically, endogenous metabolites that exist at physiological concentrations suitable
for in vivo imaging. The first part of this chapter will describe the CEST theory and
current uses. The remainder of this chapter will provide motivation for further
development of CEST for studying metabolism in vivo and a review of the mitochondrial
function and structure that underlies many metabolic processes. In Chapter 2, we will
focus on metabolism in skeletal muscle, the currently used “gold-standard” spectroscopy
technique, and then the development of a specific CEST biomarker, creatine (Haris,
Nanga et al. 2012), and its initial in vivo applications to skeletal muscle metabolism in
healthy subjects (Kogan, Haris et al. 2013, Kogan, Haris et al. 2013) followed by a pilot
reproducibility study (DeBrosse, Nanga et al. 2016).
Chapter 3 will discuss the efforts made toward the application of the creatine CEST
technique to study impaired metabolism in a patient population with known
mitochondrial dysfunction (DeBrosse, Nanga et al. 2016). Chapter 4 will focus on a new
5

CEST biomarker, lactate, which was developed as part of this thesis work and validated
in skeletal muscle and in a tumor model (DeBrosse, Nanga et al. 2016). Finally, we will
summarize and discuss some future directions for these two CEST techniques.
Ultimately the goal for this thesis is to explore the following questions:
I.

What are the available CEST biomarkers for monitoring metabolism in vivo?

II.

Can we develop and apply those techniques to disease states and identify
impaired metabolism?

1.2 Chemical Exchange Saturation Transfer

1.2.1 CEST theory
Chemical exchange saturation transfer (CEST) experiments are performed on solute
protons that are in exchange with protons of a solvent. In the CEST experiments
presented in this dissertation the solutes are metabolites with exchangeable protons (such
as creatine in Chapters 2 and 3, and lactate in Chapter 4) and the solvent is water, either
phosphate-buffered saline solutions in phantom experiments, or the bulk water in
mammalian tissue.
CEST theory is typically described using a generalized case in which there are two
nuclear spin systems (spin ½), where W represents the bulk water protons, and S
represents the solute protons (Figure 1.1) (Forsen and Hoffman 1963, Ward, Aletras et
al. 2000). The protons in these systems must be in exchange with one another and have a
distinct chemical shift difference which is denoted by Δω. First, we irradiate the protons
of S with a frequency-selective radiofrequency (RF) pulse (Wolff and Balaban 1990,
6

Ward, Aletras et al. 2000). The pulse is designed to “saturate” the magnetization of the
protons of S. This means that in the presence of a static magnetic field, when the RF
pulse is applied, the population of the two spin states of S will be equalized, i.e., the
number of spins aligned with the field is equal to the number of spins aligned against the
field. The result is saturated magnetization of the S protons; in other words, we would
observe zero MR signal from those saturated protons. Because the spins of S are
exchanging with the spins of W, the saturated magnetization of the S protons is
transferred to W protons. During the same time, the W spins are transferred to S, where
they are saturated again. This process continues during the entire period of the saturation
pulse—typically a few hundred milliseconds to several seconds. The signal of W, which
we measure with MRI, is therefore reduced in proportion to the concentration of the
exchangeable protons of S. As longitudinal relaxation occurs, both spin systems are
returned to equilibrium values as the system approaches steady state (van Zijl and Yadav
2011, Cai, Haris et al. 2012).

7

Figure 1.1 CEST theory diagram. An irradiation radiofrequency (RF) pulse is used to
selectively saturate the protons of a solute that contains exchangeable protons at some
chemical shift Δω. Here, an example is shown using the amine protons of creatine. The
solute protons exchange with the solvent protons, typically those of surrounding bulk
water. (Adapted from Liu et al. (Liu, Song et al. 2013)).

The magnetization of the water and solute protons is described by the Bloch-McConnell
equations, modified for chemical exchange (Abergel and Palmer 2004). If we apply the
RF pulse along the x-direction, the Bloch-McConnell equations for the water protons are
given by Equations 1.1-1.3, and the equations for the solute protons are given by
Equations 1.4-1.6 (see Table 1-1). Even using the simple two-site exchange model, it is
difficult to (analytically) solve the full Bloch-McConnell equations that describe the
magnetization (X, Y, and Z) of the entire system. We can make some simplifying
assumptions that reduce the Bloch-McConnell equations to the Y and Z magnetization
8

components. First, we assume that the populations of S and W are asymmetric, with the
solvent pool being much greater than the solute pool. The equilibrium magnetization
(M0) for the water is therefore much greater than that of the solute: M0W>> M0S. We also
assume that we will only be saturating the solute pool S. As described in Zhou et al., it is
simpler to re-write the equations by first defining Equations 1.7-1.12, which leaves us
with the simplified equations for the water magnetization Equations 1.13 and 1.14, and
for the solute proton magnetization Equations 1.15 and 1.16.
Then we assume that both systems reach a steady state (SS), which would require that all
left-hand sides of Equations 1.13-1.16 are zero. Solving the equations with that
assumption yields the z-axis magnetization for the water protons (Equation 1.17). We
can also define the saturation efficiency, 𝛼 or the amount of pool S that was saturated by
the RF pulse (Equations 1.20 and 1.21), from which it is apparent that we would only
fully saturate S if we use a very strong RF pulse, i.e., ω1à ∞ so that α=1.
For practical purposes, we will consider the effects of a weak pulse, where MzW(t0)=M0W
and mzW(t0)=0, and so the magnetization of the water protons is given by Equation 1.22,
where the water pool approaches steady-state at a rate 𝑟$% (Equation 1.23), which
defines the spin-lattice relaxation rate of the water protons while the RF pulse is applied
to the solute protons. The proton transfer ratio (PTR) is given in Equation 1.24 in which
the applied RF saturation time is tsat=t-t0. The analytical derivation only applies in the
steady-state condition with a two-pool exchange model (Zhou, Wilson et al. 2004,
Woessner, Zhang et al. 2005, McMahon, Gilad et al. 2006, van Zijl, Jones et al. 2007).
We use non-steady-state experimental conditions and use a numerical analysis of the full
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Bloch-McConnell equations for experimental analysis (McConnell 1958). More in-depth
theoretical considerations of CEST are available in several reviews (Zhou and van Zijl
2006, Sherry and Woods 2008).

1.2.2 Calculation of the CEST effect
The saturated, transferred magnetization from solute pool to water pool is imaged to
detect the “CEST effect”. We can visualize the CEST effect by plotting the water signal
as a function of saturation frequency, producing a “z-spectrum”. In order to observe the
signal from saturation of a particular metabolite, we calculate the CEST asymmetry ratio
by subtracting the magnetization signal obtained while saturating the exchangeable solute
proton chemical shift, defined as Msat(+Δω), from the magnetization signal obtained while
saturating at the same chemical shift on the opposite side of the water peak, defined as
Msat(-Δω). The CEST asymmetry is defined by Equations 1.25 and 1.26. This asymmetry
analysis, normalized with the magnetization signal (M0) observed when saturating very
far away from water (>20ppm), elucidates the CEST effect from the solute protons.
When implementing CEST in vivo in biological tissues, we must consider the effects of
direct saturation (DS), also called “spillover” (Sun, Wang et al. 2014) in which the
irradiating pulse applied to the solute protons also ends up saturating the water protons.
Any accidental saturation of the water peak would confound the CEST signal, so the
asymmetry calculation is performed to subtract out those effects. Additionally, the effect
of magnetization transfer (MT) can also affect the measured CEST signal (Leibfritz and
Dreher 2001) (Figure 1.2). MT is a well-studied NMR phenomenon (Bryant 1996) in
which irradiation of a frequency far from the water resonance leads to transfer of
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saturated magnetization from immobilized macromolecules or exchangeable side-chain
protons to the bulk water. Unlike CEST, MT depends on both chemical exchange and
cross-relaxation (Zhou and van Zijl 2006). Since the MT and DS are largely symmetric
around the water resonance, the asymmetry analysis described above helps to mitigate the
effects of DS and MT in biological tissues (Cai, Haris et al. 2012).

Figure 1.2 The CEST effect. When the selective RF pulse is applied to solute protons at
their specific resonance, they exchange their saturated magnetization with the bulk water
protons (shown by the decreased signal height in the red line). The resultant signal is
decreased compared to that acquired with no saturation. Applying a pulse on the
symmetric side of the bulk water peak allows for calculation of the CEST asymmetry, in
order to mitigate the effects of direct saturation and magnetization-transfer (adapted from
(Zhou and van Zijl 2006)).
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In phantom experiments where the transverse relaxation time of water (T2) is long,
normalization with M0 is sufficient, as there is not usually much DS. In many biological
tissues, such as muscle, that have short water T2 (Stanisz, Odrobina et al. 2005) the CEST
experiments require high saturation pulse amplitudes, which leads to increased DS. This
is not entirely alleviated by simply normalizing with M0; rather, for in vivo experiments
we often calculate the CEST effect by normalizing with Msat(-Δω) instead (Liu, Gilad et al.
2010) (Equation 1.27).
Although this calculation is straightforward, in practical applications of CEST imaging
we must also consider the effects of B0 (static field) and B1 (applied pulse) variations
across the tissue. Due to the asymmetry analysis, any inhomogeneity in the B0 field will
introduce errors in the CEST contrast calculation. In the experiments performed for this
dissertation local B0 fields were always mapped, either with a gradient-echo image or
with a Water Saturation Shift Reference (WASSR) image (Kim, Gillen et al. 2009) and
used to correct the CEST calculation. Similarly, B1 variations will also affect the CEST
calculation and so B1 maps and B1-dependent calibration curves were used to account for
that variation in the final CEST calculations (Singh, Cai et al. 2013).
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Table 1-1 CEST equations
Equations
𝑑𝑀(%
= −∆𝜔% 𝑀.% − 𝑅0% 𝑀(% + 𝑘3% 𝑀(3 − 𝑘%3 𝑀(%
𝑑𝑡
𝑑𝑀.%
= ∆𝜔% 𝑀(% − 𝑅0% 𝑀.% + 𝑘3% 𝑀.3 − 𝑘%3 𝑀.% + 𝜔$ 𝑀4%
𝑑𝑡
𝑑𝑀4%
= −𝜔$ 𝑀.% − $% (𝑀4% − 𝑀6% ) + 𝑘3% 𝑀43 − 𝑘%3 𝑀4%
𝑑𝑡
𝑑𝑀(3
= −∆𝜔3 𝑀.3 − 𝑅03 𝑀(3 + 𝑘%3 𝑀(% − 𝑘3% 𝑀(3
𝑑𝑡
𝑑𝑀.3
= ∆𝜔3 𝑀(3 − 𝑅03 𝑀.3 + 𝑘%3 𝑀.% − 𝑘3 𝑀.3 + 𝜔$ 𝑀43
𝑑𝑡
𝑑𝑀43
= −𝜔$ 𝑀.3 − 𝑅$3 (𝑀43 − 𝑀63 ) + 𝑘%3 𝑀4% − 𝑘3% 𝑀43
𝑑𝑡

(1.1)

𝑚4% = 𝑀4% − 𝑀6%

(1.7)

𝑚43 = 𝑀43 − 𝑀63

(1.8)

𝑟$% = 𝑅$% + 𝑘%3

(1.9)

𝑟$3 = 𝑅$3 + 𝑘3%

(1.10)

𝑟0% = 𝑅0% + 𝑘%3

(1.11)

𝑟03 = 𝑅03 + 𝑘3%

(1.12)

𝑑𝑀.%
= −𝑟0% 𝑀.% + 𝑘3% 𝑀. 𝑆
𝑑𝑡
𝑑𝑀4%
= −𝑟$% 𝑚4% + 𝑘3% 𝑚43
𝑑𝑡
𝑑𝑀.3
= 𝜔$ 𝑚43 − 𝑟03 𝑀.% + 𝜔$ 𝑀63
𝑑𝑡
𝑑𝑚43
= −𝜔$ 𝑀.3 − 𝑟$3 𝑚43 + 𝑘%3 𝑚4%
𝑑𝑡
𝑘3%
𝑀63 𝜔$0
𝑆𝑆𝑚4% = −
𝑟$% (𝜔$0 + 𝑝𝑞)
𝑘3% 𝑘%3
𝑝 = 𝑟03 −
𝑟0%
𝑘3% 𝑘%3
𝑞 = 𝑟$3 −
𝑟$%

(1.13)

(1.2)
(1.3)
(1.4)
(1.5)
(1.6)

(1.14)
(1.15)
(1.16)
(1.17)
(1.18)
(1.19)
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Equations
33
−𝑚43
𝑀63
𝜔$0
𝛼= 0
𝜔$ + 𝑝𝑞
33
𝑘3% 𝑚43
𝑚4% 𝑡 =
1 − 𝑒 >?@A (B>BC )
𝑟$%

(1.20)

𝛼=

(1.21)
(1.22)

𝑟$% = 𝑅$% + 𝑘%3

(1.23)

𝑀6% − 𝑀4% (𝑡FGB )
𝑘F% 𝛼𝑀63
=
1 − 𝑒 >(H@ IJAK )BLMN
𝑀6%
(𝑅$% + 𝑘%3 )𝑀6%
𝑀FGB (>∆S) − 𝑀FGB(I∆S)
𝐶𝐸𝑆𝑇GF.Q Δ𝜔 =
𝑀6
𝛼𝑘3% 𝑀63
𝐶𝐸𝑆𝑇GF Q Δ𝜔 =
[1 − 𝑒 > H@V IJAK BLMN ]
(𝑅$T + 𝑘%3 )𝑀6%
𝑀FGB −Δ𝜔 − 𝑀FGB (+Δ𝜔)
𝐶𝐸𝑆𝑇GF.Q Δ𝜔 =
𝑀FGB (−Δ𝜔)
ω0 = γB0 (main magnetic field)
ω1 = γB1 (applied RF field)
Δω = ω-ω0
R1 = spin-lattice relaxation rate (1/T1)
R2 = spin-spin relaxation rate (1/T2)
M0 = equilibrium magnetization
kSW = exchange rate for protons from pool S to pool W
kWS = exchange rate for protons from pool W to pool S

(1.24)

𝑃𝑇𝑅 =

(1.25)
(1.26)
(1.27)

1.2.3 CEST optimization
The CEST contrast is dependent on several factors including exchange rate, saturation
pulse parameters, and relaxation times (van Zijl and Yadav 2011). Detection of the CEST
effect necessitates that the solute protons fall in the slow-intermediate exchange regime
(k ≤ Δω) where Δω is the chemical shift between water and solute protons (Ward, Aletras
et al. 2000). Faster exchange rates where k>Δω lead to coalescence, where the solute
peak cannot be resolved from the water peak. This affects the CEST measurement: when
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the saturation pulse is applied, nearby spins will also be saturated along with the targeted
solute protons.
Due to the above requirements, the strength of the static magnetic field (B0) is also an
important consideration for CEST experiments. At higher field strengths, the chemical
shift Δω between solute protons and water protons is increased. This allows for CEST
imaging of molecules with faster exchange rates to be imaged at higher fields (≥3T)
where the condition k≤ Δω is satisfied (Kogan, Hariharan et al. 2013).
Optimal saturation parameters must be determined for each individual CEST target.
While the saturation pulse needs to be strong to fully saturate the solute protons, if it is
too strong, spillover effects will contaminate the signal. When determining the optimal
parameters for specific CEST experiments, we typically titrate combinations of B1 (pulse
strength) and saturation duration (time the pulse is left on), until the maximum CEST
asymmetry can be obtained with minimal spillover effects. As we would anticipate, the
exchange rate affects the optimal saturation parameters. If the exchange rate is slow,
maximum CEST signal can be obtained by using a low power pulse, applied for a long
duration in order to reach steady state. If the exchange rate is fast, a higher pulse power
will be required to achieve sufficient saturation, and subsequently the pulse can be much
shorter in duration (Kogan, Hariharan et al. 2013).

1.2.4 CEST of endogenous metabolites
As with the other techniques described in Section 1.1, the goal for CEST imaging is to
identify “bioresponsive” agents that provide non-invasive measures of biochemical
processes in vivo. There are exogenous agents that have been developed for CEST
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imaging, such as paramagnetic CEST (PARACEST) agents that create large Δω,
permitting selective saturation of molecules with fast exchange rates (Zhang, Merritt et
al. 2003, Woessner, Zhang et al. 2005, Zhang, Malloy et al. 2005, Woods, Donald et al.
2006). PARACEST agents provide information on processes like enzymatic activity or
redox state changes, which change the properties of exchangeable protons and, by
extension, the CEST signal (Zhang, Merritt et al. 2003, Aime, Carrera et al. 2005,
Woods, Donald et al. 2006, Yoo and Pagel 2006, Pikkemaat, Wegh et al. 2007, Yoo,
Raam et al. 2007, Chauvin, Durand et al. 2008, Viswanathan, Ratnakar et al. 2009).
Although these exogenous agents are useful, like the other contrast agents described in
the introduction, they must be injected into the subject for in vivo imaging. This is
undesirable for many reasons, including invasiveness, cost, and concern with possible
organ toxicity.
The goal for this dissertation was to further identify and develop endogenous CEST
agents, primarily to avoid the complications that arise when injecting exogenous agents.
To date, several types of endogenous metabolites have been imaged using CEST. In order
to image an endogenous metabolite with CEST, it must exist at a high concentration
(mM) in addition to having the optimal exchange conditions and chemical shift as
described above. It must also contain exchangeable protons. Typically, these are amide (NH), amine (-NH2), or hydroxyl (-OH) protons (Zhou, Blakeley et al. 2008, Haris, Cai et
al. 2011, Jia, Abaza et al. 2011, Singh, Haris et al. 2012, Klomp, Dula et al. 2013, Yadav,
Xu et al. 2014). These protons on various metabolites have been imaged with CEST to
study cancer, neurological disorders, and muscle energetics.
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Amide CEST, or amide proton transfer (APT) imaging has proven useful in imaging of
tumors that contain a high concentration of mobile macromolecular protons (Zhou, Lal et
al. 2003). APT imaging provides a means of measuring changes in concentration of
cytosolic proteins due to the CEST contrast from the slow-exchanging amide protons of
peptide backbones. It also reports on the tissue pH, which is decreased in some tumor
types and in ischemic tissue. The chemical exchange rate is highly dependent on tissue
pH and so a change in the APT signal is observed when the pH is decreased (Zhou, Payen
et al. 2003, Zhou, Blakeley et al. 2008, Jia, Abaza et al. 2011). However, when both pH
and mobile macromolecular proton content changes, it is difficult to assess the individual
contributions to APT.
In our effort to further develop CEST for study of cellular metabolism, we have chosen to
focus on small metabolites. Metabolite levels are involved in cellular regulation of
metabolism (Zimmerman 2005). Although overall cellular metabolic pathways are
complex, they share common metabolites that are highly regulated to maintain proper
cellular function (Metallo and Vander Heiden 2013). In turn, local concentrations of
metabolites provide short-term regulation of enzymatic activity (Wegner, Meiser et al.
2015). The goal of our utilization of the CEST technique is to image metabolites that are
altered in a way that is reflective of disruptions in metabolism, thus providing another
tool for probing metabolic diseases.
There have been several recent publications on imaging of small metabolites from the
Reddy lab (Haris, Cai et al. 2011, Haris, Singh et al. 2013). Amine protons of glutamate
have been imaged with CEST (Cai, Haris et al. 2012, Kogan, Singh et al. 2013) (Figure
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1.3) and validated by NMR spectroscopy. With glutamate CEST (GluCEST), the
variation in glutamate between gray and white matter in healthy human brain is clearly
visible.
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Figure 1.3 GluCEST imaging and 1H MRS from a healthy human brain acquired at
7T. A) anatomic proton image of an axial slice in human brain, showing the two voxel
locations where spectroscopic data was acquired separately in the gray and white matter;
B) B1 and B0 corrected GluCEST contrast map; C) map of distribution volumes (DVs) of
metabotropic Glu receptor subtype 5 from a PET image (Reprinted by permission of the
Society of Nuclear Medicine: J Nucl Med 31, Figure 2, copyright (2007)). The GluCEST
map and the PET image show similar distribution pattern of Glu in brain, which is higher
in GM compared to WM; D) B0 map and E) B1 map corresponding to the slice in A), and
used to correct the final CEST map for field inhomogeneity; F) 1H MRS spectra obtained
from the voxels of gray matter and white matter in A). These spectra show higher
amplitude of Glu –CH2 resonance (at 2.3 ppm.) and –CH resonance (at 3.75 ppm) in gray
matter; G) saturation pulse duration dependence of GluCEST data from human brain.
H,I) z-spectra and corresponding asymmetry plots from human gray matter and white
matter regions. The GluCEST peak at 3 ppm is ~11% from gray matter and ~7% from
white matter. (Reprinted with permission (Cai, Haris et al. 2012).)
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GluCEST has also been used to study brain neurotransmitter alterations in an
Alzheimer’s disease (Alz) mouse model (Figure 1.4) (Haris, Nath et al. 2013, Crescenzi,
DeBrosse et al. 2014) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-based
model of Parkinson’s (Bagga, Crescenzi et al. 2016). We also implemented the GluCEST
technique in a longitudinal study, demonstrating the ability of the technique for
measuring changes in GluCEST within a cohort of Alz mice over time (Crescenzi,
DeBrosse et al. 2017). These studies have shown progressive loss of glutamate associated
with neurodegenerative disease due to metabolic dysfunction. This has also provided
some exciting evidence to support the concept of glutamate excitotoxicity in
neurodegenerative diseases (Bagga, Crescenzi et al. 2016). Glutamate CEST (GluCEST)
has also been used to study neuropsychiatric disorders such as epilepsy (Davis, Nanga et
al. 2015) and schizophrenia (Roalf, Nanga et al. 2017). Overall, GluCEST has promise as
a biomarker for metabolic changes, especially in neuropathologies.

Figure 1.4 4 GluCEST maps and corresponding immunohistochemistry (IHC). A–C
i) anatomical, coronal-slice images in a mouse brain corresponding to the GluCEST slice
through the mid-hippocampus. A–C ii) GluCEST maps in a wild-type and in a
progressive tauopathy model of Alzheimer’s (PS19) mice reveal lower glutamate levels
throughout the brain of tauopathy mice, which continues to decrease with disease
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severity. A–C iii) The corresponding immunohistochemistry in the same slices of postmortem brain tissue stained for hyper-phosphorylated tau (AT8) reveal varying severity
of pathological tau protein within the PS19 cohort and show progressive loss of synapses.
(Neuron staining (NeuN) and synapse staining (Syn) were both performed on the ex vivo
tissue.) This is a clear example of the utility of the CEST method: imaging correlated to a
standard technique provides more detailed insight into the biochemical pathways during
the progression of disease.

In this work, we focused on CEST imaging of the amine protons of creatine to study
oxidative phosphorylation (OXPHOS) and the hydroxyl protons of lactate to study
glycolysis, which will be the subject of the following chapters. As discussed above,
compared to classic spectroscopic methods for measuring metabolites in vivo, CEST has
much higher spatial resolution (van Zijl and Yadav 2011). This is particularly beneficial
for studying metabolic disruption, for example, in tumors that have heterogeneous tissue,
or in skeletal muscle where specific muscle fiber types may be affected.
1.3 Metabolic Dysfunction
Metabolic disease is characterized by dysfunctional energy metabolism and underlies
conditions such as obesity and hypertension, and diseases including: cancer,
neuromuscular disorders, diabetes, primary mitochondrial diseases, and cardiovascular
disease (Lin, Wu et al. 2004). Mammalian cells use both glycolytic and mitochondrial
metabolism. In healthy tissue, in the presence of oxygen, cells typically metabolize
glucose to carbon dioxide via the tricarboxylic acid (TCA) cycle in the mitochondria
(Figure 1.5).
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Figure 1.5 Summary of key metabolic pathways. Tricarboxylic acid (TCA) cycle and
the mitochondrial respiratory chain (adapted from Adeva et al.(Adeva, Gonzalez-Lucan et
al. 2013)).

The result of glucose metabolism is production of nicotinamide adenine dinucleotide
(NADH), the electron donor for OXPHOS, which ultimately generates the adenosine
triphosphate (ATP) necessary for cellular function (Alberts, Johnson et al. 2008). By this
process, ~36 molecules of ATP are produced for every molecule of glucose. If sufficient
oxygen is not available, cells will still metabolize glucose through anaerobic glycolysis,
generating lactate and producing 2 molecules of ATP for every molecule of glucose
(Adeva, Gonzalez-Lucan et al. 2013). One of the most widely studied metabolic
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alterations is the “Warburg effect” in cancer cells (Warburg 1956). Unlike the scenario
for healthy tissue, cancer tissue converts the majority of consumed glucose into lactate
even in the presence of sufficient oxygen (Warburg 1956). This is also called “aerobic
glycolysis” (Wang, Marquardt et al. 1976) and much research is still underway to
determine exactly why cancer cells preferentially use it over the pathways used by
healthy tissue. The altered metabolic state of cancer cells begs an interesting question –
why would cells undergo aerobic glycolysis when, from an energy standpoint, it is much
more efficient to produce ATP by means of oxidative phosphorylation (DeBerardinis,
Sayed et al. 2008). In proliferating cells (like cancer cells), there is a continuous supply of
glucose obtained from the bloodstream. As they continue to proliferate, although they do
require ATP for energy, cancer cells have a demand to build up necessary cellular
components, such as lipids, amino acids, fatty acids, etc., or the “biomass” of new cells
(Pizer, Wood et al. 1996, Rashid, Pizer et al. 1997). Essentially, cancer cells need to use
the glucose carbon source for anabolic processes at a higher demand than the need to
generate ATP by catabolic processes. The answer to this question – why do cancer cells
preferentially utilize aerobic glycolysis? – is complex, involving both oncogenic and
metabolic reprogramming, and far outside the scope of this thesis work, but has been
explored in many reviews (DeBerardinis, Lum et al. 2008, Hsu and Sabatini 2008,
Heiden, Cantley et al. 2009, Hanahan and Weinberg 2011, Carrer and Wellen 2015,
Hirschey, DeBerardinis et al. 2015, DeBerardinis and Chandel 2016). We will focus on
one aspect, excess production of lactate by cancer cells, which provided the motivation to
develop lactate CEST imaging and is the subject of Chapter 4.
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Altered metabolism affects many biological processes in cancer cells such as signaling,
growth suppressors, and apoptosis, and the exact metabolic changes that drive cancer cell
reprogramming are incredibly challenging to identify. Recently, it has been suggested
that study of so-called “inborn errors of metabolism” (IEM) may help to elucidate
individual aspects driving cancer cell metabolism (Erez, Shchelochkov et al. 2011). IEM
are due to genetic defects that lead to disruption of a single metabolic pathway (Dipple
and McCabe 2000, Pampols 2010). The complexities of the overall metabolic network
can begin to be simplified by identifying an IEM and observing all of the metabolic
consequences (Erez and DeBerardinis 2015). This has strong implications for cancer as
well as other metabolic diseases. We will discuss some IEM in Chapter 3 in context of
CEST imaging of creatine to study muscle metabolism.
The rest of this introductory chapter will focus on the metabolic pathways of glycolysis
and OXPHOS with emphasis on the latter, which occurs in mitochondria. Mitochondrial
structure and function can be affected in metabolic disorders. Mitochondrial processes
help regulate an array of other biological processes. In addition to cellular respiration,
they are responsible for generation of reactive oxygen species (ROS), maintaining redox
status, and calcium homeostasis (Venditti, Di Stefano et al. 2013). Therefore,
mitochondrial function is indicative of health of individual cells, as well as whole-body
metabolic state. In recent decades our understanding of the mitochondrion has evolved
from the basic description (“mitochondria make ATP for energy”) as we’ve realized the
complex and ubiquitous role it seems to play in almost every medical discipline (Picard,
Wallace et al. 2016). Mitochondrial dysfunction is observed in cancer, in skeletal muscle
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in type 2 diabetes, and in cardiovascular disease (Wallace 1989, Wallace 1992, Mecocci,
Macgarvey et al. 1993, Ballinger, Shoffner et al. 1994, Wallace 2005), which necessitates
the study of mitochondrial function noninvasively and in vivo.
In Chapter 2, we will describe how the CEST technique has been applied to observe
mitochondrial function in healthy skeletal muscle. As the importance of the mitochondria
in many disease states has become increasingly evident across multiple disciplines, the
past few decades have seen an enormous amount of literature about mitochondrial DNA
(mtDNA) mutations. In the 1980s, it was discovered that mtDNA, inherited maternally,
could be the culprit in human disease due to point mutations or deletions(Giles, Blanc et
al. 1980, Wallace 1992). Although a complete description of mtDNA defects is not the
focus of this work, the effects are far-reaching into neurology, endocrinology, oncology,
immunology, etc. Chapter 3 of this dissertation will discuss a small, heterogeneous group
of mitochondrial impairments and our application of CEST for assessing impaired
mitochondrial function in skeletal muscle. The next section summarizes the function of
the mitochondrion and the process of OXPHOS.
1.4 Mitochondria and Oxidative Phosphorylation
The mitochondrion was essential for the evolution of present-day eukaryotic cells (Gray,
Burger et al. 1999) by providing a method for metabolism of sugars in order to produce
energy. Mitochondria are large (0.5-1µm) organelles within the cytoplasmic space of
cells (Alberts, Johnson et al. 2008), and have a wide range of functions, depending on the
cell type requirement. Different cell types also contain specific numbers of mitochondria,
depending on their particular energy demands (Szewczyk and Wojtczak 2002). Tissues
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that are very metabolically active, such as brain, liver, cardiac, and skeletal muscle,
contain the highest number of mitochondria. Although this work will primarily focus on
their function in skeletal muscle, mitochondria are also the center of ion homeostasis and
other biochemical pathways (Pagliarini, Calvo et al. 2008). In the 1950s, Britton Chance
and others (Lardy and Wellman 1952, Low, Siekevitz et al. 1958, Mitchell and Moyle
1967) identified and described the mitochondrial respiratory chain and the process of
OXPHOS, by which mitochondria generate ~80-90% of their ATP (Chance and Williams
1956). Mitochondria use the products of the TCA cycle and fats derived from diet to
produce ATP and heat. OXPHOS measurement in human mitochondria using CEST will
be the focus of the next two chapters.

1.4.1 Mitochondrial structure
The structure of the mitochondrion contains two membranes, outer and inner, that
perform two distinct functions (Alberts, Johnson et al. 2008). These membranes create
two compartments within the mitochondrion: the matrix, and the intermembrane space.
The outer membrane is permeable to molecules and small proteins that are < 5000
daltons. This permeability is due to the transport proteins, called porins, which form
channels through the lipid bilayer. Molecules that pass through the outer membrane can
enter the intermembrane space, but the inner membrane prevents them from entering into
the matrix. The matrix contains the “major working part” of the mitochondria, which
means that only highly specific molecules are permitted to pass through the inner
membrane. The inner membrane is highly selective due to its unique lipid bilayer, which
is made up of cardiolipin (a double phospholipid) that contains four fatty acids. Because
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the matrix is where key metabolic processes take place, it contains many mitochondrial
enzymes that require specific small molecules for metabolism. The inner membrane
allows those small molecules to enter the matrix through specialized transport proteins.
Some of the most important processes that occur in the matrix are metabolism of
pyruvate and fatty acids, producing acetyl coenzyme-A (CoA), which is then oxidized in
the TCA cycle. When acetyl CoA is oxidized, carbon dioxide (CO2) is produced and
leaves the cell as a waste product. More importantly, this oxidation of CoA is the first
step in generating the high-energy electrons that enter the electron-transport chain, which
is referred to in mitochondria as the respiratory chain. These products of the TCA cycle,
NADH and flavin adenine dinucleotide (FADH2), carry the high-energy electrons to the
inner membrane where they enter the respiratory chain (Alberts, Johnson et al. 2008).
The respiratory chain is composed of enzymes that facilitate the process of OXPHOS,
which generates most of the ATP required by the cell.

1.4.2 Respiratory chain components
The respiratory chain (RC) is composed of five key enzyme complexes (I-V) that are
imbedded within the inner membrane (Hatefi 1985). Electrons are donated from NADH
and FADH2 and flow through the complexes. As mentioned previously, NADH is
generated in the matrix and electron transport in the respiratory chain begins with
reoxidizing NADH by removing a hydride ion (2 electrons) to regenerate NAD+
(Equation 1.28).
These two electrons are passed to the first of many electron carriers in the RC. They start
with very high energy, which is gradually lost as the electrons are passed along the chain
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(Alberts, Johnson et al. 2008). Essentially, the electrons pass along metal ions bound to
proteins, altering the electron affinity of the metal ions. The proteins are grouped into the
RC enzyme complexes that are held in the inner mitochondrial membrane by
transmembrane proteins. The complexes have increasing levels of affinity for electrons,
which are passed along each complex until they are transferred to oxygen, which has the
highest affinity. This complicated process of electron transfer exists in cells in order to
avoid the huge free-energy drop of simply transferring the electrons from NADH directly
to molecular oxygen (O2), in which the majority of the energy would be released as heat
(Alberts, Johnson et al. 2008). Instead, cells manage to store approximately half of the
energy that is released by utilizing the electron transport chain (ETC).
It is important to briefly define some of the other proteins and enzymes that are involved
in the RC. Flavoproteins are a polypeptide that contains a flavin adenosine dinucleotide
(FAD) or a flavin mononucleotide (FMN) prosthetic group. Flavoproteins can accept or
donate electrons as pairs (Equation 1.29-1.30) (Karp 2008). Cytochromes are proteins
that contain bound heme groups and only facilitate one-electron transfers. They
accomplish this by changing the oxidation state of their iron atom from Fe3+ to Fe2+ when
accepting an electron (Karp 2008). There are other iron-sulfur proteins that can carry
electrons, and like cytochrome, participate in one-electron transfer. Usually, these contain
either two or four iron atoms bound to an equal number of sulfur atoms and to cysteine
side-chains. Another important component is Coenzyme Q (CoQ), quinone (Q), or
ubiquinone (uq), which is is a small, soluble electron carrier within the lipid bilayer of the
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inner membrane (Equation 1.31). Bound to these respiratory chain proteins are flavins,
and two copper atoms that also carry electrons.
Table 1-2 Electron transfer in mitochondria
Equations
𝐻> → 𝐻I + 2𝑒 >
𝐹𝐴𝐷 + 2𝑒 > + 2𝐻I → 𝐹𝐴𝐷𝐻0
𝐹𝑀𝑁 + 2𝑒 > + 2𝐻I → 𝐹𝑀𝑁𝐻0
𝑄 + 2𝑒 > + 2𝐻I → 𝑄𝐻0
2𝑂0> ∙ +2𝐻I → 𝐻0 𝑂0 + 𝑂0
𝐻0 𝑂0 + 𝐹𝑒 0I → 𝐹𝑒 bI + 𝑂𝐻 ∙ +𝑂𝐻>

(1.28)
(1.29)
(1.30)
(1.31)
(1.32)
(1.33)

The individual complexes contain several electron carriers (Table 1-3) (Karp 2008).
1. Complex I, known as NADH dehydrogenase (or NADH-coenzyme Q reductase)
is the largest complex, containing over 45 polypeptides (Guenebaut, Schlitt et al.
1998). It accepts two electrons from NADH, making it the first link between the
products of the TCA cycle / fatty acid oxidation and the respiratory chain. Within
Complex I, electrons flow from: NADHà FMNà iron-sulfur centersà
ubiquinoneà cytochrome bc1 complex. The end result is the net transport of
protons from the matrix to the intermembrane space, generating a proton-motive
force (Grivennikova, Kapustin et al. 2001).
2. Complex II, known as succinate dehydrogenase (or succinate-coenzyme Q
reductase) (SDH) provides another direct link to the TCA cycle, as it is the only
enzyme of the TCA cycle that is also an integral membrane protein. Here,
succinate binds and a hydride is transferred to FAD, resulting in electron transfer
to iron-sulfur centers before a final transfer to 2 electrons to CoQ: succinate +
CoQ à Fumarate + CoQH2. Unlike complex 1, there is no proton-motive force
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generated due to the small free energy of the reaction, and only ~1.5ATP are
generated per FADH2, contrasted with the 2.5ATP per NADH (Cecchini 2003).
3. Complex III, or coenzyme Q reductase, transfers electrons from CoQH2
generated either by Complex I or Complex II to reduce cytochrome c. Complex
III functions as a dimer and utilizes a pathway known as the Q-cycle. Briefly,
CoQH2 binds to the Q site, and then one electron is transferred to an iron-sulfur
protein, and then to cytochrome c1. This allows 2 protons to be released into the
intermembrane space. The second electron is transferred to a heme, generating
CoQ, which can diffuse from the Q site. This process occurs twice within to
complete a Q-cycle, with a net result of two electrons transported to cytochrome
c1, and finally to cytochrome c (Karp 2008).
4. Complex IV, or cytochrome c reductase, transfers electrons, one at a time, from
cytochrome c, which are passed (four at a time) to reduce molecular oxygen into
water. This is a key point: that the cell can use O2 for respiration because this
complex holds onto molecular oxygen at a special bimetallic center until it picks
up four electrons, and can be safely released while avoiding the generation of
superoxide radicals (𝑂0> ∙). This reaction accounts for ~90% of total oxygen
uptake in most cells, and is vital for aerobic respiration (Alberts, Johnson et al.
2008).
5. Complex V or ATP synthase is composed of two principle sectors, F1 and F0. It
has a ring of six subunits that project out onto the matrix side of the inner
membrane. This ring is held in place by an “arm” that connects it to a group of
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transmembrane proteins that form a “stator” within the membrane. This piece is in
contact with the “rotor”—a ring of 10-14 transmembrane protein subunits
(Abrahams, Leslie et al. 1994).

Table 1-3 Properties of the components of the mitochondrial respiratory chain
Complex

Mass (kD)

# subunits

Substrate binding
site sides

Electron
carriers

I

850

46

NADH (matrix)
CoQ (lipid)

FMN
Iron-sulfur

II

140

4

Succinate (matrix)
CoQ (lipid)

FAD
Iron-sulfur

III

248

11

IV

162

13

Cytochrome c

13

1

Cyt c
(intermembrane)
CoQ (lipid)
O2 (matrix)
Cyt c
(intermembrane)
Cyt c1,a

Iron-sulfur
Heme
Heme
Copper
Heme

1.4.3 Oxidative phosphorylation
As a result of the flow of electrons through the complexes, which is energetically
favorable, protons are pumped out of the inner membrane through complexes I, III, and
IV (Karp 2008). Overall, protons are pumped from the matrix, across the inner
membrane, into the intermembrane space. This generates both a pH gradient (ΔpH) and a
voltage gradient (membrane potential, ΔV), across the inner membrane, known as the
electrochemical proton gradient (ΔP= ΔV+ ΔpH). In the matrix, then, the pH is higher
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(>7) in the matrix than in the cytosol. The voltage gradient creates a negative “inside”
and positive “outside”. The pH gradient drives protons back into the matrix, which in turn
reinforces the effect of the membrane potential. The membrane potential attracts positive
ions into the matrix and pushes negative ions out. This proton-motive force is measured
in units of millivolt (mV). An average proton-motive force of mitochondria undergoing
respiration is approximately 190mV across the inner membrane (Alberts, Johnson et al.
2008).
The electrochemical proton gradient drives ATP synthesis during the process of oxidative
phosphorylation. ATP synthase, which is bound to the membrane, creates a hydrophilic
pathway across the inner membrane. In turn, protons flow down the electrochemical
gradient (Mitchell 1991). This is how cells are able to achieve the energetically
unfavorable reaction of adenosine disphosphate (ADP) + inorganic phosphate (Pi) to
produce ATP. In the ATP synthase, there is a narrow channel between the stator and the
rotor. When protons pass through this channel their own movement causes the rotor ring
to spin. When the rotor spins it moves the attached stalk. This mechanical energy of the
rotating stalk proteins moving against the rigid head of the ring proteins is generated by
the flow of protons. In the ring, three of the six subunits contain binding sites for both
ADP and inorganic phosphate. The ultimate production of ATP occurs thanks to the
chemical bond energy derived from the mechanical energy of the conformational protein
changes that are caused by the rotating stalk. ADP and Pi are bound, condensed, and then
released as ATP (Mitchell and Moyle 1965). ATP synthase is capable of producing 100
molecules of ATP per second, generating 3 molecules of ATP per revolution. ATP is then
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exchanged from the matrix in return for cytosolic ADP by the adenine nucleotide
translocator (Wang, Rennert et al. 2008).
ATP produced by OXPHOS in the matrix is rapidly pumped out into the cytosol. ATP
and ADP are constantly exchanged through a carrier protein in the inner membrane.
When ATP is hydrolyzed in the cytosol, the resulting ADP is quickly exchanged back
into the matrix for generation of more ATP. Cells maintain, in general, a ratio of
ATP:ADP of 10:1. Cells also make use of the hydrolysis of ATP, which is energetically
favorable, to drive other, unfavorable reactions by coupling them to that process. After
subtracting the energy required to release ATP into the cytosol, the result of OXPHOS is
that for every pair of electrons donated by NADH, enough energy is produced to form 2.5
molecules of ATP. Additionally, for every molecule of FADH2, OXPHOS can produce
1.5 molecules of ATP. In total, when considering the combined energy production from
both glycolysis and the TCA cycle, for one molecule of glucose approximately 30
molecules of ATP are generated during OXPHOS. The efficiency of OXPHOS to turn
substrates from diet into ATP is called coupling efficiency. This term encapsulates the
efficiency of: 1) the ability of Complexes I, III, and IV to pump protons out of the matrix,
2) generating ATP via the proton flux through Complex V, and 3) any other proton flow
through the inner membrane. When there are variations in mitochondrial proteins, the
coupling efficiency is affected, meaning that the proportion of calories used by
mitochondria for ATP generation (vs. heat production and other processes) is altered.
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1.4.4 Respiratory states
In mitochondria literature, there are often references to the “respiratory states” that were
first described by Chance and Williams in 1955 (Chance and Williams 1955). These
states are defined based on an in vitro experiment in which mitochondria were added into
a phosphate-containing medium, which causes slow respiration or a “substrate starvation”
condition (State I). When ADP is then added, respiration starts to increase slowly and the
“substrate starvation” is exacerbated by the increased ATP demand (State II). If
substrates (pyruvate, etc.) are added, then respiration increases rapidly to a high rate
(State III) and then decreases to a slower rate as the added ADP is converted into ATP
(State IV). Respiration continues until oxygen is exhausted, causing an anoxic state (State
V). In vivo, we typically refer to mitochondria in States III and IV. These are summarized
in Table 1-4.
Table 1-4 Summary of respiration states
State
I
II
III
IV
V

Respiration
rate
Slow
Slow
Fast
Slow
--

Substrate
levels
Low
Low
High
High
High

ADP levels
Low
High
High
Low
High

Oxygen
present?
Yes
Yes
Yes
Yes
No

The important takeaway from this discussion of respiration states is: mitochondrial
oxygen consumption is regulated by the matrix concentration of ADP. If there’s no ADP,
then the consumption of oxygen is regulated by proton leakage across the inner
membrane, which is a slow process (State IV respiration). When ADP is present it binds
to the ATP synthase and is rapidly converted into ATP, which requires the use of the
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electrochemical gradient. Thus, when protons flow through the ATP synthase proton
channel the gradient becomes depolarized. When this occurs, stored fats or carbohydrates
are then utilized to provide the needed electrons to the ETC in order to pump the protons
back out of the matrix in order to maintain OXPHOS.

1.4.5 Reactive oxygen species (ROS) and mitochondrial damage
In the process of generating ATP needed for cellular function OXPHOS creates byproducts, including reactive oxygen species (ROS) (Chance, Sies et al. 1979). ROS are
consistently generated in the cell during the process of electron transport, but are
typically kept at a steady-state concentration (Cadenas and Davies 2000). Trouble arises
for the cell when there is an excess production of ROS (Venditti, Di Stefano et al. 2013).
Increased numbers of ROS can cause free-radical chain reactions, in turn causing damage
to vital cell components including proteins, lipids, and polysaccharides. Furthermore,
ROS can cause damage to mtDNA and nDNA, ultimately disrupting mitochondrial
function and causing oxidative stress (Lenaz 1998).
Reactive oxygen species are derived from molecular oxygen (O2) (Inoue, Sato et al.
2003). Oxygen plays a dual role: on one hand, it is essential for aerobic respiration, and
on the other, it acts as a toxin (Gerschman, Gilbert et al. 1954) and is also the precursor to
dangerous ROS. Molecular oxygen itself, a vital part of the electron-transport process, is
not very reactive when in its electronic ground state. In the electronic ground state, it is
bi-radical, which means it contains two unpaired electrons in the outer shell and is a
“triplet”. Because those two electrons have the same spin, O2 can only react with one
electron at a time. When it is in contact with two electrons in a chemical bond then it is
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not prone to reaction. However, if one of its two electrons changes spin and becomes
excited, the resultant “singlet” oxygen is highly reactive, since two electrons with
opposite spins can react with other pairs of electrons, like those found in chemical bonds
(Turrens 2003).
Approximately 90% of consumed oxygen ends up reduced to water by cytochrome
oxidase as described previously. However, one-electron reduction of O2 can occur,
creating superoxide anion 𝑂0> ∙. Formation of 𝑂0> ∙ can happen both enzymatically and
non-enzymatically. Examples of enzymatic sources include NADPH oxidases which are
located on the cell membrane (Babior 2000). More relevant to this discussion, nonenzymatic production of 𝑂0> ∙ is the result of processes along the electron transport chain
in mitochondria. ROS that are produced by mitochondria are often generated when
electron carriers in the first steps of electron transport remain reduced, meaning that they
have more electrons than they should. This happens if OXPHOS is inhibited, or if there is
an excessive supply of substrates – such as when too many are derived from dietary
calories.
Superoxide anion itself is a relatively stable intermediate, but is the precursor to ROS
generated during a process called dismutation, often catalyzed by enzymes called
superoxide dismutases (SOD) (McCord and Fridovic.I 1969) (McCord, Keele et al.
1971). 𝑂0> ∙ can be converted into H2O2 and oxygen (Fridovich 1995) (Equation 1.32).
The role of the SOD enzymes is to maintain the rate of dismuatation so that the levels of
𝑂0> ∙are kept low at steady-state (Muller, Liu et al. 2004). 𝑂0> ∙ can be converted to H2O2
by a specific mitochondrial matrix enzyme, Mn superoxide dismutase (MNSOD) (Sod2)
36

or by Cu/ZnSOD (Sod1) within the mitochondrial intermembrane space. H2O2 ideally
diffuses out of the mitochondria and is converted into water.
The rate at which 𝑂0> ∙ is produced by the respiratory chain increases if electron flow is
reduced (Turrens, Freeman et al. 1982), which can happen in the absence of ADP.
Without ADP, the proton gradient “builds up”, causing the respiratory chain to become
more reduced (State IV respiration). This ultimately leads to an increase in oxygen
concentration (Boveris, Chance et al. 1972) .
If there is a subsequent increased steady-state concentration of 𝑂0> ∙, enough H2O2 can be
generated that it reacts with reduced transition metals, creating hydroxyl radicals (𝑂𝐻> ∙)
(Boveris and Chance 1973) (Equation 1.33), which are strong oxidants that are quite
reactive and can disrupt the function of proteins, thus interfering with the function of the
mitochondria. This reaction is catalyzed by the transition metals, which can start a chain
reaction as they can be reduced again by 𝑂0> ∙. Because there are so many iron-sulfur
centers in the mitochondrial enzymes, they are especially vulnerable.
The in vivo location of superoxide generation is difficult to fully pinpoint due to the
complexity of the enzyme structures. Several of the redox centers can “leak” electrons to
oxygen (Duchen 2004), for example during electron transfer to oxygen by reduced
coenzymes, flavins, or iron-sulfur complexes (Andreyev, Kushnareva et al. 2005).
Complex I can produce superoxide from reduced flavin of FMN in the presence of highly
reduced NAD. It can also produce superoxide during reverse electron transport, when
NAD+ is being reduced (Abramov, Scorziello et al. 2007). A two-site (FMN and
ubisemiquinone) model was proposed to account for the high rate of production of
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superoxides during both forward and reverse electron transport (Treberg, Quinlan et al.
2011). At Complex I, II, and III, the unpaired electron of ubisemiquinone can be donated
to molecular oxygen to create superoxide anions (Lambert and Brand 2004).
Although there are many opportunities for mitochondria to produce ROS, they also
possess antioxidant defense systems. These primarily aim to prevent the production of
𝑂𝐻> ∙ while continuously repairing damage. A concise review of these methods is
available in (Venditti, Di Stefano et al. 2013). As mentioned, once there is an imbalance
of ROS that cells are no longer able to mitigate, oxidative stress develops (Sies 1997).
The ability of mitochondria to remove ROS is dependent on several complicated factors.
Different tissue types contain varying numbers of mitochondria. Higher cellular
mitochondria levels may indicate higher production of ROS, but as mitochondria
themselves are capable of preventing and repairing ROS damage, higher number of
mitochondria can also protect against cellular stress (Droge 2002).
The production of ROS can eventually damage many mitochondrial components leading
to disruption of mitochondrial function. As OXPHOS is so vital to cellular respiration,
when mitochondria are damaged or impaired there can be severe consequences.
Mitochondrial myopathy was first observed in the 1960s and described as a “defect of the
biochemical function of mitochondria” in skeletal muscle of a patient with “severe
hypermetabolism of unknown origin” (Luft, Ikkos et al. 1962). Over the past few
decades, it has become more and more evident that mitochondrial defects are present in
disease states ranging from diabetes to cancer to neurodegenerative diseases (Wallace
1999).
38

1.5 Glycolysis
While Chapters 2 and 3 will focus on CEST in the context of OXPHOS, in Chapter 4 we
will discuss a novel CEST biomarker for monitoring glycolysis in vivo. Glycolysis,
unlike OXPHOS, produces ATP without molecular oxygen. Through glycolysis, which
occurs in the cytoplasm, cells oxidize glucose by converting each molecule of glucose (6
carbons) into two molecules of pyruvate (3 carbons each) (Figure 1.5). Two molecules of
ATP are required for this process, which eventually produces four molecules of ATP, for
a net gain of 2 ATP per molecule of glucose. Briefly, glycolysis contains ten reactions
that are catalyzed by individual enzymes to produce intermediate sugar molecules
(Alberts, Johnson et al. 2008). Oxidation of those sugar molecules, which involves
removal of electrons by NAD+, occurs in these small steps so that as much energy as
possible can be stored in the carrier molecules, NADH. Two molecules of NADH are
produced through glycolysis for every molecule of glucose and they donate their
electrons to the electron transport chain described in the previous sections. For most
mammalian cells, glycolysis is the initial step in the breakdown of fuel (glucose), and the
pyruvate produced enters the TCA cycle in the mitochondrial matrix to be converted into
acetyl CoA and CO2, as described in the previous sections. In certain tissues, when
conditions are anaerobic, instead of moving into the mitochondria and used for
OXPHOS, the pyruvate and NADH remain in the cytosol. In skeletal muscle, for
example, the pyruvate is converted into lactate and NAD+ is regenerated for additional
glycolysis.
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The glucose used in glycolysis is obtained through diet; mammals have developed a
means of storing fatty acids and sugar for periods of fasting. Sugar is stored as a large
polysaccharide, glycogen, which is made up of glucose subunits. This provides shortterm storage, so when cells need more ATP than they can generate from available food
molecules they can break down glycogen to produce glucose for glycolysis. Glycogen is
found in liver and muscle cell cytoplasm. Glycogen does not provide as efficient a means
of storage as fat, which releases twice as much energy upon oxidation (Alberts, Johnson
et al. 2008). We will discuss lactate production in tumor cells with altered glycolysis, and
in skeletal muscle under anaerobic conditions in Chapter 4.
1.6 Summary
Within the constantly developing field of molecular imaging, researchers are always
looking for new ways to study biochemical processes in vivo. This dissertation explores a
new MRI technique, CEST, and its applications to study metabolism noninvasively. In
Chapter 2 we will focus on skeletal muscle metabolism and the current ways it is studied
in vivo and then describe the development of the CEST technique for skeletal muscle
applications. Tissues that have large energy demands, such as cardiac, renal, and skeletal
muscle are especially compromised by metabolic dysfunction. We have targeted
mitochondrial function and developed the CEST technique in order to identify OXPHOS
impairment in vivo. Within the last 20 years, it became possible to study the genetics of
metabolic diseases in a much more robust way, which have been linked to diseases
ranging from cancer to mitochondrial myopathy. The clinical study that is the subject of
Chapter 3 will discuss several specific genetic mutations that result in defects in
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OXPHOS. We will demonstrate the ability of CEST to identify impaired mitochondrial
function in vivo. Finally, in Chapter 4 we will discuss the development of the CEST
technique for measuring lactate in vivo, and its relevance to metabolic disorders.
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Chapter 2 - Development of Creatine Chemical Exchange Saturation Transfer
(CrCEST)
2.1 Introduction
Mitochondrial bioenergetics have been studied extensively with in vitro methods in an
attempt to understand overall mitochondrial function. Techniques such as fluorescence
imaging have provided much information about mitochondrial function in cells and are
especially useful for studying mitochondria in different cell types. This method of
studying mitochondrial function extends back to the 1960s and 70s, when Britton Chance
showed that mitochondrial metabolism could be identified through fluorescence arising
from NADH and flavoproteins, which provides information about the redox states and
respiratory capabilities of individual cells (Scholz, Thurman et al. 1969, Chance,
Schoener et al. 1979). While much of what we know about mitochondrial function has
come from such studies, we would prefer to observe mitochondria in vivo without
disrupting the native environment. Ideally, noninvasive in vivo measurements of
mitochondrial function would provide enhanced information about biochemical processes
in entire systems, especially those disrupted by pathophysiological conditions (Duchen
2004). Mitochondrial function is an ideal target for molecular imaging techniques as
discussed in the introduction of Chapter 1. In the 1980s it was suggested that nuclear
magnetic resonance (NMR) spectroscopy could be used to study oxidative metabolism in
intact muscle tissue. This chapter will review the current spectroscopic techniques used to
monitor mitochondrial function and then discuss the initial motivation and work to
develop creatine CEST (CrCEST) technology and apply CrCEST imaging in healthy
human skeletal muscle.
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2.1.1 Skeletal muscle metabolism
CEST imaging for study of in vivo metabolism, which will be the focus of the rest of this
chapter and Chapter 3, was validated in healthy human skeletal muscle. In this section,
we will briefly review some relevant muscle structure and function. Skeletal muscle
makes up ~40% of total human body weight and contains ~75% of all body proteins
(Frontera and Ochala 2015). It is a significant contributor to many metabolic functions; in
addition to maintaining basal energy metabolism, it stores amino acids and carbohydrates
that are substrates for other metabolic processes and protein synthesis. It helps maintain
body temperature by producing heat and participates in blood glucose regulation. Skeletal
muscle is comprised of highly-ordered muscle cells called fibers, which are generally
~100um in diameter and ~1 cm in length. Individual fibers are surrounded by a
membrane called the sarcolemma. Muscle fibers are arranged in groups and surrounded
by a layer of connective tissue. Individual muscle fibers are mostly composed of protein.
The nucleus of muscle fibers controls protein synthesis in particular cellular regions
(Alberts, Johnson et al. 2008) (Wolfe 2006). Several proteins, including actin, form a
complex that is associated with the sarcolemma and physically connected to the internal
proteins or myofilaments. Each fiber is comprised of thousands of myofibrils and
millions of myofilaments that form sarcomeres. Sarcomeres are the fundamental
contractile units of skeletal muscle. Two important myofilaments are myosin and actin,
which make up ~80% of the total fiber protein content (Alberts, Johnson et al. 2008).
Myosin is the main molecular motor driving muscle contraction and movement. Muscle
fibers are generally classified according to color, red or white, which corresponds to
myoglobin content. Myoglobin is a protein that binds iron and carries oxygen to muscle
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tissue. Muscle fibers are also distinguished by type of metabolic pathways they utilize:
glycolytic vs. oxidative (Schiaffino and Reggiani 2011). Muscle oxidative capacity is
correlated with the mitochondrial content. Overall classification is into one of three
muscle fiber types (Zierath and Hawley 2004):
1. type I: slow, oxidative, fatigue-resistant
2. type IIA: fast, oxidative, intermediate metabolic properties
3. type IIb or IIx: fastest, glycolytic, fatigable
Muscles produce adenosine triphosphate (ATP) by using glucose, glycogen, fatty acids,
or triglycerides through the biochemical pathways of mitochondria discussed in Chapter
1. Utilization depends on the intensity and duration of exercise (Liu, Mac Gabhann et al.
2012). Exercise that is performed at sustainable durations is supported by ATP produced
by mitochondrial oxidative phosphorylation. Glycolysis produces ATP rapidly during
intense exercise but quickly leads to fatigue and generation of lactate, which will be
discussed in more detail in Chapter 4.
Skeletal muscle is very heterogeneous in terms of mechanical, biochemical, and
metabolic properties. Muscles contain different compositions of muscle fiber types. This
is one of the key motivations for developing an imaging technique that has high spatial
resolution capabilities: to provide a more complete view of metabolism across entire
large muscle regions.
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2.1.2 The creatine-kinase reaction
To provide some context for the use of spectroscopy to study mitochondrial metabolism,
first we will examine the creatine-kinase reaction, which utilizes high-energy phosphates
that are detectable by MRS. During resting-state conditions, cells produce the majority of
their ATP through OXPHOS in the mitochondria. Some tissues, such as cardiac and
skeletal muscle, brain, retina, etc., have a very high, rapidly changing demand for ATP
(Wallimann, Wyss et al. 1992). What happens when there’s a sudden increase in cellular
ATP demand, such as during exercise? Cells can’t simply increase the intracellular
concentration of ATP, because there are many metabolic processes that are tightly
regulated by local concentrations of ATP, as well as the overall ratio of ATP/ADP. If
cells generated high levels of ATP in response to increased energy demands, many other
metabolic processes would be disturbed. Typically, resting cells have a low ATP
concentration of ~5mM, maintained by OXPHOS (Infante and Davies 1965). Instead, to
accommodate fluctuating energy demands, tissues contain an enzyme called creatinekinase (CK) that provides a shuttle system for storage of high-energy phosphate in the
form of phosphocreatine (PCr). There are isoforms of CK specific to cytosolic muscle or
brain tissue, and two mitochondrial-associated isoforms (Mi-CK): ubiquitous and
sarcomeric. Those isoforms are located in the mitochondrial intermembrane space and are
compartmentalized at the locations where energy is either produced or consumed (Wyss,
Smeitink et al. 1992). The function of the CK enzymes is to catalyze the reversible
transfer of the γ–phosphate group of ATP to the guanidino group of creatine (Cr),
generating ADP and PCr.
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𝐶𝑟 + 𝐴𝑇𝑃

cd

𝐴𝐷𝑃 + 𝑃𝐶𝑟 + 𝐻I

(Equation 2.1)
During the CK reaction, ATP is produced from the conversion of phosphocreatine and
ADP to Cr (Cain and Davies 1962). Creatine is synthesized in the liver and then
transported to muscle and other tissues through the bloodstream. ATP is synthesized in
the mitochondrial matrix, and the γ–phosphate group is transferred to creatine by the
mitochondrial CK isoform in the intermembrane space to generate ADP and PCr. ADP
that is generated by the CK reaction is transported into the matrix to be re-phosphorylated
into ATP. When cells undergo processes that require an increase in energy, like muscle
contraction, PCr is depleted to maintain the available supply of ATP, while keeping the
ATP concentration constant. This mechanism allows cells access to an immediate energy
supply, without requiring storage of large amounts of ATP (Wallimann, Wyss et al.
1992). PCr diffuses out of the mitochondria into the cytosol to places where it is required
to facilitate ATP consumption. Once the instantaneous energy demand is reduced,
generation of ATP through OXPHOS leads to a subsequent increase in PCr production to
restore it to its previous concentration. The “liberated” or “free” creatine diffuses back
into the mitochondria.
There are differences in high-energy phosphate requirement for various tissue types. In
fast-twitch skeletal muscle that performs short bouts of intense exercise, there is a large
pool of PCr (~25mM). This form of energy demand causes high activity of cytosolic CK,
and the overall reaction is near-equilibrium, with the concentrations of ATP and ADP
kept constant over the activity period. This allows skeletal muscle cells to buffer the
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phosphorylation potential needed for ATPases to function. Other tissue types, like cardiac
or slow-twitch muscle, have different energy demands. They require a more continuous
supply of high-energy phosphates to perform biochemical reactions that constantly
require ATP. In those tissues, like brain and smooth muscle, the CK shuttle acts more like
a transport system for PCr, which is present at ~10mM. This is a general explanation of
the buffer/transport models of CK enzymatic function, however, there is evidence that the
CK system can adapt to new physiological requirements, such as the effects of endurance
training in skeletal muscle, and “switch” the function of the CK system, e.g., from buffer
to transport (Saks, VenturaClapier et al. 1996).
From the above discussion, it’s clear that small metabolites like creatine and
phosphocreatine play a vital role in bioenergetics. Unlike ATP and ADP, creatine and
PCr can exist at high cellular concentrations without disrupting other biochemical
processes. Cells that contain CK systems are capable of high intracellular flux of
phosphates, and are also able to buffer the cytosolic phosphorylation potential at a higher
level than other cell types. This indicates that cells that utilize the CK system depend on
it for proper function of other enzymatic processes. In muscular diseases and metabolic
disorders, creatine kinase kinetics are often affected (Bottomley, Lee et al. 1997).
How does the CK system report on mitochondrial function? After a period of increased
energy demand, like exercise, PCr is temporarily depleted. The rate of “recovery” of PCr,
or the return to baseline concentrations, is reflective of the oxidative phosphorylation
capacity of the mitochondria. In other words, the rate at which PCr recovers is correlated
to the return of the cells to resting-state oxidative phosphorylation by mitochondria. A
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delayed recovery of PCr has shown to be associated with metabolic disorders where
mitochondrial function is compromised. Luckily, it was discovered that PCr, along with
inorganic phosphate, and the three phosphate groups of ATP, are visible by a specific
type of NMR to look at phosphorus resonances,
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Phosphorus magnetic resonance

spectroscopy (31P MRS).
2.1.3 31Phosphorus MRS
Metabolism of exercising muscle and myocardium has been studied extensively through
non-invasive magnetic resonance (MR) techniques. While 1H MRS methods can be used
to measure total creatine (PCr+Cr), they cannot be used to differentiate PCr from Cr and
thus have had limited application towards muscle energetics. The most commonly used
technique has been
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P MRS (Gorenstein 1984). For many decades, it has been the

standard technique for the study of phosphorus compounds in vivo (Chance and Bank
1995, Lee, Komoroski et al. 2012). It is an extremely useful tool due to particular
properties of phosphorus: its natural abundance (100%), spin (1/2), and large range of
chemical shifts (Hoult, Busby et al. 1974, Gorenstein 1984). Inorganic compounds had
been studied using
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P MRS since the early 1950s (Dickinson 1951, Cohn and Hughes

1962), and during the 1970s it was applied to the study of biological phosphorus
compounds (Burt, Glonek et al. 1977). Since then, it has been an invaluable technique for
the study of muscle metabolism. In muscle tissue,

31

P MRS can noninvasively measure

the phosphate components of the creatine-kinase (CK) reaction (Kemp, Meyerspeer et al.
2007). Concentrations of these metabolites (PCr, ATP, inorganic phosphates (Pi),
phosphomonoesters (PME), and phosphodiesters (PDE)) can be obtained from
48

31

P

spectra. Additionally, changes in intracellular pH can be estimated by changes in
chemical shift of the inorganic phosphate (Pi) peak (Moon and Richards 1973,
Thompson, Kemp et al. 1995).
As mentioned in Section 2.1.2, during exercise of healthy muscle tissue, the CK reaction
maintains a constant concentration of ATP by conversion of PCr to Cr. 31P MRS spectra
of exercising skeletal muscle shows the depletion of PCr and any changes in intracellular
pH (Burt, Glonek et al. 1976). It can be applied during dynamic exercise studies to
monitor the PCr depletion and follow the recovery after cessation of exercise (Figure
2.1). Conditions of muscle fatigue (Dawson, Gadian et al. 1978, Bendahan, Giannesini et
al. 2004) or muscle injury can be studied by 31P MRS. Muscle related disorders, such as
muscular dystrophy, mitochondrial myopathies (Chance, Eleff et al. 1981, Argov and
Bank 1991), and cardiac disease (Yabe, Mitsunami et al. 1995) have also been studied
using 31P MRS. More background about mitochondrial 31P MRS studies will be given in
Chapter 3.

Figure 2.1 31P MRS spectra. 31P MRS spectra from skeletal muscle shown at rest, and
following a period of mild exercise. The three ATP phosphate groups are visible, as well
as inorganic phosphate.
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The

31

P MRS technique has been critical to understanding muscle energetics, but it has

several disadvantages that have proved particularly challenging, especially for large
clinical studies. Technical limitations of 31P MRS may have contributed to heterogeneity
in the findings of previous studies (Roussel, Bendahan et al. 2000). Characteristic of most
spectroscopy techniques, 31P MRS suffers from low sensitivity, even lower than 1H MRS,
due to the small gyromagnetic ratio of
impactful limitations is that

31

31

P (Hoult, Busby et al. 1974). One of the most

P MRS has poor spatial resolution. The disadvantage of

poor spatial resolution becomes apparent if during exercise studies, subjects utilize
muscle groups in an unexpected way. If subjects exercise a muscle that is not the target of
the study (for example, using the anterior tibialis instead of the gastrocnemius muscles in
calf muscle) and not included in the coil detection region, it will appear that the subject
hasn’t exercised. This presents a serious challenge especially for studies of patient
populations who often can’t follow instructions precisely due to physical limitations.
Being able to produce a more accurate “snapshot” with higher resolution of every muscle
simultaneously would perhaps allow data to be salvaged from a different muscle group,
even if the target muscle wasn’t utilized. It may also help to ensure a comprehensive
understanding of the metabolic response to disease in muscle. Techniques for studying
muscular diseases and secondary conditions that also affect muscle energy metabolism
would be greatly benefitted by a more robust method for studying OXPHOS in vivo.
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To this end, in 2011 the Reddy lab began developing a chemical exchange saturation
transfer (CEST) (Sherry and Woods 2008) for imaging of creatine (CrCEST). The
concentration of creatine, like PCr, should be altered after a period of exercise. Creatine
is suitable for CEST studies as it contains amino groups in the slow-intermediate
exchange regime and exists at high cellular concentrations (~7-20mM in skeletal muscle).
The goal for creatine CEST (CrCEST) was to observe increases in [Cr] after a dynamic
exercise study analogous to the decrease in [PCr] observed by spectroscopy.
The rest of this chapter will review the original development of CrCEST in phantoms
(Haris, Nanga et al. 2012) and the preliminary applications in skeletal muscle (Kogan,
Haris et al. 2013, Kogan, Haris et al. 2014) and cardiac tissue (Haris, Singh et al. 2014),
and discuss the capability of CrCEST imaging in the brain (Cai, Singh et al. 2015). The
rest of this chapter will detail a small reproducibility study performed at 3T and include
the designs for a custom-built MRI-compatible ergometer. Chapter 3 will be entirely
focused on a clinical CrCEST study that was performed at 7T in a population affected by
mitochondrial dysfunction.
2.2 Development and application of CrCEST

2.2.1 CrCEST in phantoms
Creatine (Cr) was originally targeted for CEST experiments in light of some of the
shortcomings of

31

P MRS described above. The general CEST methodology can be

adapted to metabolites that possess adequate concentration in vivo and have an amenable
exchange rate (Kogan, Hariharan et al. 2013). The following discussion of CrCEST
implementation is adapted from a review chapter on CrCEST imaging to which the
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author contributed (McMahon, Gilad et al. 2017). During initial development of creatine
CEST, limited information was available about exchange rates of the creatine kinase
metabolites under physiological conditions (i.e., in phosphate-buffered solution, at
physiological pH and temperature). Using high-resolution

1

H NMR (9.4T), the

resonances from the CK components with exchangeable protons (Cr, PCr, and ATP) were
identified (Figure 2.2A).

Figure 2.2 High-resolution NMR-derived location of exchangeable protons and
CEST maps. A) high resolution 1H NMR spectra obtained at 9.4 T showing sharp amine
proton resonances of Cr (1.8 ppm), PCr (2.5 ppm and ~ 1.8 ppm) and ATP (2.0 ppm) at
lower temperatures while broadening was observed at higher temperature due to
exchange with bulk water; B) CEST mapping at 3 T acquired at 1.8 ppm from different
concentrations of creatine, phosphocreatine, and ATP overlaid on the proton image show
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the predominant CEST contrast from Cr. (Reprinted with permission (Haris, Nanga et al.
2012))

Creatine in its ionic form has two groups of guanidinium protons (imine: =NH2+ and
amine: -NH2) that show a single resonance at 1.8 ppm away from water (Haris, Nanga et
al. 2012). Phosphocreatine has one amide group (2.5 ppm), and one amine group (1.8
ppm), while the amine group of ATP resonates at 2.0 ppm (van Zijl and Yadav 2011).
When the exchange rates for these protons were determined (McMahon, Gilad et al.
2006), it was discovered that Cr has a much faster exchange rate (950±100 s-1) than the
other components (<140±50 s-1) of the CK reaction. This result was anticipated due to the
observed line broadening of creatine’s exchangeable protons at physiological temperature
(37°C), and pH (7.0). Line broadening indicates that the Cr protons are in faster exchange
with bulk water compared to those of PCr or ATP. The pKa values determined for the
CK metabolites at 37°C validate the exchange rates. Under physiological conditions,
creatine has a lower pKa than both PCr and ATP, suggesting a faster dissociation, which
leads to faster exchange with bulk water spins. From these initial experiments, it was
determined that at 3T, the exchange rate of Cr is in the slow-intermediate exchange
regime (k≤ Δω, Δω=1300rad/s). On the other hand, the exchange rates of amine protons
of PCr (Δω=1900rad/s) and ATP (Δω=1500rad/s) are in a slow exchange regime at 3T
(k<<Δω). Based on the exchange rate information it was determined that CEST imaging
could be performed on the exchangeable protons of creatine. An initial study was
performed on creatine phantoms, as well as the other creatine-kinase reaction components
that contain exchangeable protons (PCr, ADP, and ATP).
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Figure 2.3 Schematic for the CEST pulse sequence

Phantom experiments typically consist of a CEST imaging protocol performed on an
NMR tube containing the metabolite of interest in a buffered saline solution at a
physiological temperature and pH. This provides a concentration-dependent CEST
contrast that can then be used to guide subsequent in vivo experiments. CEST imaging of
creatine-kinase metabolites was performed at 3T on separate phantoms containing
components of the CK reaction (Cr, PCr, ATP, and ADP) at approximate physiological
concentrations (Wallimann, Tokarska-Schlattner et al. 2011), (Figure 2.2B): Cr: 10, 20,
and 30mM; PCr: 10mM; and ATP: 5mM. The same experiment was performed on a
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5mM phantom of ADP, the amine protons of which had a similar exchange rate and pKa
value to those of ATP (data not shown). Although the target metabolite for CEST was
creatine, the other metabolites that may be present physiologically were also included so
as to determine whether they also contribute to any observed CEST contrast. A
preliminary z-spectrum (Ward, Aletras et al. 2000) was gathered on a 30 mM Cr
phantom, and showed a broad resonance centered at ~ 1.8 ppm (Figure 2.4), attributed to
the (-NH2) protons, also observed in those earlier 1H NMR experiments.

Figure 2.4 CEST effect from creatine. A) Z spectra and B) CEST asymmetry curve
collected at 3 T on a 30mM creatine phantom show a broad resonance from creatine
amine protons centred at ~ 1.8 ppm. (Reprinted with permission (Haris, Nanga et al.
2012).)

For the CEST experiments in this dissertation work, a specially optimized saturation
pulse train was used that consisted of 20 Hanning windowed rectangular pulses of 49 ms
duration, each with a 1 ms delay between them, for total saturation duration of 1s. The
saturation pulse excitation bandwidth was 5 Hz for 1s pulse, with a 1% bandwidth of 20
Hz (~0.15 ppm at 3T). CEST contrast for Cr was computed using Equation 1.25, and
mapped onto a T2* weighted reference image. Msat (-Δω) and Msat (+Δω) are the B0
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corrected MR signals acquired while saturating at -1.8 ppm and +1.8 ppm from water
resonance. The CEST contrast map was further corrected for B1 inhomogeneity.
With these parameters, the CrCEST contrast observed in Cr phantoms showed a linear
relationship to Cr concentration with a slope of 0.6%. For CrCEST imaging of phantoms
at 3T, the optimal saturation pulse amplitude (B1rms) was 3.64 µT. No appreciable CEST
was observed from the other components of the CK reaction, which is likely due to their
slower exchange rates. As discussed previously, one of the expected benefits of using
CEST instead of traditional spectroscopy is an increase in sensitivity. This was observed
using single voxel point resolved spectroscopy (PRESS) on the 30mM Cr phantom
(Figure 2.5).
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Figure 2.5 Sensitivity of CrCEST compared to 1H MRS. A) image of a 30mM creatine
phantom, showing the single voxel localization; B) 1H MRS PRESS water suppressed
spectrum from the voxel. The measured amplitude of the Cr peak at 3.02 ppm was 1.5 x
105 units; C) Two water 1H resonance spectra obtained when a saturation pulse was
applied at ± 1.8 ppm. The subtracted spectrum is shown in D, with an amplitude of 2.3 x
108 units. Therefore, the sensitivity of Cr CEST was ~ 1500 times higher than 1H MRS
(2.3x108 / 1.5x105 = 1533). Data acquired at 3T. (Reprinted with permission (Haris,
Nanga et al. 2012).)

Furthermore, the sensitivity of CrCEST is approximately three orders of magnitude
greater than 31P MRS due to the low receptivity of 31P compared to 1H (Kogan, Haris et
al. 2014). The benefit of such increased sensitivity is the ability to detect relatively small
changes in Cr levels at high resolution (Haris, Nanga et al. 2012).
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2.2.2 in vivo CrCEST: skeletal muscle exercise at ultra-high field
After establishing that CrCEST images could be obtained from simple phantoms the next
goal for CrCEST was implementation in skeletal muscle in vivo. The ultimate goal was to
detect creatine in muscle through the CEST technique and then to measure dynamic
changes in creatine induced through an exercise paradigm. Analogous to

31

P MRS of

PCr, this would provide an indirect measure of OXPHOS as discussed in Chapter 1. The
expected result from CrCEST of muscle post-exercise, based on our understanding of the
creatine-kinase reaction, was an increase in CrCEST signal proportional to the decrease
observed in the

31

P MRS signal of PCr. This was primarily the thesis work of Feliks

Kogan in the Reddy lab (Kogan, Haris et al. 2013) and is the basis for the subsequent
reproducibility and clinical studies that were the focus of this work. The first in vivo
CrCEST study on healthy humans was performed at 7T. An important initial step for in
vivo optimization was maximizing both the CrCESTasym and the signal-to-noise (SNR)
ratio. While CrCEST signal increased with increasing B1rms, this led to a decrease in SNR
(Figure 2.6).
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Figure 2.6 CEST asymmetry vs. SNR. Plot of the CESTasym as well as the signal-tonoise ratio (SNR) of the anatomic image as a function of saturation pulse B1rms for a 500
ms pulse. (Reprinted with permission (Kogan et al).)

To maximize both of these parameters, a saturation pulse train with a B1rms of 123Hz
(2.9µT) and 500ms duration, with a SHOT TR of 8s were chosen for CrCEST in vivo at
7T. Another consideration for in vivo imaging was the fat content of the muscle tissue. In
order to reduce the fat signal, a chemical shift selective fat saturation pulse was applied
before image readout.
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CrCEST of human skeletal muscle was performed on calf muscles at 7T using a 28channel 1H knee coil. One of the complexities of CEST data lies in calculating accurate
CEST contrast when there are B0 and B1 inhomogeneities. To correct for any
inhomogeneities, water saturation shift reference images (Kim, Gillen et al. 2009) and B1
maps were collected along with CEST maps using a double-angle method. By utilizing
higher order shimming, B0 inhomogeneities for a human skeletal muscle (imaging slice
thickness = 4mm) could be kept within 0.3 ppm (ΔB0<0.3ppm) and thus CrCEST images
were collected in a chemical shift range of ±1.5 to ±2.1 ppm, acquired in steps of 0.3ppm,
for a total of 6 images. As Cr amine protons have a chemical shift of 1.8 ppm downfield
from water (Haris, Nanga et al. 2012), this allows for adequate B0 inhomogeneity
correction in calculating CrCESTasym. To correct for B1 inhomogeneities, B1-field maps
were obtained using the double angle method as described previously (Cai, Haris et al.
2012, Singh, Cai et al. 2013), using a 2D single-slice fast spin echo (FSE) readout
sequence, acquiring two images using preparation square pulses with duration (t) and flip
angles (q) 30° and 60°. We used the RF pulse amplitude for the 30° flip-angle as a
reference B1 (B1reference). Flip angle maps were generated by solving:
cos (2𝜃) 𝑆(2𝜃)
=
cos (𝜃)
𝑆(𝜃)
where S(q) and S(2q) represent pixel signals in the image with the preparation flip angle
𝜃 and 2𝜃 respectively. We generate a B1 field map from the flip angle map using
B1=q(360t)-1. The CEST contrast maps were corrected using the coefficient of
B1/B1reference. Then, second-degree polynomials were fitted to the measured CEST
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contrast over a range of B1 amplitudes. The CEST asymmetry was corrected based on the
coefficients of the polynomial for a given tissue (muscle, in this case) and using the B1
field map described above.
In resting muscle tissue, CrCEST maps showed a uniform CrCESTasym ≈ 12-15% on
average (Figure 2.7A,B). The exercise paradigm consisted of two minutes of mild
plantar flexion, a type of exercise designed to utilize the muscles in the posterior
compartment of the lower leg. Exercise was performed in the magnet using a MRIcompatible, pneumatically controlled foot pedal set at a constant pressure for all of the
subjects. CrCEST images were acquired with a temporal resolution of 48s both before (2
min total) and after (8 min total) exercise. CrCEST imaging during exercise is not
feasible due to the extreme sensitivity of CEST to motion.
For this initial study of CrCEST in vivo, only mild exercise was performed in order to
maintain a consistent pH. During strenuous exercise, the pH of the muscle can drop, due
to breakdown of glycogen and production of lactate (Iotti, Lodi et al. 1993). A pH
decrease would consequently decrease the exchange rate between Cr amine protons and
water protons, leading to a lower CEST contrast (Singh, Haris et al. 2011). An example
set of CEST images for one subject are shown in Figure 2.7C, where an increase in the
MG and LG is observed post-exercise and recovers within two minutes. Two minutes of
mild exercise was sufficient to induce creatine changes in exercising muscle without
changing the pH of the muscle tissue. In CrCEST maps post-exercise, an increase in
CrCESTasym from 1%-7% was observed in various muscle groups (Figure 2.7D) for 8
subjects.
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Figure 2.7 CrCEST application in healthy skeletal muscle. A) CrCEST asymmetry
plot showing a peak at 1.8ppm; B) resting-state CrCEST image showing uniform contrast
over the whole muscle region, demonstrating the enhanced spatial resolution of CEST; C)
baseline CEST maps from one subject followed by post-exercise images acquired with a
temporal resolution of 48s; D) CrCESTasym (%) plotted for 8 healthy subjects, showing an
increase in creatine immediately after exercise followed by a decrease to baseline.
(Reprinted with permission (Kogan, Haris et al. 2014).)

The results from the CEST experiments were compared to the results from

31

P MRS,

performed on the same subjects in a separate bout of exercise, using the same paradigm.
Creatine recovery over 8 minutes, measured by CrCEST, was strongly correlated to PCr
recovery measured with
PCr (measured by

31

31

P MRS. The recovery times of Cr (measured by CEST) and

P MRS) showed good agreement (Figure 2.8). At 7T, 0.84%

CrCESTasym was reported per mM Cr. An exciting finding was the ability of CrCEST to
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distinguish between specific muscle group utilization while exercising. Plantar flexion
exercise primarily causes utilization of the soleus muscle and the medial (MG) and lateral
(LG) heads of the gastrocnemius muscles. Following exercise, creatine changes were
observed primarily in the gastrocnemius and soleus muscles, depending on individual
subject utilization. The CrCEST technique was able to distinguish between varying levels
of muscle utilization between subjects. Other muscle groups, primarily the tibialis
anterior (AT), did not show a significant increase in Cr post exercise. Less than a 1%
increase in CrCESTasym was observed in that muscle in the majority of subjects. This
demonstrated the precise spatial resolution of CEST. From this pilot study in healthy
subjects, it was determined that this method of observing the CK reaction in vivo has
excellent spatial resolution, which is an important improvement over 31P MRS.
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Figure 2.8 CrCEST vs. 31P MRS. The signal from creatine measured by CEST in
skeletal muscle pre- and post-exercise showed good agreement with the results from 31P
MRS measurements of PCr with the same exercise paradigm. (Reprinted with permission
(Kogan, Haris et al. 2014).)

In addition to the benefits of spatial resolution, the anticipated enhanced sensitivity was
indeed observed in in vivo CrCEST compared to spectroscopy. As noted previously, 31P
has low sensitivity, due to the lower gyromagnetic ratio of 31P (17.235 MHz/T) compared
to that of 1H (42.576 MHz/T) which leads to a receptivity of 31P that is only 0.066 that of
1

H (Levitt 2008). The water of muscle tissue has a proton concentration of 82.5 M. Based

on the 0.84% CEST observed per mM Cr, 1 mM Cr signal leads to ~700 mM change in
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water. Therefore, CrCEST has over three orders of magnitude higher sensitivity than 31P
MRS.
In Section 2.2.1, we noted that phantom experiments showed no contribution from ATP,
ADP, and PCr to the CrCEST effect at 1.8 ppm. During the 7T exercise study, there was
no observed change in pH, T2, or MTR, and the CEST effects from other CK reaction
metabolites were negligible. Based on this initial work, it was concluded that the CrCEST
technique in vivo provides an accurate measure of the changes in muscle Cr concentration
following exercise (Kogan, Haris et al. 2013).

2.2.3 Implementation of in vivo CrCEST at clinical-strength field
As noted in Chapter 1, there are numerous disease states that could benefit from study of
noninvasive molecular imaging techniques. Despite the impressive results at high field
(7T), in order for the CrCEST imaging technique to be applicable to widespread patient
populations, it also needed validation at clinical-strength fields (3T) (Kogan, Haris et al.
2014). There were several challenges in translating CrCEST from 7T to 3T. At lower
fields, the chemical shift (Δω) between Cr amine protons and free water protons is
decreased (~540 Hz at 7T vs. ~225 Hz at 3T). This means that at 3T, the saturation pulse
is necessarily applied closer to the water resonance than it would be at 7T. The result is
increased direct saturation of bulk water. Increased direct water saturation confounds the
CEST measurement and also leads to a loss of SNR in the CEST images. To mitigate
direct water saturation, a lower B1 is required for optimal CEST, but consequently
decreases the labile proton saturation efficiency, and decreases the overall CrCESTasym.
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Despite these drawbacks, CrCEST is possible at a lower field thanks to the exchange rate
of Cr amine protons, which still falls in the slow-intermediate regime at 3T. The
dependence of the change in CrCEST on the change in creatine concentration following
exercise at 3T (0.45% CrCESTasym/mM Cr) is approximately half of that observed at 7T
(0.84% CrCESTasym/mM Cr). The T2 relaxation times in muscle are longer at 3T, (T2 (3T)
= 29.3 msec, T2 (7T)=23.0 msec) (Jordan, Saranathan et al. 2013). This somewhat lessens
the SNR lost due to increased direct water saturation at 3T.
There are also advantages to CrCEST imaging at 3T, including the shorter T1 relaxation
times at 3T than at 7T. This allows for increased temporal resolution, since the time
necessary to allow for complete longitudinal relaxation between saturation pulses (SHOT
TR) is directly correlated to the T1. Temporal resolution is an important consideration
when applying CrCEST to studies of creatine kinetics, which have a time course on the
order of 30 seconds to a few minutes following exercise (Argov and Bank 1991). When
implementing the CrCEST sequence at 3T, the TR was minimized to optimize the
temporal resolution while maintaining adequate SNR, and we were able to achieve a
temporal resolution of 24s.
Similar to the experiments performed at 7T, changes in CrCEST in the calf muscles of
healthy human volunteers were mapped at 3T following plantar flexion exercises (Kogan,
Haris et al. 2014) (Figure 2.9).
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Figure 2.9 CrCEST in skeletal muscle at 3T. The baseline, resting CrCESTasym and
post-exercise maps acquired with a temporal resolution of 24s demonstrate the feasibility
of CrCEST at lower field strengths. (Reprinted with permission (Kogan, Haris et al.
2014).)

Creatine metabolism is vital not just in skeletal muscle, but also in cardiac muscle and in
the brain. The next two sections will summarize some of the initial work that is currently
underway to develop the CrCEST technique for application in those tissue types.

2.2.4 Application of CrCEST in imaging of myocardial metabolism
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Myocardial metabolism can be disrupted due to an event such as cardiac ischemia or
infarction, making it another desirable candidate for CrCEST. CrCEST imaging and
spectroscopy were first performed on non-infarcted, excised, lamb heart tissue.30. Ex vivo
tissue was used in order to optimize the imaging parameters for myocardial tissue and
total Cr concentration was measured using 1H MRS. The Cr concentration was validated
using the perchloric acid (PCA) extraction method, in which a positive correlation was
observed between the imaging method and the biochemical method. For this tissue, the
mean sensitivity (n = 26) of CrCEST is 0.8% CrCEST contrast per 1 mM of Cr at 37 °C.
For a comparison of infarcted tissue to non-infarcted tissue, CrCEST maps were acquired
from ex vivo swine myocardial tissue. Infarcted tissue has lower CrCEST contrast (4.7
±1.2%) than non-infarcted tissue (10.4 ±2.0%) (Figure 2.10).

Figure 2.10 Ex vivo CrCEST of noninfarcted and infarcted myocardial tissue from
swine.
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A) an infarcted region (shown with a dotted arrow) is clearly visible in the ex vivo tissue;
B) CEST maps overlaid onto an anatomical image show lower creatine in the infarcted
region; C) 1H MRS of creatine and choline validate the CEST results, showing lower
creatine signal in the infarcted area. (Reprinted with permission (Haris, Singh et al.
2014).)
In vivo CrCEST for myocardial imaging was performed on swine and sheep with
infarctions, using healthy animals as a control (Figure 2.11) (Haris, Singh et al. 2014).
CrCEST maps from two healthy swine displayed uniform CrCEST contrast in
myocardium. Swine and sheep with infarcted myocardia had lower CrCEST contrast in
the infarcted regions compared to the normal myocardial regions. CrCEST imaging gave
consistent regional (infarcted vs. non-infarcted) contrast values across all animals studied.
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Figure 2.11 In vivo CrCEST data. A, B) the first two columns show normal swine
hearts; C, D) two infarcted sheep hearts; E) one infarcted swine heart. Row 1: anatomical
CEST-weighted images of the left ventricle, gray scale; row 2: CrCEST maps; row 3:
color-coded CrCEST maps; row 4: overlaid color CrCEST maps. (Reprinted with
permission (Haris, Singh et al. 2014).)

In myocardial imaging, there may be changes in CrCEST in the ischemic and infarcted
regions of myocardium due to changes in T2, MTR, and water content. In these tissues,
there is the potential for an increase in water content. This leads to a reduction in Cr
concentration and hence CrCEST. However, there is also a decrease in MTR and an
increase in water T2, which would cause an increased CrCEST. Thus, the effects of
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changes in water content, MTR, and T2 compete with each other, and appear to have no
appreciable contribution to the CrCESTasym.
As mentioned in Chapter 1, CrCEST contrast may also be affected by pH. The CrCEST
contrast in infarcted regions of myocardium may be underestimated, because infarcted
tissue is expected to have a pH between 6.5 and 7.0. Consequently, the lower CrCEST
contrast observed in the infarcted myocardium may be the result of an integrated effect of
both lower exchange rate resulting from the decreased pH and lower Cr concentration
compared to those in healthy tissue. Thus, although pH may influence the magnitude of
CrCEST, it would only enhance the capability of CrCEST in discriminating between
healthy and infarcted myocardium (Haris, Singh et al. 2014).

2.2.5 CrCEST application in brain imaging
CrCEST also has the potential to be used for study of creatine levels in the brain (Singh,
Haris et al. 2011). There is increasing evidence for creatine depletion in the brain of those
with inborn errors of metabolism (IEM), which leads to clinical features of movement
disorders, epilepsy and autism (Nasrallah, Feki et al. 2010). 1H MRS shows low total
creatine (tCr) concentration in the brain of those with known creatine deficiency
syndromes (Nouioua, Cheillan et al. 2013). The improved spatial resolution of CrCEST
compared to conventional spectroscopy techniques makes it an ideal tool for studying
these disorders. Recent work has shown CEST imaging of brain creatine in a rat brain
tumor model (Cai, Singh et al. 2015) that characterized the multiple exchangeable
components through a simplified Z-spectral fitting method. The CEST peak observed at
+2ppm was reduced in brain tumor tissue compared to normal tissue (Figure 2.12), and
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continued to decrease with tumor progression. The 2ppm CEST peak also correlated with
1

H MRS-derived concentrations of creatine. This noninvasive way to look at Cr levels in

the brain may aid in future developments for imaging of cancer and other brain diseases
in which creatine metabolism is disrupted.

Figure 2.12 CrCEST of a rat brain tumor model. A, B) in the brain tumor region, the
CEST signal at 2ppm was decreased compared with normal brain tissue and further
reduced with tumor progression; C) 1H MRS results show a similar trend for the creatine
change (Cho=choline, Cre=creatine, NAA=N-acetylaspartic acid.). (Reprinted with
permission (Cai et al. NMR in biomed. 2015).)
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2.3 Preliminary Reproducibility Study
One of the primary goals of this dissertation was to build upon the work described in the
previous sections. The studies in healthy humans indicated that CrCEST could be used to
study the CK reaction in vivo, but an important step for biomarker development is
application to a disease state. As a preliminary step to establish this technique as a
method for examining metabolic dysfunction, an attempt was made to standardize the
exercise protocol, fit recovery times and calculate time constants, and report on
reproducibility. A small reproducibility study was performed on five subjects at 3T.
Before adapting this technique for more widespread clinical use, a significant effort must
be made to further establish reproducibility. A large-scale, well-controlled reproducibility
study will be the subject of future work.

2.3.1 Methods
The pilot reproducibility study was performed on a 3T whole-body scanner (Siemens
Prisma, Siemens Medical Systems, Erlangen, Germany), with a 15-ch knee coil.
Imaging parameters.
Imaging parameters consisted of the optimized CEST parameters for creatine at 3T, as
determined by Kogan et al. (Kogan, Haris et al. 2013), and TR=5.6ms, TE=2.7ms,
FOV=160x160mm2,

matrix

size=128x128,

B1rms=2.25µT,

flip

angle=10°,

slice

thickness=10mm,tsat=500ms, SHOT TR=5s.
MRI setup.
For the CrCEST studies described in the next few sections, the MRI setup was generally
the following: subjects were placed feet-first, supine into the magnet with the knee coil
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placed around the right calf, centering the widest part of the calf muscle at the center of
the coil (Figure 2.13).

Figure 2.13 Coil positioning around the calf muscle for CrCEST imaging. The right
foot was placed into a custom-built foot pedal, operated by a pneumatically controlled
piston with constant pressure (set at 7.5 psi for all subjects). A 3-plane, localized image
was acquired to determine optimal slice positioning, with the preferred slice containing
the largest possible portion of the gastrocnemius muscles (Figure 2.14), determined from
the axial image. (Reprinted with permission (Kogan, Haris et al. 2014).)
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Figure 2.14 Anatomical, axial calf muscle image. A) optimal slice positioning with
large areas of the soleus and gastrocnemius muscles. The anterior tibialis (AT) is outlined
in red, the soleus (Sol) in blue, the medial gastrocnemius (MG) in green, and the lateral
gastrocnemius (LG) in purple; B) poor slice positioning with a very small lateral
gastrocnemius area visible. The plantar flexion exercise used in this study targets
activation of the gastrocnemius muscles.

Building an MRI-compatible ergometer
For this study, and the subsequent clinical study in Chapter 3, a new MRI-compatible
ergometer was built by Allen Bonner and Michael Carman at the University of
Pennsylvania Research Instrumentation Shop (3620 Hamilton Walk, Room 75,
Philadelphia, PA 19104 USA), with assistance from the author. This ergometer was
updated from the previous version used in the initial 7T and 3T studies from Sections
2.2.2 and 2.2.3 to include a piston made of aluminum, rather than stainless steel, in order
to ensure MRI safety during the clinical study, as well as reduce any possible risk of
artifact. The parts used to build the ergometer, a picture of the ergometer, as well as a
schematic for the cylinder, are described and shown below.
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The base of the ergometer was made out of white PVC purchased from MSC Industrial
Supply (75 Maxess Road, Melville, NY 11747 USA). For reference, the MSC Part # is
93633188, and the material is Type I White PVC, with ½ inch thickness. The foot pedal
was also built out of the same PVC. To accommodate the affected patient population who
may have particular constrictions on leg/foot positioning, a new design feature was added
to this ergometer (Figure 2.15) that allowed for adjustable leg positioning via a sliding
mechanism on the custom base.

Figure 2.15 Custom-built MRI-compatible ergometer.
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As mentioned, the ergometer used in studies by Kogan et al. contained a stainless steel
pneumatic cylinder used to pressurize the foot pedal; in the new ergometer we worked
with American Cylinder Co., Inc (481 Governors Highway, Peotone, Illinois 60468) to
build a custom cylinder out of aluminum. This custom, round-body air cylinder consisted
of a pivot-mounted, double-acting 1 ½” bore with a 6” stroke and was based on the
cylinder available from McMaster-Carr (200 New Canton Way, Robbinsville NJ 086912343 USA) Part #6498K678 (Figure 2.16).

Figure 2.16 Schematic for pneumatic air cylinder.

The cylinder was attached to the PVC base with brass and nylon nuts/washers/screws
from McMaster-Carr (Part #s: 98853A029, 92676A029, 92446A542, 93465A542,
92174A675, 9273K653, and 95606A130). The ergometer cylinder was connected to a
pressured air tank (Figure 2.17) via ¼” (inner diameter) PVC tubing available from
Kuriyama of America, Inc. (360 E. State Parkway Schaumburg, IL 60173-5335 USA),
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part #: K3130-04X100, CLEARBRAID® K3130 Series BF Heavy Wall PVC Hose. The
air tank was MRI-safe, equipped with an MRI-safe regulator (Part #AI USPEAMRI, Part
# WESM1-950-PG), obtained from AirGas (Greater Philadelphia Metro Area, 850 April
Hill Way, Harleysville PA 19438 USA) allowed for adjustable pressure; for the CrCEST
clinical study this was kept at 7.5psi.

Figure 2.17 Air cylinder and pressure gauge.

Subjects.
Five healthy individual male subjects (age 25-40) were scanned on two separate days
within 1 week. For this initial study of reproducibility, care was not taken to standardize
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important clinical factors including fasting status, previous exercise, or time of day. A
tightly controlled and standardized clinical study is presented in Chapter 3.
Imaging protocol.
Subjects were imaged at rest for two minutes in order to establish baseline CrCEST. They
were then instructed to perform two minutes of plantar flexion at the rate of 45
flexions/minute, guided by a metronome to indicate when to push the pedal. Given the
diameter of the piston (1.5in) and the pressure (7.5psi), we estimated the work/s for each
flexion to be ~3.5watts. Obtaining precise work measurements in-magnet, over the course
of dynamic exercise, will be the focus of future work. Following cessation of exercise,
CrCEST images were acquired every 30s for a total of 8 minutes. The CEST contrast was
calculated with in-house MATLAB routines as will be described in the next section. For
every timepoint, the corresponding CrCEST image was overlaid onto an anatomical
image. The individual muscle groups (anterior tibialis, soleus, medial gastrocnemius, and
lateral gastrocnemius) were manually segmented in order to determine the CrCEST
signal in each muscle. Time constants for recovery from each individual muscle group
were then calculated from the segmented regions of interest (ROIs). We assessed the
degree of agreement between i) resting, pre-exercise CrCEST % asymmetry (in medial
gastrocnemius, lateral gastrocnemius, and soleus) and ii) post-exercise τCr, which was
calculated from each individual muscle group and fit to an exponential decay. For
preliminary reproducibility studies, the within-subject coefficient of variation between
Day 1 and Day 2 measurements was calculated for each participant. All statistical
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analyses were conducted using R (version 3.1.3), and statistical significance was taken as
two-sided p-value of < 0.05.
CrCEST Post-processing
During this project, a graphical-user interface (GUI) for processing CrCEST exercise data
was developed by Neil Wilson, a post-doctoral researcher in the Reddy lab with
functionality input and initial testing from the author. This development was a vital part
of the project, as it allowed data to be processed quickly and with minimal user input,
thus limiting user bias or error. The GUI encompasses the MATLAB routines as written
by Dr. Hariharan in the Reddy lab for analysis by Kogan et al., but incorporates a more
sophisticated data-sorting routine (Figure 2.18) (Wilson 2016).

Experimental
directory with all
scan subdirectories:
1. Anatomical
reference images (no
saturation)
2. CEST images (4 preexercise + 16 postexercise)
3. B1 (2, pre-exercise
and post-exercise)
4. B0 (2, pre-exercise
and post-exercise)

Push
button
1

1. Automatically
organize all scans
2. Read all DICOMS into
matrices
3. Populate the GUI
fields with appropriate
scan files
4. Apply appropriate
field map corrections
5. Calculate corrected
CEST using asymmetry
analysis

Push
button 2

1. User can manually
draw ROIs
2. Evaluate mean and
standard deviation of
CEST asymmetry
3. Values are fit as a
time series
4. Images are
generated and saved
5. Time constants for
recovery are generated

Figure 2.18 Flowchart for the GUI processing application.

Briefly, the GUI first organizes all the scans from the experiment, saved in DICOM
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(Digital Imaging and Communications in Medicine) format, when the user selects the
experimental directory in which each scan subdirectory exists. The subdirectories include
a series of CEST-weighted images with saturation acquired symmetrically around 0 ppm
(in the case of CrCEST: ±1.5-1.8-2.1 ppm), a series used to generate field maps, a series
used to generate B1+ maps, and a reference series with no saturation. Each series of scans
is acquired both pre-exercise and post-exercise (in the case of CrCEST experiments). The
individual scan subdirectories are automatically organized and populated (Figure 2.19).

Figure 2.19 GUI interface for processing CrCEST exercise data.
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With a single button push, all DICOMS are read into matrices, appropriate field map
corrections are applied, and then both raw and corrected CEST maps are calculated using
asymmetry analysis (Figure 2.20). B0 correction is applied to the CEST maps by
interpolating a partial z-spectrum of the CEST-weighted images, shifting the interpolated
spectrum based on the measured inhomogeneity, and evaluating at the desired offset. B1
inhomogeneity can then be normalized either with user-provided calibration parameters
or assuming a linear dependence.

Figure 2.20 GUI image output. The GUI generates the CEST maps for the four baseline
scans (inside the white box), and for the sixteen post-exercise scans acquired for this
CrCEST experiment at 3T. The pixel intensity represents the CEST signal. An increase is
observed in the gastrocnemius muscles of this subject following plantar flexion exercise.

A second button allows the user to manually draw ROIs on the reference images. From
the individual ROIs (in the case of CrCEST in muscle, the four muscle groups referenced
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above: AT, Sol, MG, and LG) the mean and standard deviation of the CEST asymmetry
is evaluated in each before fitting those values as a time series (Figure 2.21).

Figure 2.21 GUI ROI calculation output. With the GUI, the user can manually draw
regions of interest (ROIs), from which the average CESTasym is calculated separately for
every acquired image. The values for each time point from each ROI are fit to a decaying
exponential to calculate the time constant for creatine recovery. The second output box
shows the initial baseline CrCEST values, the increase above baseline, the recovery time
constant (s), and number of voxels included in the ROI.
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With the GUI application, high quality CEST images as well as intermediate images such
as B0/B1 field maps can be generated and saved in a variety of formats. This application
allows for fast post-processing of clinical data.

2.3.2 Results
Results of the preliminary reproducibility study of CrCEST-based measures are shown in
Figures 2.22 and 2.23. In 5 healthy individuals who underwent 3T CrCEST imaging on
two separate days within one week, the mean within-subject coefficient of variation
(COV) for resting CrCEST % asymmetry, an index of free creatine concentration, was
3.4%±1.4% (SEM) in lateral gastrocnemius, 8.2±1.8% in medial gastrocnemius, and
4.5±1.4% in soleus. All participants engaged the lateral gastrocnemius in exercise, and
most engaged medial gastrocnemius, thus post-exercise τCr results are shown for these
two muscle groups. Mean within-subject COV for τCr was 16.0±7.0% (SEM) in lateral
gastrocnemius and 13.5±6.1% in medial gastrocnemius.
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Figure 2.22 Reproducibility of baseline CrCEST % asymmetry, an index of free
creatine concentration. For each of five subjects (shown in different colors), CrCEST
measurements were obtained on a 3T MRI scanner on each of two different days,
separated by less than one week. The degree of agreement between individual
measurements and summary within-participant coefficient of variation (COV) estimates
for these measurements are shown. LG = lateral gastrocenmius; MG = medial
gastrocnemius; Sol = soleus.
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Figure 2.23 Reproducibility of post-exercise CrCEST decline exponential time
constant (τCr), an index of free creatine concentration. For each of five subjects
(shown in different colors), CrCEST measurements were obtained on a 3T MRI scanner
on each of two different days, separated by less than one week. The degree of agreement
between individual measurements and summary within-participant coefficient of
variation (COV) estimates for these measurements are shown. LG = lateral
gastrocenmius; MG = medial gastrocnemius; Sol = soleus.

2.3.3 Discussion
This pilot study was performed at 3T because MRI scanners at this field strength are
more widely available, and thus may be used for future, larger studies and/or adapted for
clinical use. As this study reflected a sample of convenience, it did not include
standardized clinical factors including fasting status, previous exercise, or time of day.
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For this reason, the resulting reproducibility estimates represent the lower bound of what
would be achievable with careful standardization of pre-analytic factors in future
CrCEST studies. Even without pre-analytic standardization of clinical factors and with
the “low” MRI field strength (compared to 7T), we observed that a reasonable degree of
consistency is achievable. A complete assessment of the reproducibility of CrCESTbased measures obtained at 7T of in vivo creatine metabolism would be beneficial in
future before implementing multi-site studies, and will be the subject of future work.
2.4 Summary
This chapter has reviewed the development and application of CrCEST for studying
muscle energetics in vivo. We have presented the original work from the Reddy lab to
determine the exchange rates of creatine amino groups and locate their chemical shift
with high-resolution NMR, and the demonstration that creatine can be imaged with the
CEST technique in phantoms, without significant contribution from other associated
metabolites. We have shown that it is feasible to establish CrCEST-derived measures of
OXPHOS capacity in healthy human skeletal muscle, as well as preliminary applications
in other key metabolic tissues, myocardium and brain. Together, these studies
demonstrate the utility of the creatine CEST technique for studying metabolism in vivo,
with high spatial resolution and enhanced sensitivity compared to traditional
spectroscopic methods. For this dissertation work, we built upon those initial studies by:
building a new ergometer with the specific needs of research subjects in mind
(adjustability, comfort); developed the GUI for streamlined data processing including
calculation of time constants of recovery; performing the reproducibility study to
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demonstrate feasibility in translating the CrCEST technique to a larger clinical study. The
next chapter will focus on the implementation of CrCEST in a clinical study of OXPHOS
capacity in patients with mitochondrial dysfunction.
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Chapter 3 - Application of CrCEST for measuring impaired muscle oxidative
phosphorylation in vivo
3.1 Introduction
It is evident from the discussion in the previous chapters that mitochondrial dysfunction
would have a wide-reaching and damaging effect on cells. Perhaps unsurprisingly,
mitochondrial dysfunction is linked to many disease states. The first section of this
chapter will review mitochondrial impairment in common diseases and specific disorders,
beginning with a discussion of the mitochondrial genome. The rest of the chapter will
focus our efforts to apply CrCEST to detect mitochondrial impairment in a population
affected by mitochondrial dysfunction.
3.2 The mitochondrial genome and mutations that disrupt OXPHOS
In an effort to understand mitochondrial involvement across many pathophysiological
conditions, the mitochondrial genome has become the subject of intense research,
especially as inheritable diseases show more and more links to defects in mitochondrial,
rather than nuclear DNA (Wallace 2005). In humans, the mitochondrial DNA (mtDNA)
encodes for 13 polypeptides that are core components of the respiratory complexes that
perform

OXPHOS

(summarized
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in

Table

3-1):

Table 3-1 Respiratory complexes encoded for by mtDNA
Complex

# subunits encoded by
mtDNA

Polypeptides encoded by
mtDNA

I

7

ND1-4, 4L, 5 and 6

III

1

Cytochrome b

IV

3

COI-III

V

2

ATP6, 8

These complexes that have mtDNA-encoded polypeptides are the complexes that
transport protons (Wallace 2010). The importance of OXPHOS is highlighted by that
fact—the major components must coevolve to preserve OXPHOS function, and are all
maintained on a single piece of DNA. All 13 of the mtDNA-encoded protein genes are
translated on the mitochondrial ribosomes. Mitochondrial DNA also contains the genes
for the 12S and 16S RNAs, and 22 tRNAs that are needed for protein synthesis (Wallace
2005). The majority of the genes (~1500, ~80 of which are for OXPHOS) of the
mitochondrial genome are actually contained in the nuclear DNA (nDNA), and are
translated on the cytosolic ribosomes before being imported into the mitochondria.
Interestingly, Complex II is encoded for by nuclear DNA (nDNA) along with the rest of
the mitochondrial proteins, including the mitochondrial DNA polymerase (POLG)
subunits, and the RNA polymerase components and transcriptions factors (Friedman and
Nunnari 2014). Mitochondrial metabolic enzymes and mitochondrial ribosomal proteins
are also encoded for by nDNA.
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Mitochondrial DNA is only inherited maternally, as the mtDNA in each cell’s cytoplasm
are transmitted through the oocyte’s cytoplasm during fertilization. Often, mitochondrial
dysfunction is due to mutated mtDNA. Mitochondrial DNA has a very high mutation rate
(Schriner, Ogburn et al. 2000). This is due in part to the ROS production within the
mitochondria. It is also a function of species survival mechanisms, which only invest
enough energy in maintaining mtDNA long enough for the species to reproduce (Wallace
2007). When an mtDNA mutation first occurs, there’s a mix of wild-type and mutant
DNA present within the cell (heteroplasmy). When the cell goes on to divide, the
daughter cell receives a random distribution of both the wild-type and mutant mtDNA.
That means that over time, there can be an increase in the mutant mtDNA or in wild-type
DNA until the genotype is fully mutant or wild-type. If the mutant mtDNA is in the
majority, then mitochondrial dysfunction occurs with disease becoming progressively
worse. Because the distribution of mtDNA is random during cell division, this means that
both inheritance and expression of mtDNA mutations is highly variable. This, along with
the fact that the total mitochondrial genome is encoded for by both mtDNA and nDNA,
makes the overall genetics incredibly complicated (Wallace 2013). Likewise, the genetics
of mitochondrial diseases are extremely complex, and a complete description is outside
the scope of this work. However, we will discuss some of the common pathways and
mechanisms of mitochondrial damage. A more complete discussion can be found in
several reviews (Wallace 2013, Wallace 2013, Wallace 2015). Here, we will discuss the
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types of mutations that can occur and provide brief descriptions of the resultant disorders
(Wallace 1992).

3.2.1 Missense mutations
A missense mutation occurs when there is an amino acid substitution, and have been
observed in most of the respiratory enzyme complex genes. These are largely associated
with neurological and ophthalmological disorders. Commonly known phenotypes include
Neurogenic muscle weakness, Ataxia, and Retinitis Pigmentosa (NARP), and Leber’s
Hereditary Optic Neuropathy (LHON). NARP is the result of a TàG transversion at np
8993, causing a leucineà arginine at amino acid 156 in ATPase6 (Holt, Harding et al.
1990). This disease has a wide range of symptoms including ataxia, seizures, dementia,
neuropathy, retinitis pigmentosa, and muscle weakness. LHON has several associated
mtDNA mutations, and 50% of affected patients have a missense mutation at np 11778
causing an arginineàhistidine at amino acid 340 on the ND4 protein (Wallace 1992).
Several other missense mutations can occur, including in Complex I (ND1,2,4 and 5) and
Complex III (cytochrome b) genes. The consequence of these mutations is inhibition of
the electron transport chain (Wallace 1992). This causes blindness in affected patients
from damage to the optic nerve, and can also cause cardiac conduction defects (Newman,
Lott et al. 1991, Wall and Newman 1991).
3.2.3 Insertion-deletion mutations
Mitochondrial DNA deletions can cause ocular myopathy and Pearson Syndrome (Rotig,
Cormier et al. 1990). These usually consist of a single mtDNA deletion, but the position
and size can vary widely amongst patients. Most are spontaneous, rather than hereditary,
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indicating developmental mutations. The deletions extend to the sequences required to
initiate replication (Larsson, Holme et al. 1990). Ocular myopathy can include a wide
range of symptoms: ophthalmoplegia, ptosis, and mitochondrial myopathy (chronic
external ophthalmoplegia (CPEO), retinitis pigmentosa, lactic acidosis, hearing loss,
ataxia, heart conduction defects, and dementia (Kearn-Sayre Syndrome or KSS)
(Shanske, Moraes et al. 1990). mtDNA with deletion mutations replicate quicker than
normal DNA, meaning that over time the deleted mtDNA is enriched (Wallace 1989).
These diseases progress with age as the proportion of deletions increases. An interesting
note about ocular myopathy patients is that muscle biopsies for cytochrome c oxidase
show that activity varies from positive to negative along the length of individual muscle
fibers. High concentrations of deleted mtDNA is found in cytochrome c oxidase-negative
regions, with low levels of mRNA for the deleted genes (Shoubridge, Karpati et al.
1990).

3.2.4 Copy number mutations
Mitochondrial DNA depletion can cause lethal infantile respiratory failure, lactic
acidosis, and muscle, liver, and kidney failure. Levels as low as 2% of normal mtDNA
levels have been observed in lethal cases of mitochondrial myopathy (Moraes, Shanske et
al. 1991).
3.2.5 Biogenesis mutations
Most biogenesis mutations are tRNA mutations, causing abnormal mitochondria and
mitochondrial myopathy, which will be the subject of Chapter 3. tRNA mutations cause
syndromes include: Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF);
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Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke (MELAS); and
Maternally Inherited Myopathy and Cardiomyopathy (MMC).
MERFF is a hereditary disease caused by mutations in mtDNA at np 8344, that
changes a loop in tRNALys leading to reduced mitochondrial protein synthesis. It is
associated with pleiotropic OXPPHOS defects in Complexes I and IV, which have a large
proportion of mitochondrially-encoded subunits. General symptoms include myoclonic
epilepsy and mitochondrial myopathy. More severe symptoms can include hearing loss,
dementia, cardiomyopathy, renal dysfunction, and respiratory failure (Shoffner, Lott et al.
1991). OXPHOS capacity in MERFF patients is partially correlated with the percentage
of mutant mtDNA. Enzyme levels in MERFF patients fall as they age, meaning that an
affected individual could have normal phenotype at a young age when the initial
OXPHOS defects are above tissue expression thresholds. Once aging has caused an
expression below threshold, clinic symptoms are then observed. This explains why many
mtDNA mutations manifest later in life and progressively worsen.
MELAS primarily results from a mutation at np 3243 that changes a loop in
tRNALeu(UUR), thereby inactivating the transcriptional terminator, and reducing efficiency
of translation by changing the ratio of mitochondrial rRNA and mRNA transcripts (Goto,
Nonaka et al. 1990, Penn, Lee et al. 1992). It leads to Complex I defects. Symptoms
include stroke-like episodes and mitochondrial myopathy. Like MERFF, effects of
MELAS worsen with age.
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MMC is due to a mutation at np 3260, also in tRNALeu(UUR), in the stem of the
anticodon loop. This creates an OXPHOS defect in both Complex I and IV.

3.3 Mitochondrial involvement in other disorders

3.3.1 Mitochondrial impairment in cancer
As discussed in Chapter 1, cancer cells utilize aerobic glycolysis preferentially over
mitochondrial oxidative metabolism. Mitochondrial biology is being increasingly
targeted in the search for new cancer therapies. The importance of mitochondria in so
many key biological processes means that any disruption to mitochondrial function could
contribute to the change from normal cell to rapidly proliferating cell. Mutations in
mitochondria DNA have been observed in cancer cells, leading to altered mitochondrial
metabolism that can give rise to cancer cell adaptability. For example, there are now
well-established defects in the genes for succinate dehydrogenase (SDH), respiratory
complex II, associated with cancer (Jackson, Nuoffer et al. 2014).
Though Warburg initially predicted that cancer cell reliance on aerobic glycolysis was
due to mitochondrial defect, we now understand that intact mitochondrial function is
necessary for cancer cells to grow rapidly and spread. Certain cancer cell signaling
pathways affect mitochondrial function by shifting metabolism from oxidative to
glycolytic, which enables cancer cells to shuttle nutrients toward anabolic processes.
Transcription factors activated in cancer can alter mitochondrial function such that
substrates are provided to the TCA cycle for producing increased citrate, which
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contributes to lipid biogenesis and protein modifications, further allowing cells to grow
and proliferate. Reactive oxygen species are also involved in cancer progression as
reduced mitochondrial function drives increased lactate production that is then used as
fuel for the oxidative metabolism, providing the energy for tumor growth. There is
extensive research on the link between mitochondria function and cancer, and so
development of noninvasive techniques for measuring mitochondrial function is clearly
beneficial to the field of cancer research.

3.3.2 Mitochondrial impairment in neurodegenerative disease and aging
In neurodegenerative diseases such as Alzheimer’s, there is evidence of impaired
mitochondrial OXPHOS, and mtDNA rearrangements have been found in brain tissue.
Mitochondrial reactive oxygen species play an important role in aging and degenerative
diseases. An increased rate of ROS production ultimately causes cell loss, like neuronal
degeneration, associated with age-related disease. Although there is a wide array of
clinical features between individual neurodegenerative disorders, impaired mitochondrial
energy metabolism is a convincing link, considering that neurons are highly dependent on
oxidative energy metabolism (Coskun, Wyrembak et al. 2012).
3.3.3 Mitochondria in cardiovascular disease and diabetes
Impaired mitochondrial function has clear consequences for cardiac tissue, as
cardiomyocytes have huge concentrations of mitochondria due to their intense energy
demands. Mitochondria and disruptions to bioenergetics are implicated in cardiovascular
disease. Mitochondrial function has also been investigated in the context of type 2
diabetes. Diabetes mellitus is a chronic disease wherein the body develops resistance to
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insulin, and consequently has elevated levels of glucose in the blood. Studies of diabetes
in skeletal muscle have shown that there is reduced glucose uptake into the muscle that
contributes to insulin resistance when fatty acid intermediates interfere with insulin
signaling (Kelley, He et al. 2002). This eventually leads to reduced glucose transporter in
the muscle cells. Ultimately, this means that there is reduced fat oxidative capacity and
mitochondrial metabolism. This is supported by the observation that there is a reduction
in some OXPHOS-protein encoding genes within diabetic skeletal muscle. There is also
evidence of mitochondrial dysfunction in cardiac tissue of type 2 diabetes patients. There
is an increased risk to diabetes patients of developing heart failure (SchrauwenHinderling, Kooi et al. 2016).
The widespread occurrence of mitochondrial dysfunction in a variety of disease states
provides motivation to study it in vivo. Although the CrCEST technique is novel and still
requires further work to become a sophisticated method for clinical use, the goal for this
dissertation was to demonstrate initial feasibility for using CrCEST to identify
mitochondrial impairment in vivo.
3.4 31P MRS and mitochondrial impairment
Before moving on to discuss CrCEST in a clinical population, we will briefly review the
current “gold standard” of

31

P MRS for assessing mitochondrial function in disease

states. In individuals with clinical mitochondrial diseases,

31

P MRS studies have shown

deficient OXPHOS capacity, i.e., rate of mitochondrial ATP production, as evidenced by
a delay in PCr recovery post-exercise (Arnold, Taylor et al. 1985, Matthews, Allaire et al.
1991, Penn, Lee et al. 1992, Chance and Bank 1995). 31P MRS has been validated using
97

multiple in vitro techniques, including measurement of state III respiration in isolated
mitochondria (Lanza, Bhagra et al. 2011).

31

P MRS can also demonstrate the pro-

mitochondrial effect of exercise training (Kent-Braun, McCully et al. 1990). This method
has been adapted for use in diverse subjects, and has also yielded insights with respect to
insulin sensitivity, growth, and exercise capacity in children (Fleischman, Kron et al.
2009, McCormack, McCarthy et al. 2011, McCormack, McCarthy et al. 2013). Several
limitations for

31

P MRS were discussed in Chapter 2. One of the most impactful

limitations is that 31P MRS has poor spatial resolution. In genetic or acquired defects of
muscle OXPHOS, where muscle fiber type is closely coupled to metabolism and function
(Shoffner, Lott et al. 1991, Proctor, Sinning et al. 1995, Zierath and Hawley 2004,
Horiuchi, Fadel et al. 2013), it would clearly be advantageous to measure OXPHOS from
individual muscle groups. With the current

31

P MRS technology (Parasoglou, Xia et al.

2013), (as of this writing), this would require multiple bouts of exercise to obtain separate
voxels for each muscle group. It would therefore require wait times in between each
round of exercise to ensure full recovery. The time that would be necessary for such a
paradigm clearly isn’t feasible within a clinical MRI timeframe, especially in subjects
suffering from mitochondrial disease, which often includes exercise intolerance (Andreu,
Hanna et al. 1999). In addition to study of primary mitochondrial dysfunction

31

P MRS

studies have shown a decreased PCr/ATP ratio, a marker of cardiac energy status, in
cardiac studies of diabetes. As diabetes, cardiovascular disease, and associated clinical
features are some of the costliest burdens on healthcare systems, it is imperative to
continue developing techniques for assessing diabetic mitochondrial function in vivo. 31P
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MRS has shown delayed recovery in PCr after exercise in diabetic skeletal muscle
(Bajpeyi, Pasarica et al. 2011), indicating that the CrCEST technique would be a good
candidate for future work in areas of research that extend beyond primary mitochondrial
disease.
3.5 Clinical MRI Study

3.5.1 Motivation
In Section 3.2, we reviewed the systemic defects in mitochondrial bioenergetics that
occur in primary mitochondrial disorders, as well as in various age-related human
disorders, including diabetes mellitus, cardiovascular disease, neurodegenerative
diseases, and cancer (Wallace 2013). Energy deficiency is most apparent in tissues with
large energy demand, including exercising skeletal muscle. As we saw in Chapter 2, with
CEST the creatine content can be simultaneously measured in every muscle of a leg in
vivo (Kogan, Haris et al. 2013, Kogan, Haris et al. 2014). The capacity of mitochondrial
OXPHOS is reflected in the exponential time constant for the decline in Cr post-exercise
(τCr), which corresponds inversely to the exponential time constant for the recovery of
PCr post-exercise (τPCr) observed with 31P-MRS. The previous studies were carried out
in healthy volunteers, and so the next step was to perform these experiments in subjects
with known mitochondrial dysfunction. The objective of this proof-of-principle study
was to determine whether CrCEST-derived measurements of post-exercise
exponential decline in free creatine were prolonged in individuals with primary
genetic-based mitochondrial diseases, as compared to matched healthy volunteers
(DeBrosse, Nanga et al. 2016). By demonstrating the feasibility of this technique in
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affected individuals, we sought to highlight the utility of CrCEST as a longitudinal
biomarker of in vivo tissue OXPHOS capacity in patient populations.

3.5.2 Methods
Design and Subjects. Individuals ranging in age from 18-65 years were recruited for this
study. They all had a clinical diagnosis of a disorder of the mitochondrial respiratory
chain. We prioritized eligible subjects with disorders confirmed to be caused by
pathogenic mtDNA or nDNA mutations, affecting subunits or assembly of mitochondrial
respiratory chain complexes and are associated with known clinical/pathological features.
These disorders included chronic progressive external ophthalmoplegia (CPEO), Kearns–
Sayre syndrome, mitochondrial encephalomyopathy, lactic acidosis and stroke-like
episodes (MELAS), mitochondrial encephalopathy and ragged red fibers (MERRF),
neuropathy, ataxia and retinitis pigmentosa (NARP) or Leigh syndrome (Stacpoole,
deGrauw et al. 2012). Individuals affected with Friedreich’s ataxia were also studied.
Friedreich’s ataxia is a mitochondrial disease in which ATP production is reduced due to
GAA triplet repeat expansions in frataxin, a mitochondrial protein involved in the
formation of iron sulfur clusters necessary for respiratory chain complex function
(Kaplan 1999). Finally, individuals were studied who had genetic deficiency of isoforms
of succinate dehydrogenase (SDH), respiratory chain complex II (Jackson, Nuoffer et al.
2014, Alston, Ceccatelli Berti et al. 2015).
Although collectively these subjects are heterogeneous with respect to their specific
molecular diagnoses, the functional consequence of their defects is expected to include a
deficiency in skeletal muscle OXPHOS capacity. Because multiple studies have used 31P100

MRS to demonstrate impaired skeletal muscle OXPHOS in individuals with type 2
diabetes mellitus (Scheuermann-Freestone, Madsen et al. 2003), individuals with diabetes
mellitus were excluded, to avoid confounding results. In order to verify diabetes status,
fasting blood glucose hemoglobin A1c was measured on the day of the study. Healthy,
non-diabetic volunteers were recruited to generate a cohort that was balanced compared
to the group of affected individuals with respect to age, sex, and body mass index (BMI).
Thirty-one subjects were enrolled, 1 was excluded because of a pigmented tattoo, 2 were
claustrophobic and 1 failed to remain still, thus data are presented on 27 subjects with
available MRI data.
Additional Metrics. Height and weight were measured according to standard procedures.
Blood specimens were collected after an overnight fast and processed using standard
techniques for glucose, lipid panel, and hemoglobin A1c (HgbA1c). Several validated
instruments were used to measure important potential covariates affecting mitochondrial
function, including self-reported physical activity, using the Chronic Renal Insufficiency
Cohort (CRIC) Physical Activity Questionnaire (Feldman, Appel et al. 2003),
mitochondrial disease severity, using the Newcastle Mitochondrial Disease Adult Scale
(NMDAS) (Bates, Hollingsworth et al. 2013), and physical function and overall health,
using the NIH Patient-Reported Outcomes Measurement Information System (PROMIS)
Global Health and Physical Function Scales (Barile, Reeve et al. 2013). Subjects were
sedentary from the moment they arrived on the morning of the visit prior to the MRI
scan. All were also instructed to refrain from intensive exercise for at least 24 hours prior
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to the MRI. All MRI scans were performed in the early afternoon, approximately 4 hours
after a standardized breakfast.
Magnetic resonance imaging and magnetic resonance spectroscopy. CrCEST images
were acquired on a 7T whole body scanner (Siemens Medical Systems, Erlangen,
Germany). Imaging experiments were performed using a 28-channel 1H knee coil. The
MRI setup was as described in Chapter 2: subjects were placed feet-first, in the supine
position, into the magnet with the knee coil placed around the right calf, centering the
widest part of the calf muscle at the center of the coil (Figure 2.11). The right foot was
placed into a custom-built, MR-compatible ergometer consisting of a foot pedal
connected to a pneumatically controlled piston set at constant pressure (Figure 2.13).
Anatomical, axial images were acquired of the right calf in all subjects to find the optimal
slice positioning and to be used in post-processing for segmentation (Figure 2.12).
Subjects were imaged at rest for two minutes in order to establish baseline CrCEST.
CrCEST imaging parameters were as follows: saturation pulse: 500 ms, B1rms = 123 Hz
(2.9µT), slice thickness = 10 mm, flip angle = 10°, TR = 6.0 ms, TE = 2.9 ms, field of
view = 160 x 160 mm2, matrix size = 128 x 128, SHOT TR=5s. Four baseline images
were acquired over 2 minutes with a temporal resolution of 30s, followed by 2 minutes of
mild plantar flexion exercise. Exercise was performed in the magnet using the ergometer,
with pressure held constant at 7.5 psi for all subjects. The subjects were instructed to
fully depress the ergometer pedal at a constant rate of 90 flexions over two minutes (1
flexion every ~1.3s), with an average work/s of ~3.5 watts per flexion. Adherence was
assured by 1) verbally coaching the exercise with aid of a metronome to keep accurate
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pace, and 2) visually confirming pedal depression via a direct read-out of a dynamometer.
For this study, we did not attempt to vary exercise intensity according to each
participant’s capacity. Rather, percentage change in CrCEST in response to this light,
standardized exercise workload was an important outcome of interest assessed in affected
individuals as compared to controls. To test for the potential effects of differential
exercise intensity on τCr, percentage change in CrCEST was included as a covariate in
statistical models.
Immediately after exercise, 8 minutes of CrCEST images were acquired with the same
30s resolution (16 consecutive images). Image processing was performed using in-house
MATLAB scripts and a processing GUI (described in the next section). WASSR (Kim,
Gillen et al. 2009) maps to correct B0 inhomogeneities, and B1 maps were acquired preand post-exercise, and used to generate corrected CrCEST images as described for the
previous muscle study in healthy subjects. As described in Chapter 2, CrCEST contrast
was computed by subtracting the normalized magnetization signal at the Cr amine proton
frequency (Δω = +1.8 ppm), from the magnetization at the corresponding reference
frequency on the opposite side of the water resonance (-Δω). CrCEST changes in
individual muscle groups pre- and post-exercise were determined by overlaying CrCEST
maps onto manually segmented anatomic images. τCr was calculated using a MATLAB
fitting routine (‘nlinfit’) by fitting the CrCEST contrast decay post-exercise from each
kN

segmented muscle to a single exponential of the form 𝐶𝑟 𝑡 = 𝑎 1 ∗ 𝑒 M l + 𝑎(3) where
a(1), a(2), and a(3) are constants and t=time.
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31

P MRS was performed with a 7-cm diameter 1H/31P dual tuned surface coil using an un-

localized free induction decay (FID) sequence with the following parameters: number of
points = 512, averages = 5, and TR = 2.4 s, with 4 “dummy scans” per acquisition, in
order to obtain similar time resolution to the CrCEST image acquisition (21.6s vs. 30s).
31

P MRS spectra were phased and baseline corrected and fitted using nonlinear least

squares method with Lorentzian functions. τPCr was determined by calculating the area
under the curve for the PCr peak from every FID post-exercise, and fitting the recovery to
kN

a single exponential equation of the form 𝑃𝐶𝑟 𝑡 = 𝑎 1 ∗ (1 − 𝑒 M l ) + 𝑎(3) where
a(1), a(2), and a(3) are constants and t=time. The intracellular pH was calculated as
described by McCormack et al. for both pre- and post-exercise by comparing the
chemical shift difference between the PCr peak and the Pi peak using 𝑝𝐻 = 6.85 +
𝑙𝑜𝑔 (𝜕 − 3.56)/(5.64 − 𝜕) (McCormack, McCarthy et al. 2011).
Statistics. Clinical characteristics were summarized with standard descriptive statistics
and compared between affected and unaffected individuals using parametric or nonparametric methods, as appropriate given the variable distributions. Pearson’s correlation
coefficient was used to measure the correlation between continuous variables. τCr was
log-transformed due to non-normal distribution, and linear mixed effects regression
analyses were performed to assess the effect of mitochondrial disease status on τCr
measured over time, adjusted for other clinical covariates in separate statistical models.
These statistical models account for within-subject correlation due to repeated measures
by including a subject-specific random effect. In each model, mitochondrial disease
status and muscle group analyzed are included as fixed effects along with others as
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follows: in Model 1) no additional fixed effects, i.e., mitochondrial disease status and
muscle group alone; in Model 2) mitochondrial disease status, muscle group, resting
CrCEST, and percent change in CrCEST; in Model 3) mitochondrial disease status,
muscle group, and total self-reported total physical activity (MET-hours per week); and
in Model 4) mitochondrial disease status, muscle group, age, and gender.
The independent effects of clinical covariates on log-transformed resting CrCEST were
also assessed using mixed-effects regression analysis. Included in these models were:
between-subject variability (random effect), mitochondrial disease status, and muscle
group (fixed effects) and, as additional fixed effects, as follows: Model 1) no additional
factors, i.e., mitochondrial disease status and muscle group alone; in Model 2)
mitochondrial disease status, muscle group and, total physical activity (MET-hours per
week); and in Model 3) mitochondrial disease status, muscle group, age, and gender. All
of the clinical covariates were considered as fixed effects in separate models as shown to
avoid over-fitting given the sample size and number of observations in this study.
For physical activity, total physical activity (MET-hours per week) was chosen because
of the statistically significant differences observed between affected individuals and
healthy volunteers on this covariate. Aikaike Information Criterion (AIC) and Bayesian
Information Criterion (BIC) values are calculated for each model to permit goodness-offit comparisons. Sensitivity analyses were performed by analyzing subsets of participants
with established genetic diagnoses (i.e., excluding the 2/13 individuals with variants of
uncertain significance), and also the subset of subjects not taking creatine (i.e., excluding
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the 3/13 subjects with mitochondrial disease who were taking supplemental creatine), to
assess for any potential associated source of bias.
For analyses of the association between habitual intentional exercise, collected via
validated instrument, with imaging parameters, non-parametric correlation analyses were
performed on non-normally distributed variables, stratified by i) group (all participants,
participants with mitochondrial disease, participants without mitochondrial disease); ii)
imaging technique (CrCEST,

31

P MRS), and iii) parameter type (baseline, post-exercise

decline or recovery time constant). Both nominal and Bonferroni-adjusted statistical
significance thresholds are shown. Since we observed an association between intentional
exercise and both baseline and post-exercise CrCEST values, we also performed a
sensitivity analysis, repeating mixed-effects regression analyses with intentional exercise
(MET-hours per week) in place of total physical activity (MET-hours per week) in the
models to determine the independence of effects. For preliminary reproducibility studies,
the within-subject coefficient of variation between Day 1 and Day 2 measurements was
calculated for each participant. All analyses were conducted using R (version 3.1.3), and
statistical significance was taken as two-sided p-value of < 0.05.
Study approval. This cross-sectional, observational study enrolling both cases and
controls was performed under an approved Institutional Review Board protocol of the
University of Pennsylvania (www.clinicaltrials.gov: NCT02154711) and was conducted
according to the Declaration of Helsinki. Written, informed consent was obtained from
all participants prior to their inclusion in the study.
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3.5.3 Results
Subject characteristics (n=27). Characteristics are summarized in Table 3-2. The two
groups were well-matched with respect to age, sex, and body mass index (BMI). Some
affected individuals were non-ambulatory, as reflected in overall group differences in
weekly physical activity (MET-hours, p=0.049). Self-reported physical activity (A) is
estimated over the 4 weeks prior to the study. A higher NMDAS score (B) indicates more
severe disease. Symptoms were estimated by the subject over the 4 weeks prior to the
study. Although the NMDAS scale has not been validated in healthy adults, we
administered it here to indicate the degree of comparable symptom burden. A higher NIH
PROMIS physical function score (C) indicates better physical function. A higher NIH
PROMIS global health score (D) indicates better overall health. All statistically
significant differences are shown in bold text. IQI = interquartile interval; MET =
metabolic-equivalent (*p<0.05, **p<0.01, ***p<0.001 for difference between subjects
with mitochondrial disease versus healthy volunteers by two-sample t-test, Wilcoxon
rank sum test, or chi-square test, as appropriate).
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Table 3-2 Subject characteristics
Mitochondrial
Disease

Healthy
Volunteers

(n=13)

(n=14)

Sex (% female, n)

62 (8)

57 (8)

Age (years)

42.1 ± 12.9

45.5 ± 13.7

Body Mass Index (kg/m2)

26.5 ± 6.7

25.9 ± 4.7

Underweight, <18.5 (%, n)

8 (1)

0 (0)

Normal weight, 18.5 – 24.9 (%, n)

38 (5)

43 (6)

Overweight, 25 – 30 (%, n)

31 (4)

43 (6)

Obese, >30 (%, n)

23 (3)

14 (2)

92 (12)

100 (14)

HgbA1c (%)

5.00 ± 0.28

5.22 ± 0.30

Glucose (mg/dL)

85 ± 8

90 ± 9

Cholesterol, total (mg/dL)

190 ± 36

188 ± 43

Triglycerides (mg/dL)

116 ± 56

121 ± 75

52 ± 12

52 ± 10

115 ± 26

112 ± 38

Total (hrs per wk)

7.3 ± 4.5

9.3 ± 3.3

Total (MET-hrs per wk)

16.4 ± 11.8*

25.4 ± 10.5

Self-reported
white, n)

Population

Ancestry

(%

Laboratory Studies

High-density
mg/dL)

Lipoprotein

(HDL,

Low-density
mg/dL)

Lipoprotein

(LDL,

Self-reported Physical ActivityA
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Mitochondrial
Disease

Healthy
Volunteers

(n=13)

(n=14)

0.9 ± 1.3*

2.5 ± 1.9

Moderate-heavy activity, >3 METs)
(hrs
per week)
Moderate-heavy activity, >3 METs
4.8 ± 6.4*
(MET- hrs per week)

11.2 ± 8.3

Intentional exercise (hrs per wk)

1.5 ± 0.9

0.7 ± 0.8*

Intentional exercise (MET-hrs per
4.0 ± 4.9
week)

7.2 ± 3.8

Newcastle Mitochondrial Disease Adult ScaleB
0, asymptomatic (%, n)

8 (1)*

38 (5)

1 – 5, mild (%, n)

38 (5)*

64 (9)

6 – 20, moderate (%, n)

46 (6)*

0

>20, severe (%, n)

8 (1)*

0

NIH PROMIS Physical Function ScaleC

41.8 ± 7.6***

56.8 ± 2.9

NIH PROMIS Global Health ScaleD

32.8 ± 4.2***

39.5 ± 3.0

Results of CrCEST imaging, including: resting-state CrCEST values, % change postexercise, and τCr; and

31

P MRS measurements of: baseline ratio of PCr to inorganic

phosphate (PCr/Pi), % change of PCr, pH, and τPCr, are provided in Table 3-3. Not all
subjects completed

31

P MRS imaging given time constraints (1), as CrCEST was

prioritized (n=11 mitochondrial disease subjects, n=12 control subjects). No attempt was
made to exclude any outlier values for this summary table. Means are presented ±SD
except where indicated in cases of non-normal variable distributions, in which case
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medians ±IQI are shown. The Shapiro-Wilk test was used to assess normality of
distribution except a normal distribution was assumed for normalized scales. All
statistically significant differences are shown in bold text. IQI = interquartile interval;
MET = metabolic-equivalent (*p<0.05, **p<0.01, ***p<0.001 for difference between
subjects with mitochondrial disease versus healthy volunteers by two-sample t-test,
Wilcoxon rank sum test, or chi-square test, as appropriate).
Table 3-3 Creatine CEST imaging results
Mitochondrial
Disease

Healthy
Volunteers

(n=13)

(n=14)

Resting CrCEST (% asymmetry, index of free creatine concentration)
Medial gastrocnemius (median, IQI)

11.5
12.4)

(11.1

– 12.1
12.7)

(11.7

–

Lateral gastrocnemius (median, IQI)

11.5
12.1)

(11.0

– 11.5
14.0)

(11.0

–

Soleus (median, IQI)

12.3
13.5)

(11.7

– 12.4
13.2)

(11.7

–

% change in CrCEST with exercise (% change from baseline)
Medial gastrocnemius

32.9 ± 15.6

23.7 ± 15.3

Lateral gastrocnemius

37.8 ± 22.7

29.9 ± 20.1

Soleus

21.2 ± 11.1

17.4 ± 9.6

Medial gastrocnemius (median, IQI)

2.2* (1.7 – 2.9)

1.4 (0.8 – 1.7)

Lateral gastrocnemius (median, IQI)

2.0 (1.2 – 3.6)

1.4 (0.6 – 2.0)

Soleus (median, IQI)

2.1 (1.7 – 3.7)

1.7 (1.1 – 2.7)

τCr (in minutes)

31

Phosphorus-Magnetic Resonance Spectroscopy Parameters1
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Mitochondrial
Disease

Healthy
Volunteers

(n=13)

(n=14)

8.5 ± 2.2

9.3 ± 2.1

22.8 ± 11.2

16.2 ± 15.9

Resting pH

7.09 ± 0.04

7.08 ± 0.04

End-exercise pH

6.99 ± 0.05*

7.04 ± 0.06

τPCr (in minutes; median, IQI)

1.10
1.83)

Baseline PCr/Pi ratio
% change in PCr with exercise
(% from baseline)

(0.87

– 0.77
1.40)

(0.69

Diagnostic details for individuals with mitochondrial disease (n=13) are provided
in Table 3-4. Subjects had clinical and/or biochemical features consistent with
disorders of the mitochondrial respiratory chain, and molecular diagnoses as
noted. In 2/13 subjects, the identified mutations were variants of uncertain
significance (VUS), with causality as yet to be established.

Table 3-4 Diagnoses in individuals with mitochondrial respiratory chain diseases
Diagnoses (n=13)
Chronic progressive external ophthalmoplegiaplus: C10ORF12 (c.1110C>G; p.F370L), 1
subject; mtDNA deletions on muscle biopsy, 2
subjects
MFN2 (c.1699A>G; p.M567V)
POLG
(ND5)

(c.2209G>C;

p.E441G);

m.13064T>C

MELAS: m.3288A>G (tRNA-Leu)
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–

Diagnoses (n=13)
MELAS-like: m.1630A>G (tRNA-Val)
GJB1 (c.14G>T; p.G5V); VUS
SYNE1 (c.1162G>A;
p.L2356F); VUS

p.D388N,

c.7066C>T;

Friedreich Ataxia: FXN GAA triplet expansions
(2 subjects; triple expansion lengths 454/777 and
525/1050 for these, respectively)
SDHD (c.209G>T; pR70M)
SDHB (c.600G>T; pW200C)

Physical activity, which is expected to impact muscle OXPHOS capacity, was included
as a covariate in mixed-effects regression models (Table 3-5). Each of the models
include the subject from which the measurement was obtained (as a random effect) and
the clinical covariates shown (as fixed effects). For all models, n=26 subjects contributing
a total of 74 muscle-specific post-exercise CrCEST recovery estimates (i.e., if subjects
exercised more than one muscle group, then more than one post-exercise recovery time
constant could be calculated); the mixed effects modeling strategy accounts statistically
for the effects of obtaining multiple measurements per subject. Coefficients are
represented as standardized β values, with their corresponding p values; statistically
significant results are shown in bold text. Aikaike Information Criterion (AIC) and
Bayesian Information Criterion (BIC) values are calculated for each model to permit
goodness-of-fit comparisons (NS = not significant; AIC = Aikaike Information Criterion;
BIC = Bayesian Information Criterion).
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Table 3-5 Mixed effects regression models of log-transformed post-exercise CrCEST
decline time constant (τCr, in minutes)
Model 1
standard
-ized β

Model 2
standard
-ized β

Model 3
standard
-ized β

Model 4
standard
-ized β

(p-value)

(p-value)

(p-value)

(p-value)

0.32
(0.017)

0.26
(0.045)

0.40
(0.007)

0.32
(0.020)

Mitochondrial disease status
Muscle group
Lateral gastrocnemius (reference)

-

-

-

-

Medial gastrocnemius

0.06 (NS) 0.09 (NS) 0.06 (NS) 0.05 (NS)

Soleus

0.14 (NS) 0.22 (NS) 0.15 (NS) 0.14 (NS)

CrCEST parameters
-

-0.03
(NS)

-

-

-

0.21 (NS)

-

-

-

-

0.19 (NS)

-

Age

-

-

-

0.002
(NS)

Sex

-

-

-

0.09 (NS)

AIC

224

236

231

236

BIC

238

254

248

254

Baseline CrCEST
% change CrCEST with exercise
Total physical activity
(MET-hours/wk)

Exponential time constant for the decline in Cr post-exercise (τCr). Figure 3.1 shows
representative images of resting CrCEST levels (panels A and E), and τCr (panels B and
F). Figure 3.1C-D and G-H shows the corresponding post-exercise CrCEST and PCr
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profiles. Overall, subjects in both groups demonstrated a measurable muscle groupspecific increase (range 17.4% to 32.9%) in CrCEST signal after exercise. τCr was not
normally distributed.

Figure 3.1 Example resting and post-exercise CrCEST recovery images and
summary curves. A-D (left) is from a heathy 21-year-old female, and Figure 3.1E-H
(right) is from a 21-year-old female with an mtDNA mutation, m.1630G>A (tRNA-Val)
with hearing impairment, short stature, and stroke(Glatz, D'Aco et al. 2011). Panels 1A
and 1E show the sequential resting CrCEST images (one image every 30 seconds at rest),
overlaid on the manually segmented, anatomical axial calf muscle image, for the healthy
and affected individuals, respectively. The images encompass the muscle region of the
right calf. The intensity of the color in each image, as shown on the color bar, is in
proportion to the CrCEST % assymetry signal, reflecting the amount of free creatine.
Resting CrCEST appears lower in the affected individual as well (e.g., in soleus, CrCEST
asymmetry is 11.1% in the affected individual versus 13.2% in healthy individual).
Panels 3.1B and 3.1F show the sequential post-exercise images (one image every 30
seconds after cessation of exercise) in the healthy and affected individuals, respectively.
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Both subjects exercised, as indicated by the increase in free creatine, although the
specific muscle groups used differ, and the % change in CrCEST for the same exercise
was higher in the affected individual (e.g., in the soleus, 28% in the affected individual
versus 10% in the healthy control). By ~2 minutes post-exercise, the healthy volunteer’s
CrCEST image resembles the baseline image, but in the affected individual, τCr is
prolonged (e.g., in the soleus, 5.9 minutes in the affected individual versus 1.1 minutes in
the healthy control). Panels 3.1C and 3.1G show the post-exercise CrCEST signal
recovery summarized over the anatomic region corresponding to the approximate area of
the surface 31P-MRS coil. Panels 3.1D and 3.1H show the post-exercise PCr signal
recovery in this same anatomic region. In both modalities, prolonged post-exercise
recovery is observed in the affected individual relative to the healthy individual.
(Reprinted with permission (DeBrosse et al. 2016).)

Non-parametric bivariate analysis of the medial gastrocnemius (MG) (Table 3-3) showed
a significant difference between affected individuals and controls in τCr (p=0.026). Other
muscle groups were less consistently exercised in all subjects, and results for τCr were in
a similar direction, but did not achieve statistical significance. Mixed-effects regression
models of τCr (log-transformed given non-normal distribution, Table 3-5) demonstrated
a statistically significant effect of mitochondrial disease in all models. None of the other
clinical covariates examined showed a statistically significant effect. Figure 3.2 is a box
plot for post-exercise CrCEST exponential time constants (τCr), which are longer in
individuals with mitochondrial diseases, though an overlap is observed even after
adjustment for covariates. Log-transformed τCr values were used in statistical modeling.
Mean model-derived estimates illustrate the longer τCr for individuals with
mitochondrial diseases as compared to controls (p=0.017 in Model 1).
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Figure 3.2 Box plots for post-exercise CrCEST exponential time constant (τCr), an
index of skeletal muscle OXPHOS capacity (red = control, blue = mitochondrial
disease). The horizontal line corresponds to the median, the lower and upper margins of
the boxes correspond to the 25%ile and the 75%ile, respectively, and whiskers show 1.5
x the inter-quartile interval (IQI). The distribution of τCr is not normal so non-parametric
statistics are shown here. Log-transformed τCr values were used in statistical modeling.
A prolonged τCr values corresponds to less OXPHOS capacity. Mitochondrial disease
increases τCr by 0.32 SDs (p=0.017). The range of values shown results in part from the
inter-subject variability of the which muscle groups were engaged in exercise and to what
extent. (Reprinted with permission (DeBrosse et al. 2016).)

Resting CrCEST. Resting CrCEST, an index of free creatine concentration, showed no
statistically significant differences between affected and unaffected individuals (Table
3.3 and Table 3-6). In Table 3-6, each of the models include the subject from which the
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measurement was obtained (as a random effect) and the clinical covariates shown (as
fixed effects). For all models, n=27 subjects contributing a total of 84 muscle-specific
post-exercise CrCEST recovery estimates (i.e., if subjects exercised more than one
muscle group, then more than one post-exercise recovery time constant could be
calculated); the mixed effects modeling strategy accounts statistically for the effects of
obtaining multiple measurements per subject. Coefficients are represented as
standardized b values, with their corresponding p values; statistically significant results
are shown in bold text. Aikaike Information Criterion (AIC) and Bayesian Information
Criterion (BIC) values are calculated for each model to permit goodness-of-fit
comparisons (NS = not significant; AIC = Aikaike Information Criterion; BIC =
Bayesian Information Criterion).
Table 3-6 Mixed effects regression models of log-transformed resting CrCEST (%
asymmetry)
Model 1
standardized β

Model
2 Model
3
standard- standardized β
ized β
(p-value)

(p-value)

-0.16 (NS)

-0.07 (NS)

-0.17 (NS)

-

-

-

Medial gastrocnemius

0.06 (NS)

0.06 (NS)

0.06 (NS)

Soleus

0.35
(0.0029)

0.35
(0.0028)

0.35
(0.0031)

-

0.23 (0.07)

-

(p-value)
Mitochondrial disease status
Muscle group
Lateral gastrocnemius (reference)

Total physical
hours/wk)

activity

(MET-
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Model 1
standardized β
(p-value)

Model
2 Model
3
standard- standardized β
ized β
(p-value)

(p-value)

Age

-

-

-0.11 (NS)

Sex

-

-

0.01 (NS)

AIC

-72

-62

-52

BIC

-57

-45

-33

With respect to muscle group, resting CrCEST, as reflected in % CrCEST asymmetry per
unit muscle area, was highest in soleus as compared to either lateral gastrocnemius (LG)
(p=0.0058) or MG (p=0.030) by post-hoc Tukey testing in Model 1, with similar results
in Models 2 and 3. A positive association was observed between self-reported total
physical activity (MET-hours per week) and a higher resting CrCEST, but this result did
not reach statistical significance in the multivariable models (standardized β=0.23,
p=0.070). Several subjects with mitochondrial myopathy had very low levels of CrCEST,
hence the large variance in signal, but overall we did not observe a statistically significant
difference between affected individuals and unaffected volunteers in resting CrCEST.
31

P MRS. Four subjects (2 of 13 mitochondrial disease, 2 of 14 healthy controls)

completed only CrCEST imaging, and not 31P MRS. These participants elected not to reenter the scanner for the second same-day study. To examine the association between 31P
MRS and CrCEST measurements in the remaining participants, a CrCEST region of
interest was defined corresponding to the leg area (including portions of multiple muscle
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groups) assessed by the 31P MRS surface coil. A positive within-subject association was
observed between log-transformed τPCr and log-transformed τCr (Pearson’s correlation
coefficient=0.43, p=0.046) (Figure 3.3).

Figure 3.3 τPCr/τCr correlation. Correlation between the recovery time constants for
PCr derived from spectroscopy and Cr derived from CEST.

Within-subject log-transformed resting PCr/Pi was also positively associated with logtransformed resting CrCEST (Pearson’s correlation coefficient=0.44, p=0.023). In
addition, prior studies with

31

P MRS (Tarnopolsky and Parise 1999) have posited that

reduced creatine transport into muscle and lower resting creatine may be related to post119

exercise PCr recovery. Indeed, we found that lower resting CrCEST (log-transformed)
was associated with prolonged τPCr (log-transformed), with Pearson’s correlation
coefficient -0.42, p=0.046. While resting pH did not differ between mitochondrial disease
subjects and unaffected controls, post-exercise pH in the affected group was slightly
lower: 6.99 versus 7.04 (p<0.05; Table 1). This likely reflects the exercise-induced
increased % change in Cr or PCr in affected individuals, though the latter changes are
highly variable and do not reach statistical significance at the group level.
Anatomic Variation. Figure 3.4 shows images from the right leg of a 60-year-old man
with chronic progressive external ophthalmoplegia due to a pathogenic autosomal
dominant mutation in C10ORF2 (c.1110C>G; p.F370L).

Figure 3.4 Example of muscle group-specific metabolic variation captured by
CrCEST. Images from the right leg of a 60-year-old subject with chronic progressive
external ophthalmoplegia due to a mutation in C10ORF12 (c.1110C>G; p.F370L). Panel
3.4A is from a 1.5-Tesla clinical image, and shows nearly complete fatty replacement of
the MG. In Panel 3.4B, the corresponding area is indicated with a white arrow on a
resting CrCEST image obtained at 7.0-Tesla. The intensity of the color in each image, as
shown on the color bar, is in proportion to the CrCEST % assymetry signal reflecting the
amount of free creatine. In Panel 3.4B, resting CrCEST signal is much lower in the MG
than in other muscle groups. Post-exercise, there is no increase in CrCEST signal in this
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region (Panel 3.4C, white arrow). These images illustrate the advantage of performing
muscle group-specific measurements in individuals with mitochondrial diseases, given
the anatomic variation that can occur in metabolic derangement (Zierath and Hawley
2004). (Reprinted with permission (DeBrosse et al. 2016).)

Sensitivity Analyses. Main analyses were repeated while excluding specific subsets of
participants to ensure the robustness of the main findings. Exclusion of either participants
with “non-classic” mitochondrial diseases, including those with SDH mutations (2 of 13)
and sequence variants of uncertain significance (2 of 13), or participants taking
supplemental creatine (n=3) did not substantially alter the finding of prolonged τCr in
affected individuals (effect of mitochondrial disease, standardized β =0.27, p=0.060 and β
=0.32, p=0.027, respectively).

Intentional Exercise. Figure 3.5 is a correlogram showing the relationships between
intentional exercise, baseline CrCEST or PCr/Pi, and post-exercise τCr or τPCr. Nonparametric bivariate correlation analyses were performed for these non-normally
distributed outcomes. To allow for the possibility of muscle group differences in response
to habitual intentional exercise, muscle groups were analyzed separately.
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Figure 3.5 Correlogram of the association between intentional exercise) and
measured imaging parameters (expressed either as hours per week, reflecting time
spent exercising, or Mets per week, reflecting both time and intensity spent
exercising) and measured imaging parameters. The results of non-parametric
correlation analyses are shown for all participants (first group of two columns), for
participants with mitochondrial disease (second group of two columns), and for control
participants (third group of two columns). Groups are separated by horizontal black lines.
Four of the rows indicate baseline (i.e., pre-exercise) metabolite concentration: baseline
CrCEST in the soleus, medial gastrocnemius, and lateral gastrocnemius, and PCr/Pi in the
region of interest captured by 31P MRS. A higher resting CrCEST or PCr/Pi value
suggests more bioenergetic capacity at rest. Four of the rows indicate post-exercise
exponential time constants for return to baseline of CrCEST in soleus, medial
gastrocnemius, and lateral gastrocnemius, and PCr in the region of interest captured by
31
P MRS. A longer post-exercise time constant to return to baseline suggests decreased
OXPHOS capacity. The two types of imaging assessment (baseline, post-exercise) are
separated by the dashed horizontal black line. As indicated by the color bar, positive
associations are shown in red, and negative associations in yellow. The degree of
statistical significance is given by the asterisk; one asterisk indicates nominal p value <
0.05; two asterisks indicates Bonferroni p value < 0.05 (adjusted for the 16 comparisons
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shown for each group). BL = baseline; Sol=soleus; MG=medial gastrocnemius;
LG=lateral gastrocnemius. (Reprinted with permission (DeBrosse et al. 2016).)
Overall, more habitual intentional exercise, whether measured in hours per week
(reflecting time spent exercising) or MET-hours per week (reflecting both time and
intensity of exercise) was associated with higher resting bioenergetic capacity,
represented either by CrCEST or PCr/Pi. This positive association between habitual
intentional exercise and resting CrCEST persisted after statistical correction for multiple
testing in the medial gastrocnemius. In all of the muscle groups tested, and using both
imaging modalities, more habitual intentional exercise was associated with shorter postexercise return of metabolites (free Cr, PCr) to baseline, suggestive of more robust
OXPHOS capacity.
In individuals with mitochondrial disease, there was a positive association between
habitual exercise and baseline CrCEST, particularly in the soleus. Also, there was a
positive association between habitual exercise and more rapid decline of CrCEST postexercise, suggestive of greater OXPHOS capacity, particularly in medial gastrocnemius.
In control participants, we observed a nominal association between between habitual
exercise and resting CrCEST in two muscle groups, but we did not detect an association
between usual habitual exercise and imaging estimates of OXPHOS capacity. Finally,
given the observed associations of imaging parameters with intentional exercise, we
repeated mixed effects regression analyses of the effects of covariates on τCr and resting
CrCEST with intentional exercise (MET-hours per week) in place of total physical
activity (MET-hours per week), results in Table 3-6.
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Table 3-7 Mixed effects regression models including the association of
intentional exercise with (Model 1) log-transformed post-exercise CrCEST
decline time constant (τCr, in minutes), an index of skeletal muscle OXPHOS
capacity, where prolonged τCr suggests lower OXPHOS capacity and (Model 2)
log-transformed resting CrCEST (% asymmetry), an index of free creatine
concentration, where higher CrCEST may reflect greater bioenergetic capacity
at rest.
Model 1
standardized
β

Model 2
standardized
β

(p-value)

(p-value)

Outcome

τCr

CrCEST

Mitochondrial disease status

0.32 (0.027)

-0.08 (NS)

-

-

Medial gastrocnemius

0.05 (NS)

0.06 (NS)

Soleus

0.14 (NS)

0.35 (0.0027)

-0.004 (NS)

0.23 (0.064)

Muscle group
Lateral gastrocnemius
(reference)

Intentional Exercise
(MET-hours/wk)

**Each of the models include the subject from which the measurement was obtained (as a
random effect) and the clinical covariates shown (as fixed effects). For Model 1, n=26
subjects contributing a total of 74 muscle-specific post-exercise CrCEST recovery
estimates were included (i.e., if subjects exercised more than one muscle group, then
more than one post-exercise recovery time constant could be calculated); the mixed
effects modeling strategy accounts statistically for the effects of obtaining multiple
measurements per subject. For Model 2, n=27 subjects contributing a total of 84 musclespecific CrCEST measurements were included; the mixed effects modeling strategy
accounts statistically for the effects of obtaining multiple measurements per subject.
Coefficients are represented as standardized β values, with their corresponding p values;
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statistically significant results are shown in bold text. NS = not significant; AIC =
Aikaike Information Criterion; BIC = Bayesian Information Criterion.

The independent association of mitochondrial disease status with prolonged τCr was
confirmed even when habitual intentional exercise was included in the model in place of
total physical activity (for effect of mitochondrial disease, standardized β=0.32, p=0.027).
Intentional exercise was independently associated with higher resting CrCEST, but this
association did not achieve statistical significance (for effect of habitual intentional
exercise, standardized β=0.23, p=0.064).
Effects of age on CrCEST? Due to decreased oxidative capacity in muscle tissue with age
(Boffoli, Scacco et al. 1994, Wei, Lu et al. 1998, Conley, Jubrias et al. 2000) we looked
for a correlation with age and CrCEST signal in resting muscle, expected to be inversely
related (i.e., less signal correlates to less [Cr] in older muscle), and for age and τCr of
recovery, expected to be proportionally related (i.e., younger muscle recovers more
quickly). Although there is some muscle-group specific association (Figures 3.6 and 3.7)
with resting CrCEST and τCr, the small sample, as well as the age distribution precluded
any statistically significant findings.
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Figure 3.6 Resting-state CrCEST vs. age. The baseline, resting-state CrCEST values
(in %, denoted “bl_crcest”) were plotted vs. age of controls (0) and affected subjects (1).
While some association between resting CrCEST and certain muscle groups and age is
observed, no statistical significance was reached.
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Figure 3.7 The τCr values (in min, denoted “crt”) plotted vs. age of controls (0) and
affected subjects (1). While some association between τCr and certain muscle groups and
age is observed in the control group, no statistical significance was reached. A small
number of recovery time constants that were greater than 10min were excluded from this
analysis.

3.5.4 Discussion
From the clinical study described above, we have determined that incorporating CrCEST
in the imaging-based investigation of OXPHOS capacity in individuals with primary
mitochondrial disorders yields several benefits. As noted in the introduction for this
chapter, the CrCEST technique provides a measurement of free creatine, while
spectroscopic methods such as 31P MRS and proton (1H) MRS can only measure PCr and
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total creatine (tCr), respectively. The ability to measure free creatine is useful both in
static measurements of resting-state skeletal muscle, as well as in dynamic exercise
studies. As research into mitochondrial and other metabolic diseases expands, there may
be increased need for the CrCEST technique. For example, resting levels of free creatine
may be altered in subjects with neuromuscular diseases who could potentially have
reduced creatine transport into muscle (Tarnopolsky and Parise 1999, Tarnopolsky,
Parshad et al. 2001). Or, as Cr monohydrate supplements are often used for therapeutic
purposes in mitochondrial disorders (Parikh, Saneto et al. 2009), it may prove useful in
future studies to estimate free creatine with CrCEST as a potential factor influencing
clinical response to treatment. While we did observe low levels of resting creatine, as
measured by CrCEST, in several subjects with mitochondrial myopathy, the overall
group difference between affected and unaffected individuals overall did not reach
statistical significance. The subjects’ self-reported physical activity (MET-hours per
week) appeared to be positively associated with resting CrCEST levels, but the
association did not reach statistical significance in mixed effects regression analyses
including all muscle groups (standardized β=0.23, p=0.070, Table 3.7). In bivariate
correlation analyses of individual muscle groups (Figure 3.5), subjects’ habitual
intentional exercise was positively associated with higher levels of resting CrCEST and
more rapid return of CrCEST to baseline post-exercise in the medial gastrocnemius. A
positive association between exercise and CrCEST parameters was also evident in
mitochondrial disease patients analyzed separately.
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In Chapter 2, we made the case that another major advantage of CrCEST is its high
spatial resolution, which provides muscle group-specific estimates of relative free
creatine concentrations. The capacity to make muscle group-specific measurements is
critical in studies of metabolic disorders, because different muscle groups may have
distinct metabolic and contractile properties, including both mitochondrial density and
the relative ratio of type I oxidative fibers to type II glycolytic fibers (Zierath and Hawley
2004). Differences in muscle fiber type may contribute to metabolic disease; there is
some evidence that the ratio of glycolytic/oxidative enzyme activities is related to insulin
resistance in obese patients and some diabetic populations (Simoneau, Colberg et al.
1995, Simoneau and Kelley 1997). The data for all subjects at rest indicates that soleus
has a higher CrCEST % asymmetry, suggesting that this muscle has a higher
concentration of free creatine than either the medial or lateral gastrocnemius. This finding
might be expected given the higher proportion of oxidative fibers in soleus in previous,
biopsy-based studies (Johnson, Polgar et al. 1973, Trappe, Trappe et al. 2001). Muscle
groups may respond differently to genetic or acquired mitochondrial impairment, as
illustrated in Figure 3.4. In this subject, who had fatty replacement specific to the medial
gastrocnemius muscle, we also observed very low resting-state CrCEST in the medial
gastrocnemius, and no subsequent increase following exercise. CrCEST may prove a
useful tool to mechanistically investigate response of specific muscle groups to exercise
therapy. The nuances of this subject’s muscle composition may have been missed had
they participated only in a spectroscopy study.
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After dynamic exercise, τCr (representing the decline in CrCEST post-exercise) was
prolonged in affected subjects.

Prolonged τCr reflects decreased skeletal muscle

OXPHOS capacity in individuals with primary mitochondrial diseases relative to the
cohort of healthy volunteers. This statistically significant difference persisted even after
accounting for other clinical covariates that could affect OXPHOS capacity. The benefits
of CrCEST’s high spatial resolution were again evident in the exercise component of the
study, as the method provided information about all muscle groups in the exercising limb.
Historically, in

31

P MRS exercise studies, specific muscles were targeted if the entire

exercising limb could not be included in the area assessed by the coil. Unfortunately, if a
particular subject did not utilize the targeted muscles, no recovery time constant could be
calculated. Individuals with muscle diseases may need to use additional or alternate
muscle groups to complete an exercise task. With the CrCEST technique, post-exercise
recovery time constants can be calculated for each muscle group that is deployed.
It is interesting to note that although there were directionally consistent group-specific
differences between τCr and τPCr obtained from the two separate bouts of exercise
(Figure 3.3), and a positive within-subject correlation between τCr and τPCr, τCr values
tended to be longer in this study. We speculate that this could be attributed in part to the
differences in modalities, in which the surface coil used for

31

P-MRS provides an

unlocalized signal, whereas the volume coil used for CrCEST imaging enables exact slice
selection. An intensive comparison of the two methods, in which slices for CrCEST are
chosen based on the excitation profile of the surface coil, will be the focus of a future
study. We have also speculated that the increased blood flow after exercise, which could
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change the water content in the muscle tissue, could also affect the measurement of the
CEST signal. The effects of protocol design and other factors on τCr will also be the
focus of future investigation. Nonetheless, the results of our initial study further illustrate
several benefits of including CrCEST in studies of skeletal muscle metabolism. CrCEST
may ultimately provide insight into the aspects of phosphocreatine shuttle that cannot be
studied with

31

P MRS alone. Indeed, as has been previously suggested, the capacity to

estimate resting creatine levels is also important in subjects with mitochondrial
myopathies who may have altered creatine transport into muscle (Tarnopolsky and Parise
1999).
Exercise, particularly at high intensity, is one of the most potent signals for mitochondrial
biogenesis (Little, Gillen et al. 2011, Little, Safdar et al. 2011). Imaging studies of PCr
metabolism have been used to measure the effects of exercise on bioenergetic
capacity(Kent-Braun, McCully et al. 1990). To enrich our interpretation of CrCEST
imaging findings, we performed detailed analyses of the association between habitual
intentional exercise, captured by the validated physical activity data collection instrument
(Feldman, Appel et al. 2003), and the imaging parameters measured. In bivariate
analyses, we demonstrated a muscle-group specific, positive association between habitual
intentional exercise and both resting CrCEST and post-exercise CrCEST return to
baseline. In multivariate analyses where mitochondrial disease diagnosis was also
included in the statistical model, the independent effects of intentional exercise did not
reach statistical significance, likely the result of the larger effect of disease status.
However, when participants with mitochondrial disease were analyzed separately, a
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positive association between intentional exercise and both resting CrCEST and τCr was
observed. This result has a basis in both clinical and epidemiologic observations. Most
physicians recommend exercise therapy for individuals with mitochondrial disorders
(Parikh, Goldstein et al. 2014), on the basis of evidence of clinical benefit in
mitochondrial disease (Murphy, Blakely et al. 2008, Jeppesen, Duno et al. 2009) and
myriad other conditions, e.g., (Ricardo, Anderson et al. 2015). The optimal exercise
therapy for individuals with metabolic myopathy remains the focus of ongoing study.
Intriguingly, the preferred exercise strategy may be genotype-specific. For example,
resistance training may decrease mutation burden in individuals with mitochondrial DNA
deletions (Tarnopolsky 2014). We did not detect a strong statistically significant
association between exercise and CrCEST parameters in control participants, perhaps
related to small sample size and their overall higher level of function. Much remains to be
learned, and CrCEST imaging may facilitate future research into how the nature of the
intentional exercise may itself affect the chronic adaptation to training in skeletal muscle
(Cochran, Percival et al. 2014). In addition, CrCEST imaging may be used to explore
age- and muscle-group specific effects of exercise (Larsen, Callahan et al. 2012).
It must be noted that in this cross-sectional study, a causal relationship between exercise
and imaging results cannot be established. An alternative explanation for our findings
could be that individuals with mitochondrial myopathy who have higher resting CrCEST
and more rapid return to baseline of CrCEST post-exercise are also more able to engage
in intentional exercise. However, we found that affected individuals with mild disease
(NMDAS total score less than 6) engaged in an average of 1.7 MET-hours of activity per
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week, versus 6.1 MET-hours per week in those with moderate or severe disease (p=0.10
for two-sample t-test). That more severely affected individuals in our study may engage
in more habitual exercise presents an intriguing possibility: individuals with worse
disease who exercise may have better preserved physiology and function, and greater
capacity to participate in many activities, including an exercise-based research protocol.
A future exercise intervention study could explore this interesting question in detail.
We concluded that this study had several important strengths and limitations. One
strength is that the study groups were balanced with respect to age, sex and, adiposity
(BMI). Our experimental protocol minimized several factors thought to impact muscle
OXPHOS capacity (pre-testing meal, pre-study exercise, and time of day). Other
covariates were measured, including self-reported physical activity. Because some
affected subjects were non-ambulatory, they had inherently lower physical activity than
otherwise matched controls, which is a potential limitation to the study. We observed a
range of %CrCEST change in study participants after exercise with our study paradigm,
which required the same number of flexions and standardized resistance for each subject.
For this initial proof-of-concept study, variation in %CrCEST change in response to light
exercise was one focus of investigation. However, to address this potential source of
variance in τCr measurements, %CrCEST was included in statistical models as a
covariate. Future work would be further strengthened by setting exercise parameters in
accordance with individual work capacity, and including the work performed by each
subject as a covariate (Cree-Green, Newcomer et al. 2014, Sleigh, Lupson et al. 2016). In
addition, it would be useful to validate techniques for individualizing exercise intensity
133

so as to standardize % change in CrCEST across participants of different abilities and
levels of fitness when τCr is prioritized as the main outcome. While we have attempted to
account for appropriate covariates in this population, it is important to note that other
populations may have additional factors that need consideration; for example, recovery in
patients with vascular disease could be influenced by blood flow, etc. Another potential
limitation of the present study is that we used self-reported exercise data for analyses.
However, physical activity as assessed using the same instrument has been associated
with mortality in a separate study of individuals with chronic illness (kidney disease)
(Ricardo, Anderson et al. 2015), thus we expect a reasonable degree of correspondence
between our results with both imaging parameters and clinical outcomes.
Future studies may also incorporate an investigation of the relationship between τCr and
the results of muscle biopsy studies. However, in the present study, most of the affected
participants had not undergone invasive muscle biopsy for clinical purposes. Muscle
biopsy had not been recommended because the clinical features, together molecular
genetic testing results, were sufficient to establish the diagnosis of mitochondrial disease.
We therefore did not see appropriate cause to perform invasive biopsy testing requiring
general anesthetic, which may be poorly tolerated in individuals with mitochondrial
disease. Affected individuals in this study with “classical” mitochondrial disease
syndromes (CPEO-plus, MELAS, MELAS-like, Friedrich’s Ataxia (FA)) and related
genetic defects (mutations in C10orf12, POLG, MFN2, FXN) had clinical evidence of
impaired muscle mitochondrial function. Deficits in mitochondrial electron transport
chain activity via ex vivo skeletal muscle biopsy studies have been identified previously
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in each of these mitochondrial disease syndromes. For example, the gene C10orf12
encodes Twinkle, a helicase that is critical for mitochondrial DNA replication (Spelbrink,
Li et al. 2001). Mutations in C10orf12, as well as the mitochondrial replicase, POLG, are
associated with mitochondrial DNA depletion and/or deletions with muscle biopsy
findings typically involving multiple respiratory chain complex enzyme deficiency and
immunohistochemical evidence of cytochrome oxidase (Complex IV) deficient muscle
fibers (Zierz, Joshi et al. 2015). In individuals with myopathy related to MELAS, skeletal
muscle biopsy may demonstrate the presence of ragged red fibers, indicative of
mitochondrial proliferation (Milone, Klassen et al. 2013). Seminal studies are
additionally reviewed in (Dimauro, Bonilla et al. 1985). In FA, abnormal muscle
OXPHOS capacity is related to mitochondrial iron overload; decreased OXPHOS
capacity in FA has been demonstrated by skeletal muscle biopsy (Bayot, Santos et al.
2011) as well as
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P-MRS (Lodi, Cooper et al. 1999). Mutations in “non-classical”

mitochondrial disease genes, including succinate dehydrogenase (SDHx) subunit genes
have been also associated with reduced OXPHOS capacity in muscle (Alston, Davison et
al. 2012, Alston, Ceccatelli Berti et al. 2015) although the clinical association is less
clear. For this reason, in this study we performed sensitivity analyses on the effects of
excluding individuals with SDHx mutations and individuals with novel gene variants of
uncertain significance with respect to mitochondrial disease on our main analysis.

135

3.6 Summary
In this small clinical study, we demonstrated persistent differences in post-exercise
CrCEST decline exponential time constant as compared to healthy volunteers.
Heterogeneity of clinical and molecular diagnoses in affected subjects is a source of
biological variance. Despite this heterogeneity, we still observed a statistically significant
effect of disease status on post-exercise τCr. This result shows that CrCEST imaging can
identify decreased OXPHOS capacity in a genetically heterogeneous population whose
molecular gene defects are likely to share a common pathophysiology involving
decreased OXPHOS capacity (Bates, Hollingsworth et al. 2013). These studies
demonstrate that non-invasive CrCEST imaging can be used to quantitatively monitor
physiologic changes after exercise, including both creatine content and metabolic
capacity, in individuals with mitochondrial diseases. Optimally, CrCEST will be used to
complement existing
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P MRS-based assessments to perform a more complete,

comprehensive assessment of the phosphocreatine shuttle function in individuals with
mitochondrial disorders. This work lays a foundation to develop CrCEST as a potential
non-invasive imaging-based biomarker of OXPHOS capacity that may be useful in the
diagnosis, long-term monitoring, and/or evaluation of response to clinical treatments in
individuals with diverse types of mitochondrial diseases.
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Chapter 4 - Development of Lactate CEST and its applications for monitoring
glycolysis in vivo
4.1 Introduction
In the preceding chapters, we discussed the CEST imaging technique in context of
metabolic disorders, focusing on creatine as a marker of mitochondrial function. This
chapter will shift focus to lactate, which is another vital metabolite and particularly
relevant to cancer. Changes in lactate metabolism are associated with a wide variety of
diseases besides cancer (Waterhouse 1974), such as cardiac failure (Chiolero, Revelly et
al. 2000), liver disease (Jeppesen, Mortensen et al. 2013), diabetes mellitus (Misbin,
Green et al. 1998), and neurologic disorders such as epilepsy (Folbergrova and Kunz
2012). We will discuss our motivation for developing lactate CEST, the development
process using phantoms, and some initial applications in vivo.
4.1.1 Lactate metabolism
In the human body, lactate (a hydroxycarboxylic acid) is derived from glucose, which is
metabolized via glycolysis or the pentose phosphate pathway. In glycolysis, glucose is
first converted into pyruvate and then into lactate by lactate dehydrogenase (LDH). This
occurs in the cytosol and has a corresponding oxidation of NADH to produce NAD+.
This reaction is reversible; the reverse direction oxidizes lactate back to pyruvate while
generating NADH from the reduction of NAD+. In the pentose phosphate pathway,
glucose is metabolized to form NADPH and ribose-5-phosphate. As discussed in Chapter
1, NADPH is necessary for synthesizing fatty acids. Lactate can also be formed from
alanine by the enzyme glutamate pyruvate transaminase (GPT), which catalyzes the
conversion of alanine and α–ketoglutarate into pyruvate and glutamate, respectively
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(Adeva, Gonzalez-Lucan et al. 2013). This process occurs both in the cytoplasm and in
the mitochondrial network. Once pyruvate is formed through this reaction, it can be
reduced to lactate by LDH. Oxidation of pyruvate to CO2 to generate energy is required
for the oxidative metabolism process detailed in Chapter 1. Defects in the mitochondrial
respiratory chain (or in the TCA cycle) inhibit ATP synthesis from substrates like
pyruvate. This causes cells to become dependent on glycolysis instead, which doesn’t
require oxygen to generate ATP, and produces lactate as the end product (Gladden 2004).

4.1.2 Lactate in skeletal and cardiac muscle
In resting skeletal muscle, lactate generally maintains a concentration of ~3 mM,
compared to ~1mM in blood (Gaitanos, Williams et al. 1993). Skeletal muscle produces
and consumes lactate. When muscle is exercised, lactate concentration increases and is
released into the bloodstream. With high-intensity exercise, lactate levels in the blood are
increased when skeletal muscle oxygen is consumed leading to utilization of glycolysis
and a subsequent rapid rise in lactate, which is washed out into the blood. Large increase
in lactate concentration is referred to as hyperlactatemia, which the body responds to by
uptake of lactate by other tissues, for example, non-exercising muscles. In subjects who
undergo endurance training, lactate production in muscles is eventually reduced, leading
to enhanced oxidative efficiency of the mitochondrial respiratory chain (Bergman, Wolfel
et al. 1999, Steiner, Murphy et al. 2011). When tissues become hypoxic, which can occur
for a variety of reasons including heart disease, skeletal muscles respond to any amount
of activity with a dramatic increase in lactate production. Lactate may also regulate
substrate utilization in myocardial tissue, as there is correlation between levels of lactate
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in blood and the cardiac lactate extraction in healthy subjects undergoing moderate
exercise. In addition to the importance of lactate in healthy muscle metabolism, in some
of the mitochondrial disorders described in chapter 3, like MELAS, there is a clinical
feature of lactic acidosis.

4.1.3 Lactate in cancer
As a result of the Warburg effect, tumors exhibit up-regulated lactate dehydrogenase
(LDH), leading to increased levels of lactate (Fantin, St-Pierre et al. 2006). The enzyme
responsible for lactate production, LDH, has become a target for cancer therapy. In
tumors, when oxygen is absent or in short supply (hypoxia), LDH converts pyruvate to
lactate (Potter, Newport et al. 2016). Even in the presence of sufficient oxygen, tumor
cells derive their energy from glycolysis (Warburg effect) leading to increased production
of lactic acid (Heiden, Cantley et al. 2009, Dang 2010, Hirschey, DeBerardinis et al.
2015). As discussed in Chapter 1, this seems to benefit the cancer cells by allowing them
to divert more substrates into anabolic processes required for continued cell growth and
proliferation. Several studies have shown that tumor lactate levels correlate with
increased metastasis, tumor recurrence, and poor outcome (Walenta, Wetterling et al.
2000, Brizel, Schroeder et al. 2001). Lactate also plays a role in promoting tumor
inflammation and can function as a signaling molecule that stimulates tumor
angiogenesis (Doherty and Cleveland 2013). Non-invasive measurement of lactate is of
tremendous significance to the study of metabolic defects in a wide range of pathologies.
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4.1.4 in vivo measurement of lactate
Currently there are two major methods employed in measuring lactate in vivo. One is
traditional magnetic resonance spectroscopy (MRS; both 1H and

13

C) (Gribbestad,

Petersen et al. 1994, DeBerardinis, Mancuso et al. 2007), which has been used to measure
both static lactate levels and dynamic changes. However, these are limited by inadequate
sensitivity and spatial resolution. The other method involves

13

C-labeled pyruvate

infusion and dynamic nuclear polarization (DNP), which provides greater than 10,000
fold signal enhancement compared to conventional MRS (Golman, in't Zandt et al. 2006,
Golman, in't Zandt et al. 2006, Day, Kettunen et al. 2007). Despite its high sensitivity,
this method only probes fast kinetics (<1min) of lactate turnover from

13

C-labeled

pyruvate, and it requires special equipment and complex modeling for data analysis
(Nelson, Kurhanewicz et al. 2013, Walker-Samuel, Ramasawmy et al. 2013). There is a
clear need for development of new tools for noninvasive imaging of lactate in vivo.
In the context of cancer imaging, CEST has been previously used to image hydroxyl
protons from glucose (Chan, McMahon et al. 2012, Wang, Weygand et al. 2016).
Glucose serves as fuel for proliferating cancer cells, and higher glucose uptake is
observed in certain tumor types than in healthy tissue, and so it was hypothesized that an
infusion of glucose into tumor tissue would create an increase in CEST contrast. This
method utilizes standard proton MRI and requires neither 13C labeled pyruvate nor DNP
polarization. However, in some recent studies it was speculated that the observed increase
in CEST signal after glucose injection into tumor tissue could be due to combined CEST
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effect from glucose and other byproducts of glucose metabolism, like lactate, which also
have exchangeable hydroxyl protons (Wang, Weygand et al. 2016).
No previous studies had demonstrated the ability of CEST to image endogenous hydroxyl
protons of lactate in vivo. Recent work from Zhang et al. has shown that lactate can be
imaged in vitro and in vivo by means of a paramagnetic shift agent, but this requires the
injection of the contrast agent (Zhang, Martins et al. 2017). In this chapter, we will
describe the method based on endogenous lactate chemical exchange saturation transfer
(CEST) to image lactate as LATEST (DeBrosse, Nanga et al. 2016). First, we identified
the chemical shift of lactate hydroxyl protons through high-resolution NMR, and then
demonstrated the CEST effect from those protons in lactate phantoms. We determined
optimal CEST saturation parameters for lactate imaging. Then, we examined the pH and
concentration dependence of the LATEST contrast in phantoms. The feasibility of
measuring LATEST in vivo was demonstrated in a lymphoma tumor model and in human
skeletal muscle. Dynamic changes in LATEST were observed in tumors pre- and postinfusion of pyruvate and in exercising human skeletal muscle. LATEST measurements
were compared to lactate measured with multiple quantum filtered proton magnetic
resonance spectroscopy (SEL-MQC 1H-MRS) (He, Shungu et al. 1995).
4.2 Methods
Systems
•

High-resolution 1-D 1H NMR phantom experiments were performed on a vertical
bore Bruker Avance DMX 400 MHz spectrometer (Bruker Corporation,
Germany), equipped with a 5mm PABBI proton probe.
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•

MRI phantom experiments and human skeletal muscle studies were performed on
whole body 7T whole-body MRI scanner (Siemens, Erlangen, Germany) with a
28-channel QED knee RF coil.

•

Additional MRI phantom experiments and animal experiments were performed on
a 9.4T, 30cm horizontal bore magnet (Agilent, USA) interfaced to a Varian
console, with a 20mm volume coil (M2M Imaging, USA), and a custom-built
surface coil/loop coil.

4.2.1 Phantom studies
NMR experiments at 9.4T (vertical bore). For the high-resolution NMR experiments at
9.4T (vertical bore), 15M sodium lactate was prepared in PBS buffer at pH = 7.1. A
phantom was made by placing a ~0.5mL of the 15M solution into a 5mm glass NMR
tube. For NMR experiments, a sealed capillary containing a mixture of D2O (for lock)
and 10 mM tetramethylsilane (TMS) (for reference) was inserted into the sample tubes.
The spectral parameters used were 2 dummy acquisitions followed by 24 acquisitions
(pulse sequence: ‘zz30.sw’), 65536 TD (real+imaginary), 6775 Hz sweep width, and a
relaxation delay of 4s. Temperature was varied from 4°C to 37°C. For post-processing,
the 1D-1H NMR spectra were processed using Spin Works (version 4.0.0, Copyright
©2013, Kirk Marat, University of Manitoba). All the spectra were referenced to TMS.
The exchange rate was determined by obtaining T2 values from lactate phantoms (0, 10,
20, 30, and 50mM) at 25°C and from the calculated relaxivity (Ordidge, Connelly et al.
1986), and using the chemical shift of lactate obtained from the unsuppressed water
spectrum at 4°C (~0.8ppm).
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Phantom experiments at 7T. For the 7T MRI phantom experiments, sodium L-lactate
(Sigma Aldrich, USA) solutions were prepared phosphate-buffered saline (PBS) at pH 7.
First, a 50mM sample of sodium lactate in 300mL of PBS was prepared, and a phantom
was prepared by placing the ~1.5mL of the solution into a 10mm glass NMR tube. This
phantom was used for optimization of CEST parameters, including B1 strength and pulse
duration. The original 50mM solution was subsequently used to make serial dilutions for
the concentration-dependent study: 30mM, 20mM, and 10mM. The 30mM sample was
used for a pH-dependent study; the pH was adjusted to 7.4, 7, 6.8, and then 6.5, using 1N
NaOH and HCl. Phantoms were prepared in 10mm NMR tubes for all concentrations and
pH values. 7T MRI phantom studies were performed at both 25°C and 37°C. For initial
imaging at 37°C, the individual 10mm-tube phantoms were sealed and then heated in a
water bath to 37°C, before being placed into custom-made, plastic tube (volume
=280mL) with slots cut into the top to hold the tubes in place. This large tube was filled
with water (37°C) so that the phantoms were surrounded by water and the temperature
could be maintained for ~1 hr. This large phantom setup allows for multiple samples to
be imaged simultaneously, and was placed upright inside the knee coil for imaging
experiments. The temperature of the samples was measured before and after imaging.
The imaging parameters for 7T phantom experiments using a 28-channel 1H knee coil
were: slice thickness = 10mm, GRE flip angle =5°, GRE readout TR = 5.6ms, TE =
2.7ms, FOV = 130 x 130mm2, SHOT TR = 12s, matrix size = 128 x 128. A B1 titration
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(0.36 µT to 1.44 µT in steps of 0.36 µT) was performed at three different durations (3s,
4s, and 5s), to determine optimal CEST saturation parameters.
Phantom experiments at 9.4T (horizontal bore). For the concentration dependent study at
9.4T, phantoms with 10, 20, 30 and 50 mM sodium lactate (Sigma Aldrich, USA)
concentration in phosphate buffered saline (PBS) were prepared at pH 7.0 and placed in
individual 15mm glass NMR tubes. For the pH-dependent study, 30mM lactate samples
were again initially prepared in PBS at pH 7, and pH was adjusted to 6.0, and 6.5 using
1N HCl, and adjusted to pH 7.5 with NaOH. As the 9.4T is intended for animal imaging
experiments, it has a small horizontal bore coil that cannot accommodate the multisample phantom that we used at 7T. For the 9.4T imaging experiments, we performed
individual experiments for each sample, taking care to avoid air bubbles when the
samples were turned horizontally. Each sample was pre-heated in a water bath. During
the imaging experiments, the temperature was maintained at 37°C by blowing a warm air
directed at the tube and monitored using a thermocouple attached to the NMR tube.
Accurate temperature was recorded throughout the duration of the experiments. The B1
strength and pulse duration for LATEST contrast at the horizontal bore 9.4T was
optimized using a 50 mM sample of sodium lactate (pH 7.0) in PBS. Saturation pulses of
varying B1rms (1.18 µT to 4.11 µT in steps of 0.59 µT) were acquired from -1.5ppm to
+1.5ppm in steps of 0.1 ppm. CEST imaging was performed using a customprogrammed, segmented radiofrequency GRE readout pulse sequence, with a frequency
selective continuous wave saturation preparation pulse. The sequence consists of an 8s
delay, followed by a 5s saturation pulse, with 780ms total centric phase encode readout
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(128 segments, 6.1ms each). The imaging parameters were: slice thickness = 5 mm, GRE
flip angle = 5°, GRE readout TR = 5.6 ms, TE = 2.7 ms, Field of view = 25 × 25 mm2,
matrix size = 128 × 128, and one saturation pulse at a root mean square B1 (B1rms) of 100
Hz (2.34 µT). B0 correction was done by acquiring WASSR(Kim, Gillen et al. 2009)
images at 0.24 µT from -1 to +1 ppm in steps of 0.1 ppm, using the same parameters as
CEST. Z-spectra were plotted using the normalized image intensity as a function of the
resonance offset of the saturation pulse.

4.2.2 Animal studies
The Institutional Animal Care and Use Committees (IACUC) of the University of
Pennsylvania approved experimental protocols, and all experiments were carried out in
accordance with approved IACUC guidelines.
Lymphoma tumor model: Preparation of lymphoma xenografts. Male athymic nude mice
(n=4) (01B74) 4-6 weeks of age were obtained from the National Cancer Institute,
Frederick, MD, USA. The mice were housed in microisolator cages and had access to
water and autoclaved mouse chow ad libitum.
The tumor cells used in this study were diffuse large B-cell lymphoma cells from the
WSU-DLCL2 cell line, and were kindly provided by Drs Mohammad and Al-Katib
(Wayne State University, Detroit, MI, USA). The cells were grown as described in detail
by Al-Katib et al. (Mohammad, Wall et al. 2000): briefly, the cells were “maintained in
RPMI 1640 containing 10% heat-inactivated fetal bovine serum, 1% l-glutamine, 100
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units/ml penicillin G, and 100ug/ml streptomycin. The cells were incubated in a
humidified 5% Co2 atmosphere at 37°C.”
Cells were implanted subcutaneously into the right thigh of 4-6-week-old male athymic
nude mice (01B74) 4-6 weeks (National Cancer Institute) by injecting ten million WSUDLCL2 cells in 0.1mL Hanks’ Balanced Salt Solution (without calcium or magnesium;
Invitrogen/Gibco, Carlsbad, CA, USA). Lymphoma xenografts were allowed to grow
until the tumor volume reached ~500 mm3. The tumor dimensions were measured with
calipers in three orthogonal directions, and the volume was calculated using the equation,
V= π(a×b×c)/6, where a, b, and c are the length, width, and depth of the tumor.
Lymphoma tumor model: Imaging and spectroscopy. For imaging and spectroscopy
experiments at 9.4T (horizontal bore) of the lymphoma tumor mice, we used a custombuilt single frequency (1H) slotted tube resonator (inner diameter = 13 mm, outer
diameter = 15 mm, depth = 16.5 mm).
The mice were anaesthetized and maintained under 1% isoflurane in 100% oxygen,
supplied at 1 L/min for the duration of the experiment, which did not exceed three hours
per IACUC guidelines. The animal body temperature was maintained at 37 ± 1°C with
the air generated and blowing through a heater (SA Instruments, Inc., Stony Brook, NY).
Respiration and body temperature were continuously monitored using a MRI-compatible
small animal monitor system (SA Instruments, Inc., Stony Brook, NY). CEST imaging
was performed as described for phantoms at 9.4T with the following sequence
parameters: field of view = 25 × 25 mm2, slice thickness = 3 mm, flip angle = 15°, TR =
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6.2 ms, TE = 2.9 ms, matrix size = 128 × 128. CEST images were collected with B1rms =
1.17 µT for frequencies ranging from -1.5 ppm to + 1.5 ppm from bulk water in step size
of 0.1 ppm. B1 and WASSR B0 field maps were also acquired and used to correct the
CEST maps as described previously (Kogan, Haris et al. 2013).
Following acquisition of the baseline CEST images, sodium pyruvate (300 mM) was
delivered through a tail vein catheter (26 Gauge, I.V. Catheters FEP, Tyco Healthcare,
Tyco International Ltd., Schaffhausen, Switzerland) at a variable rate using a syringe
pump (Harvard Apparatus, Holliston, MA, USA) using the following protocol: (10ml/hr,
1min; 3ml/hr, 4min; 2.5ml/hr, 2min; 2.0ml/hr, 2min; 1.5ml/hr, 2min; 1.0ml/hr, 2min;
0.5ml/hr, 57min) making a constant blood pyruvate concentration of 13 mM during the
experiment. CEST images were then acquired after the infusion.
Tumor lactate was also measured using HADAMARD SEL-MQC 1H-MRS (He, Shungu
et al. 1995, Pickup, Lee et al. 2008) in separate experimental sessions. For lactate
measurements following pyruvate infusion, tumors were positioned in a home-built,
single-frequency (1H), slotted-tube resonator (inner diameter, 13 mm; outer diameter, 15
mm; depth, 16.5 mm). A slice-selective double-frequency Hadamard-selective multiple
quantum coherence transfer pulse sequence was used to detect lactate and to filter out
overlapping lipid signals. The acquisition parameters were as follows: sweep width = 4
kHz; 2048 data points; TR = 8 s; 128 scans. Since there is no published lactate visibility
data on this tumor model we have chosen to correlate the lactate peak amplitude values
with the LATEST results.
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9L brain tumor model in rats. LATEST was also implemented to probe the lactate
dehydrogenase (LDH) activity in vivo in a rat glioma model. Syngeneic female Fisher
F344/NCR rats were used to generate the model. MRI experiments were performed on
the 9.4T MRI scanner on rats that had been injected with 9L cells intracranially 3 weeks
prior. During the imaging experiments, tumor-bearing rats were maintained under 1-1.5%
isourane in O2, supplied at 1 L/min. Throughout the experiment, the body temperature
was maintained at 37º C. T2 weighted imaging was performed on the brain to locate the
tumor region in coronal slices. For these experiments, the LATEST sequence parameters
were: slice thickness=2 mm, GRE flip angle=5º, GRE readout TR=5.6 ms, TE=2.7 ms,
FOV=30×30 mm, matrix size=128×128, number of averages=4. LATEST images from 0
to ±1.5 ppm (step size 0.25 ppm) were collected at 1.17 µT saturation pulse power (B1)
and saturation duration of 4s. B0 correction on the LATEST images was performed by
acquiring WASSR images at 0.24 µT from -1 to +1 ppm in steps of 0.1 ppm. LATEST
maps were computed using the method described above. Following the acquisition of the
baseline CEST signal, sodium pyruvate (300 mM) was delivered through a tail vein at a
rate of 100uL/min via a syringe pump. Following the 15-min infusion of pyruvate (for a
total volume of 1.5mL), the CEST acquisitions were performed over a period of 90
minutes.
4.2.3 Human imaging
All human studies were performed under the approved Institutional Review Board (IRB)
protocol of the University of Pennsylvania. The studies were carried out in accordance
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with approved IRB guidelines. Written informed consent was obtained from all subjects
after explanation of the study protocol.
Lactate CEST imaging was performed on the right calf muscle of 5 healthy male subjects
(ages 21-35) on a Siemens 7T whole body scanner using a 28-channel 1H knee coil. The
coil was positioned around the calf muscle as described for the CrCEST experiments in
Chapter 2. Two baseline CEST images, as well as WASSR (Kim, Gillen et al. 2009) B0
and B1 field maps were acquired pre-exercise (Kogan, Haris et al. 2013, Kogan, Haris et
al. 2014). For this study, WASSR images to correct for B0 inhomogeneities were
collected from -1 to +1 ppm with a step size of 0.05 ppm and saturation pulse train
amplitude, (B1rms = 0.29 µT) and 3000-ms duration using the same sequence as used for
CEST imaging and identical readout parameters as described in Chapter 3.
Each CEST image was collected using a saturation pulse consisting of a 3s long
saturation pulse of a series of 99.6-ms Hanning windowed saturation pulses (B1rms =
0.73µT). The parameters for CEST imaging were: slice thickness =10mm, SHOT TR=6s,
TR=6.1 ms, TE=2.9ms, FOV = 140x140 mm2, matrix size 128x128. CEST images were
acquired from 0 - ±0.8 ppm, in steps of 0.1ppm. Like in the CrCEST experiments from
Chapter 2, plantar flexion exercise was performed in-magnet with the magnetic resonance
compatible, pneumatically-controlled foot pedal. However, for the LATEST experiments,
the pressure was held constant at 9 psi for all subjects, requiring more force to depress the
foot pedal. Unlike the mild exercise in the CrCEST experiments, the subjects in this study
were instructed to exercise until exhaustion, which was approximately 3.5 minutes of
intense exercise, with subjects indicating when they could not perform further flexions.
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Immediately post-exercise, the center frequency was recorded and, if required, was
“reset” in order to ensure accurate pulse saturation at the correct resonance for LATEST.
An anatomical reference image with no saturation was also acquired after checking the
center frequency, to allow for muscle segmentation even if motion had occurred between
the pre-exercise and post-exercise slice positions. This took approximately 60-85 seconds
for every subject. Immediately following the reference image acquisition, 10 sequential
sets of CEST images were acquired with a time resolution of 1.8 minutes, and so the first
post-exercise CEST image finished acquiring at ~3 min post-cessation of exercise.
Finally, B1 and WASSR maps were again acquired at the end of exercise for correction of
the post-exercise CEST images.
Lactate spectroscopy was acquired using image selection using inversion spectroscopy
(ISIS) (Ordidge, Connelly et al. 1986) localization followed by a selective multiple
quantum coherence (MCQ) editing sequence (Pickup, Lee et al. 2008). Spectroscopy was
performed on 3 human subjects (ages 24-65), with the same exercise paradigm. A voxel
of 30x80x40mm was placed over the gastrocnemius muscle. Pre-exercise, spectra were
acquired for 96 seconds. After the subjects performed the intense, in-magnet exercise,
spectra were acquired for a total of 20 minutes, 48s. For quantification purposes, both
water spectra and lactate spectra were acquired from the same voxel. The details of the
lactate-editing spectroscopy sequence can be found in He et al. For these experiments the
spectroscopy parameters were: TR=3s, TE=165.6ms, dummy scans=4, water averages=8,
lactate edited spectra averages=8*n, n=2 for pre-exercise, n=50 for post-exercise.
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4.2.4 Post processing Methods
As described in Chapter 2, CEST asymmetry was calculated using Equation 1.25 where
M0 is the magnetization obtained with saturation at -20ppm, Msat (±Δω) are the
magnetizations obtained with saturation at a ‘+’ and ‘–‘ offset to the water resonance with
a Δω equivalent to the resonance offset of the exchanging spins.
Because the –OH protons of lactate resonate ~0.4ppm away from water, an interpolation
routine of the z-spectrum from ±1.2ppm with a stepsize of 0.005ppm was implemented to
correct B0 inhomogeneities.
LATEST B0 correction. Previous CEST methods have typically been developed for
metabolites with resonance frequencies >0.5ppm away from the large bulk water peak,
like creatine or glutamate as discussed in the previous chapters. For those metabolites,
typically we acquire partial z-spectra for a small set of saturation offset frequencies
around +/- CEST offset of interest. Two separate polynomial fits following spline
interpolations on the positive and negative frequencies were sufficient for correction of
B0 inhomogeneities. As demonstrated in this work, the hydroxyl proton of lactate
resonates ~0.4ppm downfield from water. In this case, a more robust method for B0
correction is required in post-processing. First an under-sampled raw full z-spectrum
(including 0 ppm) is created from each image pixel. Then, a cubic spline interpolation is
used to create a finely sampled z-spectrum (x100). Using the B0 values for each pixel, the
z-spectrum is then shifted based on the B0 value: the spectrum is shifted to the left for
negative values, or to the right for positive values. From the shifted spectrum, we can
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then calculate the CEST values at the saturation offset of interest (~0.4ppm for the lactate
hydroxyl proton).
From the MQC-filtered spectroscopy data, lactate concentration was calculated using the
ratio of lactate integrals and water spectra from the same volume, accounting for lactate
visibility from double-quantum spectroscopy, and the efficiency factor of the editing.
Lactate quantification from ISIS localized Sel-MQC edited spectra. Lactate concentration
was derived from spectroscopy using Sel-MQC filtering, as described in the Methods. In
order to quantify the lactate concentration, an ISIS-localized water peak was acquired
before the Sel-MQC. The concentration of lactate was obtained using a simple formula:
[lactate] = estimated free water concentration in muscle * (lactate integral/water integral)
* c1;
c1 is a correction factor, which is given by the following equation:
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(Equation 4.1)
where ‘n’ is the number of spins (n=3 for lactate), ‘t’ is the echo position offset relative to
(1/2J) and the previously reported double exponential T2 decay of lactate rat skeletal
muscle (Jouvensal, Carlier et al. 1997) , in which 80% of the signal has a T2 of 37ms, and
20% has a T2 of 144ms.
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4.3 Results

4.3.1 Phantom studies
The first requirement for this project was determining if the lactate hydroxyl (-OH) could
be imaged using CEST. First, we identified the chemical shift of the hydroxyl proton
resonance by 1D 1H NMR. We performed a temperature-dependent study on a 15M
lactate solution prepared in phosphate-buffered saline, varying the temperature from 4°C
to 37°C (Figure 4.1).

Figure 4.1 Determination of lactate –OH resonance. High-resolution 1D-1H NMR
spectra of 15M sodium lactate (in PBS buffer at pH 7.1 ± 0.1) at varying temperatures
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acquired with Bruker Avance DMX 400 MHz spectrometer equipped with a 5mm PABBI
proton probe. (Reprinted with permission (DeBrosse, Nanga et al. 2016).)

At 4°C, we observed a sharp –OH peak at ~0.8ppm (relative to the water peak at
4.7ppm). As we changed the temperature from 4°C to 27°C, we still observed the –OH
peak, although the peak position varied from ~0.8 to 0.4 ppm. At 37°C, the –OH
resonance was not clearly visible by 1H NMR, owing to the significant exchange
broadening and proximity to the water resonance.
When we acquired a full z-spectrum (±1.5ppm) of 50mM lactate solution at 7T, it did not
exhibit any sharp features (Figure 4.2A).
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Figure 4.2 Initial phantom experiments on 50mM lactate solution at 7T: titration of
B1 pulse power. These experiments demonstrated the feasibility of measuring lactate
with CEST, despite the lack of a sharp peak in the z-spectrum. Clear resonance is
observed at ~0.4ppm at room temperature in the asymmetry plot.
The peak is masked in the z-spectrum by the overwhelming water signal. However, when
we plotted the corresponding CEST asymmetry, which subtracts the water peak, we
observed the lactate –OH resonance centered at ~0.4ppm. We then acquired another set
of z-spectra on the 50mM sample, using a 5s saturation pulse duration while titrating the
B1 (Figure 4.2B). From this, maximum lactate CEST signal was observed with B1rms
=~1.08µT. The CEST asymmetry value of lactate (“LATESTasym”) for subsequent
experiments was calculated at 0.4ppm. With the B1rms = ~1.08 µT, we observed ~10%
LATESTasym at 0.4ppm (Figure 4.3).
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Figure 4.3 B1 dependence of LATEST in phantoms at 7T.

Using the optimal B1rms, we then performed a titration of the pulse duration (Figure 4.4),
where the optimal LATESTasym was obtained with 5s.
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Figure 4.4 Initial phantom experiments on 50mM lactate solution at 7T: titration of
B1 pulse duration. In phantoms at room temperature, a long pulse of 5s provided
maximum LATEST contrast.

After establishing the optimal CEST phantom parameters on the 50mM sample, we
looked at the concentration dependence of LATEST, by calculating the LATESTasym
(Figure 4.5A), and then plotting the LATESTasym% at 0.4ppm vs. concentration. At 7T
(25°C), using a 5s saturation length with ~1.08 µT B1rms we calculated a concentration
dependence of ~0.25% CEST/mM (Figure 4.5b).
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Figure 4.5 Concentration dependence of LATEST at 7T.

We also performed a pH-dependent experiment, varying the pH of the 30mM sample and
again calculating the LATESTasym % at 0.4ppm and plotting vs. pH value (Figure 4.6).
We observed a maximum LATEST signal at approximately pH=6.8 - 7.
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Figure 4.6 pH dependence of LATEST at 7T. Initial pH studies indicated that the
maximum LATEST contrast was achieved with a pH of ~6.8, with decreasing contrast
associated with either increased or decreased pH.

These initial experiments were all performed at room temperature (25°C) in order to
establish the feasibility of imaging lactate with CEST, and to optimize the CEST
parameters. As described in the Methods section, at 7T we used a custom-made large
phantom holder placed inside a 28-ch knee coil. This phantom setup is useful for imaging
multiple samples at once, and can also be used for experiments at physiological
temperature (37°C) by pre-heating the samples. However, this setup only allowed for ~1
hr of consistently maintained heated temperature before we noted a drop. For this reason,
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we performed some initial CEST imaging of the 50mM sample at 37°C at 7T, before
moving the phantom study to 9.4T. At 37°C, we performed another B1-dependent
experiment, using a 5s pulse duration, and compared the 25°C data, and determined that
the optimal B1rms for physiological-temperature phantoms was ~1.44 µT (Figure 4.7).
Based on the experimental signal-to-noise ratio (SNR), we determined that this method
had sufficient sensitivity to detect 2 to 3 mM lactate.

Figure 4.7 Phantom temperature dependence at 7T, acquired on a 50mM lactate
phantom. With increasing temperature, the pulse power for optimal LATEST contrast is
increased.
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After establishing that CEST of lactate phantoms was feasible at 7T, we continued our
phantom experiments at 9.4T. In addition to validating the method at 9.4T, we expected
that by moving to a higher field where the chemical shift difference is larger, we would
avoid some of the effects of direct saturation (DS) to the lactate CEST signal that we
observed at 7T. With our experimental setup at 9.4T, we were able to maintain the
temperature for extended periods of time, as described in the Methods, allowing for more
thorough data collection.
As anticipated, the z-spectrum of 50 mM sodium lactate obtained at 9.4T did not exhibit
any sharp features at 37°C (Figure 4.8A). However, the CEST asymmetry plot exhibited
resonance centered between ~0.3 to 0.5 ppm (Figure 4.8B). For the 50mM phantom, we
generated a representative CEST map at 0.4ppm by overlaying the LATESTasym signal
(~14%) onto the proton reference image (Figure 4.8C).
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Figure 4.8 Characterization of LATEST at 9.4T. (A) Z-spectrum, (B) asymmetry plot,
and (C) CEST map for 50mM lactate at 9.4T, pH 7, at 37°C with B1rms titrated from
1.18µT – 4.12µT, with a saturation duration of 5s. (Reprinted with permission (DeBrosse,
Nanga et al. 2016).)

Optimal LATEST parameters in phantoms at 9.4T were B1rms= 2.35µT, with a 5s duration
(Figure 4.9A). A concentration-dependent experiment showed that, at neutral pH and
37°C, lactate exhibits ~0.4% CEST/mM at 9.4T (Figure 4.9B,C). The pH dependence of
30mM lactate at 9.4T showed maximum LATEST signal at pH=7 (Figure 4.9D,E). At
both lower and higher pH, a decrease in LATEST asymmetry at 0.4ppm was observed.
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The exchange rate (k) estimated from lactate phantoms (pH 7) at 25°C is ~350±50s-1 and
at 37°C is ~550±50s-1. Using the chemical shift determined by the high-resolution NMR
experiments, 0.8ppm, the Δω at 7T is ~1000rad/s, and at 9.4T is ~2000rad/s. Therefore,
the lactate chemical exchange rate is in the slow to intermediate condition (Δω ≥ k) and
meets the requirement for observing the CEST effect for field strengths greater than 3T.

Figure 4.9 Characterization of LATEST. A) LATEST dependence on B1 from a 50mM
lactate phantom at pH 7, at the saturation duration of 0.4 ppm offset from water; B)
asymmetry plot of LATEST at 10, 20, 30, and 50mM lactate at pH 7, with B1rms=2.35µT
and pulse duration=5s; C) concentration dependence of LATEST at 0.4ppm, pH 7, with
B1rms=2.35µT and pulse duration=5s; D) asymmetry plots from 30mM lactate, pH =6,
6.5, 7, and 7.5 E) pH dependence of LATEST at 0.4 ppm from 30mM lactate with
B1rms=2.35µT, duration =5s. All data acquired at 37°C, 9.4T. (Reprinted with permission
(DeBrosse, Nanga et al. 2016).)
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4.3.2 Animal model studies
LATEST imaging of lymphoma flank tumors. Anatomical images of flank tumors on
three mice are shown in Figure 4.10 A-C. For each animal, we first acquired CEST
images of the tumor region for several minutes in order to establish a baseline
LATESTasym. Baseline CEST maps from the tumor regions (Figure 4.10 D-F) showed an
average LATESTasym of ~3.5%. Following infusion of 300mM pyruvate through the tail
vein, the LATEST signal increased in the tumor regions (Figure 4.10 G-I).

Figure 4.10 LATEST from lymphoma tumors. A-C) Anatomical image from three
animals, with flank tumor region indicated by dotted red line, and the LATEST maps; DF) pre-infusion and (g-i) post-infusion with J) corresponding asymmetry plots
(asymmetry from Animal 3 in the third row is taken from region indicated in dotted black
line), K) LATEST change at 0.4ppm from three animals pre- and post-infusion, l)
representative SEL-MQC 1H-MRS pre- and 40 minutes post-infusion from flank tumor
showing M) increase in lactate peak amplitude from three animals (~40%) from
spectroscopy. (Reprinted with permission (DeBrosse, Nanga et al. 2016).)
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This increase is challenging to visualize in the z-spectra from the animal tumors, but,
analogous to the phantom study, the increased lactate post-infusion is readily apparent in
the asymmetry plots. Average asymmetry plots from the tumor regions (Figure 4.10J)
showed an endogenous LATEST peak and subsequent increase post-infusion, centered
~0.5ppm downfield from water. The asymmetry plot from one animal (row 3 of Figure
4.10 A-I) was obtained from the region of interest (ROI) indicated in the black dotted line
(Figure 4.10 F). This region was used in order to avoid regions with large B0
inhomogeneity, which was observed in the outer region of the tumor (Figure 4.11).

Figure 4.11 Z-spectra from the tumor region in a representative animal.
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Z-spectra were compared pre- and post-infusion of pyruvate.

Data from lymphoma tumors of three animals showed a ~60% increase in LATEST
asymmetry ~40 minutes post-infusion of pyruvate (Figure 4.10K). In vivo LATEST
imaged from the animal tumors were corrected for B0 and B1 inhomogeneity (Figure
4.12).

Figure 4.12 pre- and post-infusion B0 and B1 maps for three animals with flank
tumors. *B0 map is identical for pre- and post-infusion. No center frequency change, no
animal movement.

In tumors, endogenous lactate levels are expected to be in the range of 2 to 10 mM (Lee,
Huang et al. 2008). Baseline LATEST observed in the tumor model is largely due to
endogenous lactate, based on the ~0.4% LATEST asymmetry per mM of lactate observed
in phantoms at 9.4T. The increase in LATESTasym post-infusion is due to the conversion
of pyruvate to lactate by the tumor tissue.
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In order to validate the LATEST method, tumor lactate was also measured in three
animals with flank tumors using SEL-MQC 1H MRS. Spectroscopy results pre- and postinfusion of pyruvate are shown for a representative animal (Figure 4.10 L). The increase
in lactate peak amplitude after pyruvate infusion shown by spectroscopy from all three
animals (Figure 4.10M) showed a trend in lactate change that is similar to the trend
observed with LATEST.
LATEST imaging of 9L rat brain tumor. We have also recently implemented LATEST in
a rat brain model of glioma. The anatomical image of a representative rat brain is shown
in Fig 4.13A. In the two baseline LATEST maps from the tumor region, we clearly
observe higher LATEST contrast (~2.5%) than in the normal appearing brain region
(~2%) Fig 4.13B. This difference is presumably due to the higher LDH expression in the
tumor tissue. Additionally, the baseline LATEST contrast of 2-2.5% may arise from the
myoinositol and other metabolites containing hydroxyl protons(Haris, Cai et al. 2011).
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Figure 4.13 LATEST from 9L glioma rat brain model. A) anatomical coronal MRI
image showing the brain tumor region, which extends outside of the skull; B) the two
baseline LATEST images, with only the brain region segmented, that show higher signal
than the healthy tissue; C1-6) post-infusion of pyruvate, an increase in LATEST is
observed in the tumor region. Images were acquired for 90 minutes post-infusion, here
we are showing 6 images with a temporal resolution of 15 min.

Following the infusion of pyruvate, the LATEST signal increased in the tumor region
(Fig 4.13C) while no appreciable change in the LATEST signal was observed in the
normal appearing brain region. Average asymmetry plots from the tumor region (Fig.
4.14A) pre- and post- pyruvate infusion showed an increase in the LATEST contrast post
infusion which centered ~0.5ppm downfield from water. The asymmetry plots from the
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normal appearing brain region showed no change in the LATEST following the infusion
of pyruvate suggesting that normal brain region may not convert the pyruvate into lactate
due to less LDH activity (Fig 4.14B).

Figure 4.14 LATEST asymmetry plots from glioma model. A) pre- and post-infusion
asymmetry from the tumor region; B) pre- and post-infusion asymmetry from the normalappearing tissue.

4.3.3 Human studies: LATEST imaging of healthy human calf muscle
Healthy human calf muscle (Figure 4.15A) exhibited an average resting-state LATEST
asymmetry of 1.5% (Figure 4.15B). This is consistent with the expected low
concentration of endogenous lactate in muscle under resting conditions (Gaitanos,
Williams et al. 1993). It also indicated that, with the experimental parameters used,
contributions from any other endogenous metabolites to LATEST are negligibly small.
After intensive, exhaustive exercise was performed by the subjects, the first LATEST
image (acquired ~3 minutes after cessation of exercise) showed an increased LATEST
asymmetry in exercising muscle (gastrocnemius muscle, activated through plantar
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flexion) to ~4 - 7%, which recovered to baseline over period of 20 minutes (Figure
4.15C).

Figure 4.15 In vivo LATEST in healthy skeletal muscle. A) anatomical image of
human calf muscle; B) two pre-exercise, resting-state CEST maps showing negligible
LATEST signal at 0.4ppm, and C) after 3 minutes of exhaustive exercise, ten postexercise images acquired over 18 minutes: the first image (C1) obtained 3 minutes after
cessation of exercise shows a CEST asymmetry increase in the medial gastrocnemius
(MG) and lateral gastrocnemius (LG) muscles of ~8%. Each of the subsequent images
(C2-10), acquired with a resolution of 1.8 minutes, shows lactate recovery in the MG and
LG. All LATEST images acquired using B1rms = 0.73µT and 3s duration; Asymmetry
plots for pre- and post-exercise LATEST of the D) medial gastrocnemius (MG) and E)
lateral gastrocnemius muscles from a representative subject, acquired with B1rms =
0.73µT, 3s duration. (Reprinted with permission (DeBrosse, Nanga et al. 2016).)
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Again, it is challenging to determine the lactate change from the z-spectra of the
individual muscle regions. From the asymmetry analysis, however, it is clear that the
lactate resonance is centered at ~0.5ppm (Figure 4.16).

Figure 4.16 Z-spectra for skeletal muscle. A) Z-spectra for the lateral gastrocnemius
muscle region, B) Z-spectra for the medial gastrocnemius muscle region, from a
representative subject.

The asymmetry plots from the medial and lateral gastrocnemius muscles from a
representative subject pre-exercise, and immediately post-exercise, are shown in Figure
4.15 D-E. Similar increase in post-exercise LATEST is consistently observed in all five
of the healthy volunteers (Figure 4.17A). Again, like in the animal tumor experiments,
we sought to validate the LATEST imaging method in vivo at 7T by performing the same
exercise paradigm and measure lactate via spectroscopy. Lactate concentration derived
from SEL-MQC based edited spectra (Figure 4.17B) pre- and post-exercise from 3
healthy volunteers exhibited the same trend (Figure 4.17C) as the LATEST imaging171

derived lactate. The LATEST correlates well (R2 =0.97) with lactate spectral area
(Figure 4.17D). Based on the slope value of ~0.29% per mM of lactate from
spectroscopy, we estimate post-exercise muscle lactate levels to be approximately 14-25
mM. These results are consistent with reported lactate concentration increase of ~20mM
measured in muscle biopsy after intense exercise (Bangsbo, Johansen et al. 1993).

Figure 4.17 In vivo LATEST and SEL-MQC spectroscopy. A) LATEST at 0.4ppm in
the medial gastrocnemius (MG) of resting-state calf muscle, and post-exercise recovery
from 5 healthy volunteers; B) representative lactate MRS in a voxel from the MG/LG
pre-exercise, immediately post-exercise, and after 20 minutes of recovery, and C) preand post-exercise lactate edited MRS data from 3 healthy volunteers (representative
voxel location from one subject shown in insert); D) correlation of lactate concentration
from spectroscopy and LATEST from the MG. Error bars indicate standard error.
(Reprinted with permission (DeBrosse, Nanga et al. 2016).)
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As in the animal tumors, a key component of post-processing the LATEST data was
accurate correction for B0 and B1 inhomogeneities (Figure 4.18). Because the lactate
resonance is so close to the bulk water peak, the LATEST images are very sensitive to
any small inhomogeneity in the field or applied pulse.

Figure 4.18 B0 and B1 correction of in vivo calf muscle CEST. A) B0 (WASSR) map,
acquired with B1rms = 0.29µT and 200ms duration, collected from 0 ppm to ±0.5 ppm, in
steps of 0.05ppm and B) B1 GRE map for human calf muscle

We also considered that, due to the intense exercise performed for these experiments,
there was the possibility of muscle T2 changes, which could confound the LATEST
results. To address this issue, we computed T2 maps of skeletal muscle under identical
exercising conditions and found that T2 is elevated by <10% immediately after exercise,
and stayed constant over 20 minutes (Figure 4.19). We estimated that this very small
change in the T2 would have a negligible contribution to LATEST.
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Figure 4.19 Gastrocnemius muscle T2 measurements. A) T2 maps overlaid on the
anatomical image before exercise, and B) T2 maps post-exercise, acquired with the same
time resolution as the LATEST images; C) T2 value in ms vs. recovery time in minutes.

4.4 Discussion
The results presented on phantoms, tumor model, and skeletal muscle demonstrate the
feasibility of lactate measurement with the LATEST technique. Based on the results of
the phantom experiments, we chose B1 parameters that provide optimal CEST effect at
0.4ppm. The application of this method in tumors was demonstrated in Figure 4.10 in a
lymphoma mouse model. As discussed in the introduction of this chapter, elevated tumor
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lactate levels contribute to cancer progression and are correlated with poor patient
outcome. With LATEST, we can investigate tumor glycolysis through injection of nonenriched pyruvate or glucose. For the mouse tumor studies, due to long acquisition times,
we have acquired LATEST only at one time point following the infusion of pyruvate
solution in tumors. However, with further optimization of the protocol it is feasible to
gather time dependent data post-infusion.
When developing new CEST biomarkers, it is necessary to consider other possible
contributions to the CEST signal. Due to the presence of –OH groups from other
endogenous molecules (glucose, glycogen, etc.) it is possible that the baseline,
endogenous LATEST signal may have contributions from these molecules. Although we
have demonstrated the LATEST measurement pre- and post- pyruvate infusion, similar
studies can be performed using glucose infusion. Previous studies with GlucoCEST have
shown that there is a measurable GlucoCEST contrast in tumors after glucose infusion,
which has been attributed primarily to the extracellular glucose (Chan, McMahon et al.
2012, Walker-Samuel, Ramasawmy et al. 2013). However, it has recently been
speculated that this increased signal may also be due to the byproducts of glycolysis,
including lactate (Wang, Weygand et al. 2016). Furthermore, as shown previously, -OH
groups from glucose and glycogen have resonances at around 1 ppm as opposed to
~0.4ppm in the case of lactate (van Zijl, Jones et al. 2007, Yadav, Xu et al. 2014). Other
metabolites that may be present in tumors, such as pyruvate, do not have exchangeable
hydroxyl protons, and would not be expected to contribute to the LATEST signal at
0.4ppm. Thus, LATEST and GlucoCEST are expected to provide complementary
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information from tumors. The addition of LATEST to the available tools for studying
tumor glycolysis in vivo will be beneficial when used to complement existing methods.
In skeletal muscle, we must consider the possible contribution of creatine to the LATEST
signal. The creatine CEST experiments in chapter 2 demonstrated that the guanidine
protons of creatine resonate farther downfield at 1.8ppm from bulk water, and require a
much shorter saturation pulse (500ms) and higher B1 power of 2.9µT. Furthermore, if
creatine contributed to the LATEST effect at ~0.5ppm, we would have observed higher
signal in the resting state skeletal muscle. Additionally, increased post-exercise creatine
has been shown to recover within ~2 minutes, which is much shorter than the ~18
minutes it takes for the LATEST signal to dissipate post-exercise. Based on in vivo
asymmetry plots presented in Figure 4.15, and the intercept in Figure 4.17, the
contributions to LATEST from other metabolites are small with the given saturation
parameters. The primary use of the LATEST method is in the dynamic measurement of
changes in lactate, like in pyruvate or glucose infusion in tumor, post-exercising muscle
experiments.
The major advantage of this method is that it is not affected by lipid resonances that
confound

1

H-MRS- derived lactate. In addition, this method has a sensitivity

enhancement of two orders of magnitude compared to conventional 1H-MRS-based
detection of lactate. Considering the sensitivity differences in

13

C and 1H, LATEST

sensitivity is comparable to DNP. We have demonstrated the feasibility of LATEST in
vivo at both 9.4T and 7T.
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While there are clear advantages of LATEST imaging compared to other methods, there
are also some challenges to address. Because the hydroxyl protons of lactate resonate so
close to the large water peak, there is a greater effect of direct saturation. A robust B0
correction method is required for LATEST. In this work, the images were corrected for
B0 and B1 inhomogeneities prior to computation of CEST asymmetry. We observed that
any significant drift of the center frequency was typically due to the intense exercise in
our skeletal muscle experiments and resulting movement of the leg. Post-exercise
“checking” of the center frequency is a step that was not required for CrCEST studies
where only mild exercise was performed, and significant subject motion rarely observed.
Furthermore, a small center frequency drift is more easily corrected in post-processing
for CrCEST images as there is less contribution from DS confounding the signal. Here,
we were careful to monitor and record any major changes in the center frequency to
ensure CEST pulse saturation accuracy at 0.5ppm. Another potential limitation of
LATEST when considering clinical translation is that this must be performed at highfield strength (≥7T), due to the close proximity of the peak to the bulk water peak.
Despite this, LATEST has significant potential for research studies at high fields,
particularly for animal studies.
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4.5 Summary
Through studies of phantoms, animal models of tumors, and in exercising human skeletal
muscle, we demonstrated that the LATEST method enables high-resolution imaging of
lactate in vivo, without requiring the use of expensive contrast agents. In terms of
sensitivity, the LATEST method out-performs conventional

1

H-MRS. Given the

increasing availability of 7T MRI scanners, the LATEST method can be translated into
clinical research settings to study patients with cancer and other metabolic diseases.
Potential applications of the method include: tumors diagnosis, probing tumor glycolytic
activity, and monitoring of response to therapies in cancer and a variety of metabolic
disorders.

Thesis summary and future directions
In Chapter 1, we explored the motivation for developing novel MRI techniques for
molecular imaging, and presented two pathways (OXPHOS and glycolysis) that are of
particular interest in studies of metabolic dysfunction. The goal for this dissertation work
was to develop and optimize CEST MRI techniques, which allow for noninvasive
measurements of small metabolites. The benefits of CEST, compared to traditional
spectroscopic techniques and imaging modalities such as PET, include significant signal
enhancement and high spatial resolution, without use of invasive contrast agents or
radioactive ligands. In Chapter 2, we focused on creatine, which serves as a marker of
OXPHOS and therefore mitochondrial function in exercising skeletal muscle. Building
upon the initial development of CrCEST, we performed a small reproducibility study in
healthy skeletal muscle at clinical field strength (3T), and built new MRI-compatible,
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MRI-safe, exercise equipment. We then performed a high-field (7T) study in patients
with primary mitochondrial disorders and other inborn errors of metabolism, detailed in
Chapter 3. The results of this work showed that CrCEST has the capability to distinguish
between healthy exercising muscle and muscle that contains impaired mitochondria. The
high spatial resolution of CrCEST allowed for assessment of several muscle groups
simultaneously, providing a more comprehensive “snapshot” of the entire muscle than
could previously be obtained within a clinical timeframe. In future, CrCEST imaging has
potential use in other metabolic disease such as diabetes and cardiac disease. We are
currently working on implementing CrCEST in muscle of cardiac disease patients, and
optimizing the technique in order to reduce scan time for application in cardiac tissue in
humans.
The second goal for this dissertation work was to develop a CEST biomarker for
glycolysis. Previously, glucose was targeted for CEST imaging as it is the “fuel” for
cancer cells and therefore provides information on tumor metabolism. However, there has
been some debate about the specificity of that measurement, as the products of glycolysis
could also contribute to the measured signal. With that in mind, we developed CEST
imaging of lactate (LATEST) to provide another tool for probing the complexities of
cancer metabolism (Chapter 4). We first demonstrated feasibility of measuring lactate
with CEST in phantom experiments at 7T and 9.4T, and then validated that this technique
could detect lactate in vivo by measuring the LATEST signal in intensely exercised
human skeletal muscle at 7T. Then we implemented LATEST in a tumor models in mice
at 9.4T, and detected changes in lactate upon infusion of its precursor, pyruvate. The
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pyruvate used in our studies was unlabeled, and therefore cheaper and safer than labeled
pyruvate used in other modalities. We validated both our muscle and tumor in vivo
studies by comparing to spectroscopically-derived measures of lactate, which showed
good agreement with the LATEST measurements. In addition to the enhanced sensitivity
of our method, we predict that in future studies, the high spatial resolution of LATEST
might provide more information than previous methods when imaging heterogeneous
tumor tissue and assessing therapeutic efficacy.
Taken together, these studies demonstrate that CEST can be used to study two different
metabolic pathways, glycolysis and OXPHOS, and are particularly useful in dynamic
studies where we predict a change in metabolite concentration due to metabolic
disruption. With further development and application of these techniques, CEST imaging
has the potential for clinical translation, and will benefit research studies across a variety
of disciplines.
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